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Background: HIV remains a major contributor to the burden of disease in the Eastern and 
Southern African region, where around half of those with HIV/AIDS reside, according to the 
2016 UNAIDS estimates. Data on the direct costs and outcomes of providing health care are 
important due to competing health needs and limited budgets in resource-limited settings, 
especially if we are to reach the UNAIDS 90-90-90 goals. This thesis presents a series of studies, 
which together represent the typical journey followed within an economic evaluation, starting 
with the establishment of a cohort, then onto cost and outcome analyses and, finally, the 
development of a Markov model for the purpose of establishing the cost-effectiveness of a 
particular intervention.  
Methods: Data for this thesis come from several cohorts within South Africa, with patients 
commencing ART between 1998 and 2014, and with care provided within a number of different 
models: private (Aid for AIDS), public-private partnerships or PPP (BroadReach), and public 
sector (Khayelitsha). The study design for all were retrospective cohort analyses. These cohorts 
had important strengths in their data: adherence measures (private, PPP); initiating ART at CD4 
counts > 200 cells/µL (private); detailed cost data (private); long duration of follow-up with a 
larger proportion on second-line ART (private); ability to assess health care utilization pre-ART 
and in patient loss to ART follow-up (private ); and availability of national identity numbers, 
allowing us to confirm mortality from national death register data (private, PPP).  
Results: The results sections of this thesis are presented in the form of published papers and 
chapters. In the first analysis (Chapter 4), we present a cohort profile for Aid for AIDS, where 
we describe the history of the programme and contrast it with the public sector programme in 
South Africa. In the second analysis (Chapter 5), we present a paper highlighting the profile and 
determinants of costs on ART over time in the private cohort. We draw attention to the impact 
of baseline stage and adherence to ART on early and late costs respectively. In the third analysis 
(Chapter 6), we explore different models of HIV care: GP versus clinic for public sector 
patients and courier versus collect pharmacy for private sector patients. In the third analysis 
(Chapter 7), we present a paper which reviews cost-effectiveness studies in LMICs and 
explores the relative impact of various factors on costs and mortality in preparation for the 
final analysis (Chapter 8), which required the development of a novel HIV Markov model.  
Conclusion: Interventions, such as public-private partnerships with GPs or home-refill by 
courier, which we have found to be associated with lower costs and improved outcomes 
respectively, should be considered for implementation in South Africa, especially in light of the 
proposed National Health Insurance. The focus of this thesis on models of ART delivery and 
the inclusion of under-represented or novel models are significant strengths. 
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Preface 
This thesis includes published papers, as per general provision 6.7 in the General Rules for the 
Degree of Doctor of Philosophy in Clinical Pharmacology (Ph.D.) (University of Cape Town), 
and with the approval of the University Doctoral Degrees Board. Three papers are included as 
part of the thesis and are presented as self-contained chapters. I confirm that no part of this 
thesis has been submitted in the past, or is being, or is to be submitted for a degree at any other 
university. I hereby grant the University of Cape Town free licence to reproduce this thesis in 
whole or in part for research or teaching. This thesis is presented for examination in fulfillment 
of the requirements for the degree of Doctor of Philosophy in Clinical Pharmacology. 
Three of the manuscripts included in this thesis have been published in international 
peer-reviewed journals, as detailed below. The contents of each remain unchanged from that 
which has been published or submitted for publication. The papers are listed below, with a 
description of the contribution of each author. The contribution of the candidate is outlined in 
the acknowledgments section of each paper. The candidate was the lead author for each paper 
and prepared all the data for the analyses, conceptualized and conducted all analyses and drafted 
all versions of the manuscripts during the period of the doctoral degree registration. All co-
authors critically reviewed and approved the submitted manuscripts, and the candidate reviewed 
co-author comments and suggestions and integrated them into the manuscript where 
appropriate. All supervisors have separately confirmed to the University of Cape Town Doctoral 
Degrees Board that the included papers overwhelmingly reflect the candidate’s independent and 
original thinking and his scientific work. 
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and late direct costs in a Southern African antiretroviral treatment programme: a retrospective 
cohort analysis." PLoS Med: 6(12). 
Rory Leisegang was the lead investigator on this analysis and drafted the first version manuscript, 
with Gary Maartens as the overall supervisor. Susan Cleary and Gary Maartens contributed to 
the overall study design and methodology. Michael Hislop both collected and provided source 
data and, together with Leon Regensberg, provided input on working with the source data; Rory 
Leisegang analyzed the data. Input on statistical analyses was provided by Alistair Davidse, Gary 
Maartens, and Susan Cleary; additional statistical consultation in the revision of this paper was 
provided by Francesca Little. All authors contributed to the writing of the paper and agreed with 
the results and conclusions. 
Chapter 7: 
Leisegang R, Maartens G, Hislop M, Regensberg L, Cleary S. (2009). "Improving the evidence base of 
Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings." 
BMC Health Serv Res: 10 (Suppl 1: S3). 
Rory Leisegang was the lead investigator on this analysis and drafted the first version manuscript, 
with Susan Cleary as the overall supervisor. Susan Cleary and Gary Maartens contributed to the 
overall study design and methodology. Michael Hislop both collected and provided source data 
and, together with Leon Regensberg, provided input on working with the source data; Rory 
Leisegang analyzed the data. Input on statistical analyses was provided by Gary Maartens and 
Susan Cleary. All authors contributed to the writing of the paper and agreed with the results and 
conclusions. 
Chapter 8: 
Leisegang R, Maartens G, Hislop M, Sargent J, Darkoh E, Cleary S. (2013). "A novel Markov model 
projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public 
clinics in South Africa." PLoS One: 8(2). 
Rory Leisegang was the lead investigator on this analysis and drafted the first version of the 
manuscript, with Susan Cleary as the overall supervisor. Susan Cleary and Gary Maartens 
contributed to the overall study design and methodology. Andrew Boulle and Michael Hislop 
collected and provided source data and input on working with the source data; Rory Leisegang 
analyzed the data. John Sargent and Ernst Darkoh provided insight into the BroadReach 
programme. Gary Maartens and Susan Cleary provided input on the statistical analyses. All 
authors contributed to the writing of the paper and agreed with the results and conclusions. 
Two chapters  in this thesis are presented as papers for publication in international peer-
reviewed journals, as detailed below. The intended papers are listed below, with a description of 
the contribution of each author. The candidate was the lead author for each paper and prepared 
all data for the analyses, conceptualized and conducted all analyses and drafted all versions of the 
manuscripts during the period of the doctoral degree registration. All co-authors critically 
reviewed and approved the submitted manuscripts, and the candidate reviewed co-author 
comments and suggestions and integrated them into the manuscript where appropriate.  
Chapter 4: 
Leisegang R, Sarkin L, Ball J, Cleary S, Hislop M, Karamchund S, Naidoo P, Barnabus S, Cotton 
M , Maartens G & Nachega J. "Cohort profile: adults within Aid for AIDS (AfA) antiretroviral 
programme, South Africa." 
Rory Leisegang was the lead investigator on this analysis and drafted the first version of the 
manuscript, with Jean Nachega and Gary Maartens as the overall supervisors. Michael Hislop 
collected and provided both source data and, together with Jane Ball, provided input on the 
cohort; Rory Leisegang analyzed the data together with Lee Sarkin. All authors contributed to 
the writing of the paper and agreed with the  results and conclusions. 
Chapter 6: 
Leisegang R, Maartens G, Kalkins K &, Ball J, Hislop M, Karamchund S, Naidoo P, , Cotton M 
& Cleary S, Dowdy D & Nachega J. “The impact of antiretroviral therapy home-refill by courier compared 
to self-refill on patient clinical, immunological, and virologic outcomes: a cohort analysis in HIV-infected adults.” 
Rory Leisegang was the lead investigator on this analysis and drafted the first version of the 
manuscript, with Jean Nachega and David Dowdy as the overall supervisors. Michael Hislop 
collected and provided both source data and, together with Jane Ball, provided input on the 
cohort; Rory Leisegang analyzed the data together with Keri Kalkins, All authors contributed to 
the writing of the paper and agreed with the  results and conclusions. 
  
Glossary 
Designated service provider (DSP) is a healthcare provider/s that has been "selected by the 
scheme to provide its member's diagnosis, treatment, and care in respect of one or more of the 
PMB conditions" (Medical Schemes Act 133 of 1998). 
Emergency medical condition (EMC) is a medical condition which is of “sudden and 
unexpected onset” and requires immediate medical or surgical treatment. Should treatment for 
this condition be withheld, then “impairment of bodily functions, serious dysfunction of a bodily 
organ or part of” would  “place the person's life in serious jeopardy” (Medical Schemes Act 133 
of 1998). 
Prescribed minimum benefits (PMBs) are legislated minimum benefits that medical scheme 
members are entitled to. “Subject to the provisions of this regulation, any benefit option that is 
offered by a medical scheme must pay in full, without co-payment or the use of deductibles, the 
diagnosis, treatment, and care costs of the prescribed minimum benefit conditions” (Medical 
Schemes Act 131 of 1998). Broadly speaking this refers to (a) any emergency medical condition 
and (b) a range of conditions as specified in Annexure A of the Act. Included in this list of 
conditions are the following: Addison’s disease; asthma; bi-polar mood disorder; bronchiectasis; 
cardiac failure; cardiomyopathy disease; chronic renal disease; coronary artery disease; Crohn's 
disease; chronic obstructive pulmonary disorder (COPD); diabetes insipidus; diabetes mellitus 
type 1 and 2; dysrhythmias; epilepsy; glaucoma; haemophilia; HIV/AIDS; hyperlipidaemia; 
hypertension; hypothyroidism; multiple sclerosis; Parkinson's disease; rheumatoid arthritis; 
schizophrenia; systemic lupus erythematosus; and ulcerative colitis. The benefits are subject to 
limitations specified in Annexure A regarding cost-saving interventions established by the 
scheme (e.g., generic medication, preferred provider). Various factors influence the decision to 
include these conditions within the PMB cover, including prevalence, impact on quality of life 
years (QALY), affordability of treatment and impact on financials of medical schemes (Medical 
Schemes Act 133 of 1998).  
  
List of abbreviations 
3TC  lamivudine 
/r  ritonavir boosting 
ABC  abacavir 
ADR Adverse drug reaction 
AIDS  Acquired immune deficiency syndrome 
ALT Alanine transferase 
ART  antiretroviral therapy – i.e., antiretroviral drugs, prophylaxis, and laboratory tests 
ARV antiretroviral drugs 
AZT  azidothymidine / zidovudine 
BMI  body mass index 
CD4 CD4+ cell 
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Chapter 1:  Introduction 
1.1  Introduction 
In spite of significant progress, HIV remains a major contributor to the global burden of disease 
[1]. Eastern and Southern Africa (ESA) carries the highest burden of disease: 19.4 million people 
living with HIV/AIDS (PLWH) (53% of the global), 10.3 million accessing ART (49% of the 
global) [2] and 790,000 new infections (44% of global) in 2016 [3].  Access to ART has 
dramatically improved survival in Eastern and Southern Africa [4-6] and globally – HIV-related 
mortality accounted for 1.1 million (0.95–1,200 million) deaths in 2004, but only 420,000 
(350,000–510,000) deaths in 2016 [2].  
Given the scale of the HIV epidemic in South Africa and the need for a public sector 
response, there were significant challenges to establishing the infrastructure and finances for a 
large and intensive public sector programme [7]. Data on costs and outcomes from resource-
limited settings were important [8] but limited [9, 10], yet the ambitious goal of universal access 
to antiretroviral treatment by 2010 was established [11]. The recent and equally ambitious “90-
90-90” targets for 2020  – 90% of all PLWH knowing their HIV status, 90% of all people 
diagnosed with HIV receiving ongoing ART, and 90% PLWH on ART having viral suppression 
[12, 13] – have once again raised the importance such data. A recent review highlighted that the 
effects of interventions to improve adherence to ART not only lapsed with time but often 
required more than one intervention to achieve the desired level of effect, with effectiveness 
varying significantly across settings [14, 15]. Many challenges remain if we are to “close the gap” 
[7, 12]. 
South Africa bears the brunt of the of the epidemic in sub-Saharan Africa(SSA) and 
globally with an estimated 7.1 million or 19% of the global numbers of PLWH, 15% of new 
cases, and 11% of HIV/AIDS related mortality [2]. Life expectancy remains low by international 
standards despite large-scale ART provisions [16]. Life expectancy from birth has improved from 
54 years in 2006 to 62,4 years in 2016 [17], reaching pre-HIV life expectancy rates in the early 
1990s [18, 19]. However, in 2016 there were 270,000 (240,000–290,000) new HIV infections, 
110,000 (88,000–140,000) AIDS-related deaths, and only 56% (50%–61%) of the estimated 
7,100,000 (6,400,000–7,800,000) PLWH were accessing ART, according to UNAIDS estimates 
[20]. While some of this is due to the recently implemented “test and treat” or “treat all” policy 
[21, 22], many remain ignorant of their status [7]. Continued ART scale-up and addressing 
inequalities, therefore, remain the focus in South Africa [23].  
Data on the direct costs and outcomes of providing health care are important due to 
competing health needs and limited budgets in resource-limited settings [24], yet many of the 
published HIV economic models at the inception of this thesis have been developed using data 
from high-income countries [25, 26]. We had access to a number of cohorts in Southern Africa 
comprising different models of care: private, public-private partnerships (PPP), and public sector 
(urban and rural). These cohorts had important strengths in their data: adherence measures 
(private, PPP); initiating ART at varying CD4 counts (private > 200 cells/µL; public and PPP < 
200 cells/µL); detailed cost data (private); long duration of follow-up (all) with significant 
numbers on second-line ART (private); ability to assess health care utilisation pre-ART and in 
patients loss to follow-up (private); and availability of national identity numbers which allowed 
linkage with the national death register (private, PPP). While actual costs and outcome findings 
from these different ART programmes were unlikely to be the same in public sector 
programmes, we would argue that the variables that drive costs and outcomes are likely to be 
generalizable even if the magnitudes of the effects differ. 
This thesis, therefore, focusses on outcomes (including cost) and cost-effectiveness of 
different models of care, with the intention of informing future interventions and priority setting 
in LMICs. An improved understanding of the significant costs and poor outcomes around ART 
initiation, especially where a disease threshold was used, has resulted in a shift in priorities to 
“treat all” in LMICs, irrespective of CD4 count or WHO defined illness status. The findings in 
this thesis that delivering ART through a courier pharmacy and treating public sector patients 
through private GPs could improve outcomes (for the former) while being relatively cost-
effective (for the latter) is significant and should inform resource allocation. The South Africa 
ART programme remains the largest public sector ART programme in the world, with over 3 
million people now accessing ART in South Africa alone [20], and is, therefore, able to have a 
global impact [27, 28]. 
1.2  Human Immunodeficiency Virus (HIV) 
The human immunodeficiency virus (HIV) is a sexually transmitted retrovirus caused by two 
lentiviruses, HIV type 1 (HIV-1) and type 2 (HIV-2) [29]. HIV resulted from zoonotic infections 
of the simian immunodeficiency viruses found in African primates [29]. HIV-1 is responsible for 
the current global epidemic whereas HIV-2 is largely confined to West Africa, is less 
transmissible and characterized by a slower disease progression [29]. Four groups of HIV-1 exist 
(M, N, O, and P) [29] – group M accounts for most of the infections, with the others being 
confined to West Africa [30]. In group M, there are nine subtypes (A–D, F–H, J, and K) [29] – 
subtype C is the most prevalent and found in Africa and India; subtype B is found within 
Europe, Australia, and America. Over time circulating recombinant subtypes are becoming 
increasingly common [30].  
“Acquired immune deficiency syndrome” or AIDS was first recognized in the early 
1980s, initially clustered in men who have sex with men(MSM) and intravenous drug users 
(IDUs) [31-36]. The Centers for Disease Control and Prevention (CDC) in 1982 defined AIDS 
as “a disease at least moderately predictive of a defect in cell-mediated immunity, occurring in a 
person with no known case for diminished resistance to that disease” [33] and assigned a task 
force to begin surveillance and conduct epidemiologic investigations [37]. The causative virus 
was identified by two independent groups in 1983 [38, 39] and later named human immune 
deficiency virus (HIV).  
HIV integrates into the cell’s genome [40] and through inexact replication with high rates 
of base-pair substitution evolves rapidly [41]. The body is unable to mount an adequate immune 
response leading to viral escape [42, 43]. High and continuous viral replication results in virus- 
and immune-mediate killing of CD4+ cell lymphocytes [44] leading to the typical progressive 
CD4 count decline and associated immune function deterioration [44, 45]. Furthermore, ongoing 
inflammation in response to HIV and direct HIV-related apoptosis contribute significantly to the 
deterioration in overall health [45]. Altogether, these result in complications from 
immunodeficiency or AIDS [32], usually once the CD4 count has fallen below 200 cells/µL and 
includes opportunistic infections, cancers and/or organ damage or wasting [37]. The WHO 
guidelines adopted this CD4 count level (200 cells/µL) as the threshold for initiating ART for 
many years in patients without a WHO stage III or IV illnesses [46]. 
1.3  Antiretroviral therapy 
Combined antiretroviral therapy (cART but later referred to as ART), which consisted of a 
combination of three drugs from at least two different classes of drugs, proved durable in 
suppressing viral replication in clinical trials in high-income countries (HIC) in the mid-1990s 
[47, 48]. ART was therefore rolled-out in HIC despite its substantial costs [49]. Cohort studies 
soon confirmed the durability and impact of ART on morbidity and mortality for PLWH [50, 51] 
and, over time, demonstrated that CD4 counts recovered to near normal levels in those with 
ongoing viral suppression in LMIC and HIC settings, including in South Africa [52, 53]. Recent 
studies from South Africa and other LMICs have encouragingly shown that near-normal life 
expectancy can be achieved for certain subgroups [53, 54], in keeping with other studies from 
HIC settings (excluding those who inject drugs) [52, 55].  
ART decreases plasma viral load concentrations below the lower limit of detection, 
usually within 6-months, thus allowing immune reconstitution [9, 56]. The recovery of the CD4 
count in individuals on ART is variable [57, 58] and, in part, driven by a lower baseline CD4 
count [59]. Importantly, impaired CD4 count recovery despite virological suppression has been 
shown to be associated with an increased risk of adverse outcomes [60, 61]. Later studies soon 
showed improved clinical outcomes in patients who started ART at CD4 count > 500 cells/µL 
[62-64] and reduced transmission within serodiscordant couples [65-70], thus establishing the 
case for the “treat all” that has now been widely adopted in LMICs, including South Africa [22, 
71]. 
Adverse drug reactions (ADRs) (hepatotoxicity,  hyperlactataemia and lactic acidosis, 
dyslipidaemia, lipodystrophy, hypersensitivity, nephrotoxicity, neuropsychiatric toxicity 
dysglycaemia and gynaecomastia) [22] are not uncommon, driven in part by multi-morbidity and 
the higher pill-burden [72]. Early ART exposes patients to toxic effects of drugs and the 
development of resistance before they derive clinical benefit [73]. The recent progress towards 
affordable, durable, and tolerable regimens with simple dosing schedules (single tablet regimen 
or STR) for LMICs is, however, encouraging [22, 74]. 
1.4  Current global status of the global epidemic  
By the end of 2015, 17 million or just under half of the 36.7 million PLWH were accessing 
antiretroviral therapy (ART) – well above the goal of the 2011 Political Declaration on HIV and 
AIDS of having 15 million on treatment by 2015 [75] but still far from the current 90-90-90 
goals [76]. While incidence has flattened since 2005, total numbers on ART have continued to 
grow, in part due to the gradual relaxation of the eligibility criteria [77] and longer survival [78]. 
Further scale-up of testing and accelerated treatment are required to meet the first two of the 90-
90-90 goals, and improved retention in care and access to adequate monitoring, including VL, 
are required to meet the last goal. In the past, where VL testing was not available, alternative 
strategies were developed and included CD4 count, clinical, and adherence monitoring [79]. With 
Roche’s Global Access Program, VL testing prices have been substantially reduced and testing is 
set to expand rapidly in LMICs [27]. Newer antiretroviral drugs (ARVs) are becoming available, 
including in LMIC settings [80], which is important given the high prevalence of ARV resistance 
(>10%) in naïve patients now being observed in some settings, including several SSA countries 
[81]. 
1.5  HIV in South Africa 
South Africa has the largest number globally of PLWH and who are accessing ART and falls 
within WHO’s Southern and Eastern Africa region: nearly 4 million or 56% of the estimated 7.1 
million PLWH in South Africa had started ART by 2016, according to the latest UNAIDS 
estimates [20]. Globally, this translates to 19% of PLWH, 15% of new HIV infections, and 11% 
of AIDS-related deaths in 0.7% of the world’s population [20]. HIV prevalence is high (18.9%) 
and varies markedly between different regions [2]. The Human Sciences Research Council’s 
national HIV survey in 2012 found prevalence was highest in KwaZulu-Natal (KZN) and 
Mpumalanga (MP) and lowest in the Northern Cape (NC) and Western Cape (WC) [82]. New 
infections remain high and therefore more interventions are required [83]. 
Addressing the HIV epidemic in South Africa to meet the 90-90-90 goals is complex [7]. 
A multifaceted approach, therefore, has been adopted in the National Strategic Plan for HIV, TB 
and STIs 2017–2022 [84]. According to the World Bank’s definition of the “food poverty line” – 
defined as an income above which a household can purchase “some basic-needs food bundle 
and nothing more” [85] – more than 10 million people live below this line in South Africa [86]. 
This fact, alongside the dual burden of communicable and noncommunicable diseases, the 
persistent social disparities, the high burden of disease, the rising population and increasing 
number of refugees and economic migrants, means there are often inadequate human resources 
to provide the care required [86-88]. While South Africa is considered a middle-income country, 
the wealth remains concentrated (Gini coefficient of 0.65 for 2014): the wealthiest 20% 
consumed 65%, and the poorest 20% consumed 3% of the total expenditure on health care in 
2014 [89]. 
LMICs, in particular those in SSA, were least able to respond due to the scale of the 
epidemic and the substantial costs of ART [90]; by 2001, AIDS was the leading cause of death in 
SSA. International effects to mobilize resources – e.g. the Joint United Nations Programme on 
HIV/AIDS (UNAIDS); Global Fund to Fight AIDS, TB and Malaria (GFATM); the Global 
Fund to Fight AIDS, Tuberculosis and Malaria in 2002 (GFATM); and the US President’s 
Emergency Plan for AIDS Relief (PEPFAR) in 2003 [91, 92]. WHO’s ‘3 by 5’ campaign, a five-
year plan to combat AIDS, primarily in countries with a high number of HIV infections, 
established substantial resources to fight the epidemic ($15 billion initially). The accompanying 
2003 update to the WHO guidelines [93] for resource-limited settings was rapidly adopted by 
many LMICs, thus allowing for expanded ART provision through a public health approach [94]. 
This release and its subsequent updates continued to form the basis of care in many LMIC 
settings, including South Africa.  
The public provision of ART in South Africa was rolled out from April 2004 as part of 
the South African Department of Health’s “Operational Plan for Comprehensive HIV and 
AIDS Care, Management and Treatment” [95].  A conservative eligibility criteria for ART was 
initially implemented with CD4 count < 200 cells/ µL irrespective of stage, or with WHO stage 
IV [95]. These conservative eligibility criteria were relaxed in a stepwise fashion in keeping with 
changing WHO guidelines for resource-limited settings until CD4 and WHO stage criteria were 
dropped completely in the current “treat all” approach [22]. The adult first line ART regimen 
consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside 
reverse transcriptase inhibitor (NNRTI); second line ART regimen comprised of two NNRTIs 
and a protease inhibitor (PI) [96]. Unlike in many other resource-limited settings, viral load 
monitoring was implemented and patients who failed virologically (defined by two consecutive 
viral loads > 1,000 copies/mL with intensive counseling) were changed to the second line ART 
treatment regimen [96].  
The current recommended regimen for LMICs (TDF+3TC/FTC+EFV) [71], based on 
an accepted public health approach [97], is well tolerated [22] and effective in suppressing viral 
replications [98]. ADRs are less common with this regimen than with previous regimens [22], but 
the high prevalence of multi-morbidity in South Africa will continue to contribute to ADRs 
incidence [72, 99]. An estimated 60% of PLWH in South Africa are also co-infected with 
tuberculosis [7]. Going forward, the new “National Strategic Plan for HIV, TB, and STIs: 2017–
2022” has been established for South Africa [84] and is aligned with the UNAIDS 90-90-90 
Treatment Targets [76]. 
Knowledge of HIV status has improved substantially. In Eastern and Southern Africa, 
nearly twice as many adults aged 15–49 years knew their status in 2012–2016 compared to 2007–
2011 [2]. HIV counseling and testing (HTC) in South Africa has been expanded through the 
national campaigns launched in 2010 and 2015 and resulted in 35 million HIV tests being carried 
out [7]. More recent modeling data suggest that 86% of people know their status, which is a 
significant achievement given the scale of the epidemic in South Africa [2]. 
1.6  Resource allocation 
Ensuring adequate and appropriate resource allocation to fight the HIV epidemic is a key 
concern, especially within LMICs [100]. In SSA, the prevalence in some countries exceeds 10% 
and under this burden only middle-income countries like South Africa, Namibia, and Botswana 
have been able to mobilize sufficient domestic funding in conjunction with international aid 
organizations to establish and expand ART programmes [100]. Low-income countries, even 
those with low prevalence, still rely heavily on donor funding – e.g., Mozambique and Ethiopia. 
In a recent article, the authors argue for five key factors which influence resource allocation: 
disease burden, cost-effectiveness, external parties’ ability (and willingness) to pay, intertemporal 
trade-offs, and health equity [100].  
The financing of the ART programme in South Africa is substantial – the estimated total 
expenditure for the 2012–2016 National Strategic plan was around R133.5 billion [7]. With 
donor funding declining in recent years – historically 20% of the funding, mainly from Global 
Fund to Fight AIDS, TB and Malaria (GFATM) and the US President’s Emergency Plan for 
AIDS Relief (PEPFAR) – and projected rising future costs (driven by exchange rate, changing 
global economy, inflation, etc.), further pressure on resources is anticipated [7].  
1.7  Aims and objectives 
The overall aim of this thesis was to explore outcomes and cost-effectiveness of different models 
of delivery of antiretroviral therapy, using data from South African ART programmes. 
The specific objectives were: 
1. Describe the various cohorts included in this thesis and compare their approaches with 
WHO guidelines for resource-limited settings (Chapter 3). 
2. Establish the cohort profile for AfA (Chapter 4). 
3. Describe the costs and determinants of costs over time on ART (Chapter 5). 
4. Compare outcomes of home-refill by courier versus self refill of ART, a model of care in 
public and private sectors in South Africa (Chapter 6). 
5. Review and conduct a preliminary cost and outcome analysis of Markov models from 
LMIC settings (Chapter 7). 
6. Establish a novel Markov model to compare the cost-effectiveness of GP versus public 
sector clinic for public sector patients as alternative models of care for ART in South 
Africa (Chapter 8). 
1.8  Overview, context, and structure of this thesis 
In Chapter 2 we present a framework for an economic evaluation, together with key 
terminology and concepts. We then present a literature review of the cost-effectiveness of 
different models of HIV care in South Africa. 
In Chapter 3 we present a summary of various cohorts and their context in South 
Africa, including limitations and strengths, and common methodologies applied to the cohort 
analyses.  
In Chapter 4 we present the cohort profile of the AfA programme using the style of a 
paper in the Journal of Epidemiology. The last published update of the cohort profile was in 2004.  
In Chapter 5 we present a cost analysis exploring the direct health care costs from the 
healthcare sector perspective over time in a South African private sector HIV/AIDS 
programme. We draw attention to the high cost around ART initiation and the changing 
determinants of costs over time on ART. We present a full manuscript with the introduction, 
methods, results, discussion, and conclusions. 
In Chapter 6 we present an outcome analysis comparing patient clinical, immunological 
and virologic outcomes for home delivery by courier versus self-refill in a South African private 
sector HIV/AIDS programme. Adherence to ART is a key determinant of outcomes and costs, 
and inconvenience incurred by patients with self-refill may pose a significant access barrier, with 
implications for adherence. We present a full manuscript with the introduction, methods, results, 
discussion, and conclusions. 
In Chapter 7  we present a follow-on analysis identifying the determinants of direct 
health care costs and the likelihood of death. This is a follow-on analysis from Chapter 5 to 
inform the development of Markov models which can estimate lifetime costs and outcome and 
therefore inform scaling up of ART in a resource-limited setting. We include a literature review 
of Markov models from LMIC settings. We present a full manuscript with the introduction, 
methods, results, discussion, and conclusions. 
In Chapter 8 we present a cost-effectiveness analysis comparing the 10-year and life 
costs, outcomes and cost-effectiveness of using GPs in the private sector to treat public sector 
patients instead of primary public sector clinics. This model has been described before in 
Botswana and is an alternative model of care. We present a full manuscript with the introduction, 
methods, results, discussion, and conclusions. 
In Chapter 9 we summarize the findings and conclusions for the four analyses included 
in this thesis. We discuss the implications of the research and how it could inform allocation and 
policy in South Africa and priorities for future research on alternative models of ART delivery. 
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Chapter 2:  Literature review  
2.1  Overview 
The objective of this chapter is to briefly outline some of the key concepts used in an economic 
evaluation and to review the literature on the cost-effectiveness of different models of ART 
delivery. Public sector clinics, where doctors, nurses, and lay counselors work together, are 
considered the standard of care (SOC) model for ART delivery in South Africa.  
2.2  Key concepts in economic evaluation 
An economic evaluation is concerned with the optimal way of consuming scarce resources. 
Within the context of health economics, it most commonly includes a study of cost, outcomes, 
and cost-effectiveness. To effectively allocate scarce resources, one requires knowledge of the 
effectiveness and costs of a particular strategy to prevent or treat disease. Cost and outcome 
studies are often prioritized as they can establish whether the treatment will be effective and 
what resources and budget are required. 
2.2.1  Perspective and types 
Within a health economic evaluation, the perspective of a study should be determined upfront 
[1]. There are three common perspectives, and these perspectives determine which costs are 
collected or included in the analysis [1]:  
 Patient, where the opportunity cost of time seeking care (including travel, waiting and 
consultation times), the opportunity cost of foregone work, and out-of-pocket-expenses 
such as transportation are all considered [2]. 
 Provider or health service, where all health care expenses are included and all costs incurred 
by the patient to receive the treatment are excluded. It is the most common perspective 
and is used within the cost analyses presented in this thesis [3]. In certain analyses, a 
healthcare sector perspective can also include resources consumed in other sectors such 
as education or social welfare. 
 Societal, the broadest, includes both healthcare sector and patient perspectives [1].  
There are three types of economic evaluation commonly cited in the literature [4]: 
 Cost-benefit analysis (CBA), which resolves costs and benefits to common units that are 
usually monetary in nature. Any net monetary benefit of an intervention is then 
considered favourable as it would increase social welfare [5]. It also enables comparison 
between health interventions and those in other sectors [4]. 
 Cost-effectiveness analysis (CEA), which is the most common analysis and is used to inform 
decision making within a patient group with a particular condition. Health benefits are 
measured in natural units whereas costs are measured in monetary units and the ratio of 
incremental costs to incremental outcomes provides a tool that can inform decision 
making [6]. Importantly, CEAs provide information which will allow interventions to be 
compared in terms of technical, but not allocative, efficiency [7]. In essence, this means 
that a CEA can compare costs and outcomes within a given patient population, but is 
unable to provide guidance on whether such interventions represent value for money 
more broadly. This is because a CEA that uses natural outcome measures can only 
compare interventions that produce similar outcomes (e.g., either morbidity or mortality) 
[6]. CEA is the approach used in Chapter 8 of this thesis. 
 Cost-utility analysis (CUA), which is an adaptation of a CEA. In these analyses, utility based 
measures are used instead of natural units (e.g., QALYs and DALYs – see more below) 
[8]. This use of QALY (quality adjusted life years) or DALY (disability adjusted life years) 
enables comparisons to be made across programme or patient groups (e.g., HIV/AIDS 
versus malaria) and hence enables a fuller assessment of interventions in terms of 
whether they are allocatively efficient, meaning that their adoption will increase 
population health within a given health care budget constraint.  
2.2.1  Costs 
Costs (direct, indirect, and intangible) are defined as the opportunity costs within the context of 
a health economics evaluation and are the benefits that could have been realized from the best 
alternative intervention [9]. This differs from the financial cost, which is the actual or accounting 
cost plus borrowing charges, and the economic cost, which includes the accounting cost and the 
opportunity cost. In most health economic evaluations, unit costs (e.g., cost per casualty visit, 
cost per inpatient day) are commonly established; the total cost then becomes a product of unit 
cost and utilization. The application of unit cost is important within the analyses presented in 
this thesis. The breakdown of unit costs includes all fixed/overhead and variable costs (direct 
labour and material costs) involved in the production of goods or services [10].  
The analyses of Chapters 5, 7, and 8 use economic evaluation methods; more details are 
provided within each chapter about how costs and outcomes have been determined. With the 
private sector cohort analyses, the tariff amount (which is the amount agreed to annually 
following negotiations between private healthcare sectorand funders) was used as a proxy for 
direct health care costs. We chose the tariff amount, as opposed to the amount charged by the 
provider or the amount reimbursed to the patient, so that similar services would take the same 
monetary value. We further assumed that these tariffs were a suitable proxy for opportunity 
costs. While this could be a shortcoming, it is common to assume that market prices are a proxy 
for opportunity costs in an economic evaluation given the difficulties in evaluating the latter [11]. 
2.2.2  Outcomes 
Outcomes are often measured in natural units (viral suppression, deaths, LTFU). These units 
usually come from clinical trials but also are found in the literature. In the outcomes analysis in 
Chapter 7, we considered three common outcomes measures within HIV analyses: CD4 
response, VL suppression rate, adherence levels, and death.  
Within economic analyses, utility based measures are preferred as they take into account 
the patient’s level of wellbeing [5]. The utility based measure in a CUA is therefore preferred 
over a CEA for decision making as it allows for a more robust comparison between 
interventions – e.g., higher quality of life for fewer years versus lower quality of life for more 
years. The most commonly reported utility based units are QALYs and DALYs. In the case of 
HIV, the utility based measures are particularly important and may vary significantly across age 
group and gender [12]. 
2.2.3  Decision-making tools 
Decision making is an important aspect of an economic evaluation, given the scarcity of 
resources and the need to allocate these scarce resources appropriately. Outcome analyses are 
often the first analyses to be made available and can be useful in determining which treatments 
are effective. Cost studies, depending on the perspective taken, can also be useful in determining 
the budgetary requirements for a given number of patients who would receive the intervention. 
Neither of these by themselves will, however, gauge which treatment options are efficient [13].  
Decision making within both CEA and CUA is complex in the instance that a new 
intervention is likely to increase both costs and outcomes. Given a constant budget, 
implementing this new intervention poses an opportunity cost in that other interventions will 
need to be scaled back. In this instance, one suggestion is to compare the positive incremental 
cost-effectiveness ratio, with outcomes expressed in QALYs or DALYs, to a cost-effectiveness 
threshold. This threshold can be expressed on the demand side as the willingness to pay to gain 
health or on the supply side as the opportunity cost of foregone health and health system 
spending. Using the supply side perspective, the cost-effectiveness threshold can be empirically 
established (at least in theory) by ranking programmes from most to least cost-effective in a 
league table and, starting with the most cost-effective, fully funding each until the budget is 
exhausted. The incremental cost-effectiveness ratio (ICER) of the last programme to be funded 
before the budget is exhausted is then the cost-effectiveness threshold. It is argued that the 
supply side approach is more appropriate in that it more accurately captures the decision 
problem of maximization within a constrained budget. Despite this, the most commonly adopted 
threshold for QALYs or DALYs averted is up to three times the gross domestic product per 
capita [14, 15]. Given that this threshold has little relationship opportunitiy cost of health system 
at the margin, it has been heavily criticized and its usage is discouraged in more recent literature 
[16]. Priority setting requires some pragmaticism as no single method based on cost-effectiveness 
thresholds can be applied universally and some judgment is still required [16].  
2.4  Models of ART delivery 
The Khayelitsha programme, described in Chapter 4 and included in the analysis of Chapter 8, 
was the first public sector pilot programme in South Africa [17]. By 2004, the national public 
sector HIV programme had been established and HIV care of public sector patients was 
normalized against these guidelines [18]. Early studies raised concerns that there would be 
inadequate human resources to provide care for the anticipated numbers of PLWH in LMIC 
settings [19]. In more recent studies, limited human resources for treating PLWH remain 
important in LMICs, but so does the diversity of patient needs which also needs to be addressed 
to ensure adequate programme outcomes [18, 20, 21]. Identifying “stable patients” who could be 
down-referred (or even just referred for starting ART) to less intense ART delivery models has 
been identified as an important mechanism for improving outcomes and optimising resource 
allocation for those in need [18]. 
We have focussed our review on studies of different models of ART delivery which have 
included a cost-effectiveness analysis. Identifying interventions that represent value for money is 
important [22], especially given the ambitious 90-90-90 goals by 2020 in resource-limited 
settings. The number of doctors working within many public sector settings is inadequate given 
the disease burden in South Africa and other LMIC settings [23]. Evidence from cohort and trial 
data for task-shifting HIV care from doctors to other models of care is growing [24], but more 
research is needed and the impact these models may have on ART adherence needs to be 
considered as well [21].  
Early cost-effectiveness studies from South Africa focussed on the use and timing of 
ART and antibiotic prophylaxis [25-28]. ART was argued to be cost-effective compared to no 
ART [25, 26, 28, 29] and more cost-effective when started at a CD4 threshold of < 200 cells/µL 
[25, 27, 29] or when only first line was made available [28]. Later studies from South Africa 
focussed on regimen choice [30], task-shifting [31] [32],[33] prophylactic antibiotics [34], PreP 
[35], eligibility criteria [36, 37], and monitoring strategies [38]. In terms of ART provision, 
Granich et al. (2012) and Eaton et al. (2014) concluded that extending the CD4 eligibility 
criterion to CD4 < 350 cells/µL would be cost-saving; Rosen et al. (2008) concluded that 
switching from stavudine to tenofovir would be cost neutral; and Keebler et al. (2014) concluded 
that both CD4 and VL monitoring should only be recommended once high ART coverage was 
established. Few studies have focused on the cost-effectiveness of different models of care [13], 
which is the focus of this thesis. 
2.4.1  Nurse  
We found two cost-effectiveness analyses of nurse-based models of ART delivery [39, 40]. 
Previous studies had shown that nurse-led care was not inferior and improved access to ART 
through expanded capacity [31, 41-45]. An earlier cost analysis found doctors’ salaries to be a 
significant proportion of total clinic costs in South Africa [46]. Another study from 1993 in the 
United States found that a visit for routine care to an outpatient clinic run by nurses cost USD 
287 compared to USD 1,400 for inpatient care, and the implementation of these nurse-led clinics 
resulted in 25% fewer inpatient visits. It was therefore likely that nurse-led care would be 
comparatively cost-saving [47]. 
In an analysis by Barton et al. (2013), a cost-effectiveness analysis of nurse-led versus 
doctor-led first line ART provision within the STRETCH trial was presented [48]. Two cohorts 
were established, with over 10,000 patients who were either ART naïve or had been on ART for 
six months or more at enrollment. The main outcome measures of the trial were death and viral 
suppression (<400 copies/ml) at 12 months after enrolment, and costs were estimated. The 
authors concluded that nurse-led ART was associated with higher mean direct health care costs 
than doctor-led care but outcomes were equivocal. This study, therefore, suggests that SOC 
dominates nurse-led care [39]. Nurse-led care was associated with positive aspects such as longer 
contact time with the patient and improved CD4 count response, tuberculosis detection, and 
weight gain on ART [42].  
Using cross-sectional mixed methods study design, Foster et al. (2012) compared a 
pharmacist’s assistant (working under a pharmacist) and a nurse-led clinic with the standard of 
care (a public sector clinic) in South Africa. The authors evaluated two clinics in each setting and 
concluded that the pharmacist assistant model and nurse model would be on average cost-saving, 
with a USD 2.6 and USD 3.75 reduction in cost per patient per visit respectively. 
Given this evidence, nurse-led ART provision may not necessarily reduce costs. 
However, given the shortage of doctors in the public sector [23], nurse-led ART provision would 
be needed to enhance access [47]. More research is needed as follow-up periods were only one 
year and the effects may be temporal; more exposure time is therefore necessary [21]. 
2.4.2  Pharmacist and pharmacist’s assistant 
Pharmacist-care models with cost-effectiveness analyses have been published by Babigumira et 
al. (2011) and Foster et al. (2012) (referred to earlier). The pharmacist’s support model proposed 
by Foster et al. (2102) was the topic of a recent systematic review [49]. The WHO 
recommendation is one pharmacist per 2,300 population, but few LMICs can reach this level 
[50]. The authors of this review found only three studies [51-53] (two cluster trials from Kenya 
and Uganda and an individually randomized trial from Brazil) from LMIC settings which met the 
inclusion criteria. The conclusion of authors of this review was that the certainty for the 
intervention was low – pooled analysis found improved non-significant survival (RR 1.86; 95% 
CI 0.44 to 7.95), worsened non-significant loss to follow-up (LTFU) (RR 1.13, 95% CI 0.68 to 
1.91), and improved non-significant virological response (RR 0.92; 95% CI 0.73 to 1.15) [54].   
The standard model of care in Uganda at the time of the Babigumira et al. (2011) study 
involved monthly physician visits [55]. The intervention allowed for pharmacy-only monthly 
visits for 5 months out of 6 – i.e., patients were allowed to collect their medication without 
seeing a clinician but were asked screening questions by a pharmacy-based nurse during every 
visit. As with the adherence clubs in Khayelitsha, stable patients (were 12 months or more on 
ART, CD4 > 200 cells/µl, had attended clinic visits consistently for the preceding 6 months, had 
disclosed HIV status to spouse, were not pregnant, and had “no substantial clinical event in the 
preceding 6 months”) were identified and offered the option of transferring to the pharmacy-
refill model. The main outcome measures were having a CD4 > 500 cells/µl or favourable CD4 
response on follow-up after one year. The authors concluded that there was an adjusted non-
significant risk (OR 0.93, 95% CI 0.55–1.58) of a non-favourable CD4 response, but a significant 
cost-saving (USD 520 versus USD 655 annually) with the pharmacy-refill model. The ICER was 
USD 13,500 per favourable CD4 response. 
Given this evidence, pharmaceutical interventions for ART provision may save costs. 
However, given the shortage of pharmacists in the public sector in South Africa as well, novel 
strategies which alleviate the pharmacist medicine dispensing burden are required [50]. The 
Chronic Disease Unit, an out-sourced public sector centralized dispensing service, is an example 
of a successful programme that has been implemented in the Western Cape [56]. More research 
on the impact of this service on other potential models is required [57]. We have included an 
analysis of pharmacy delivery to homes in Chapter 6 of this thesis. 
2.4.3  Adherence clubs  
Community-based interventions have been shown to improve and sustain ART adherence in 
LMICs [58]. In South Africa, adherence clubs were established within Khayelitsha clinics and are 
well described [13, 54, 59-62]. The clubs were run by trained lay health workers and supported by 
nurses and in essence were a combination of several interventions that have been shown to be 
independently effective at improving retention in care: patient support groups, task shifting to lay 
workers, less frequent appointments (every two months), and quicker visits [13]. Stable patients 
were identified and offered the option of transferring based on the following criteria: 18 months 
or more on ART, CD4 > 200 cells/µl, viral suppression (defined as two consecutive viral loads 
<400 copies/ml, with the most recent not more than 6 months old), no adverse drug effect, no 
opportunistic infections, and consistent clinic attendance. A positive relationship between 
adherence clubs and VL suppression and retention in care has been reported [63].  
In an analysis by Bango et al. (2016), the cost-effectiveness of adherence clubs versus a 
public sector clinic for the management of stable patients is presented using a similar approach 
to that of Barton et al. (2013) above. In this analysis, the adherence clubs were found to be cost-
saving, lower costs (USD 300 versus USD 200) and better but not significant retention (98% 
versus 95%) and viral suppression (99% versus 97%). Future trials are planned to look into the 
cost-effectiveness of 3- versus 6-monthly dispensing within adherence clubs [64]. 
2.4.4  General practitioner (GP) 
The provision of ART for public sector patients through GPs in LMIC settings, including South 
Africa, has been described in the literature [65-67]. The impact of high patient burden in public 
clinics on retention in care and quality of care has also been described [68, 69]. GP models for 
ART delivery should be considered in South Africa given the significant potential resources and 
lower patient burden [70].  
In the study by Igumbor et al. (2014), a GP down-referral model was established at the 
request of the North West Provincial Department of Health, South Africa, to evaluate the 
feasibility of the model for areas where public sector resources were limited [65]. The national 
guidelines were followed and support mechanisms, including quarterly meetings with public 
hospital clinicians, were established to promote consistency of care. In the study by Innes et al. 
(2012), a GPs model for initiating ART was established in a managed-care environment (i.e., with 
clinical and programme support from the Aurum Institute). The model proposed by Innes et al. 
(2012) was similar to the GP model presented in Chapter 8 of this thesis, except that in Chapter 
8 the managed-care provider was AfA.  
We contrast the Aurum supported and AfA supported programme outcomes in Chapter 
8 in more detail. The subsequent analysis of a down-referral model for ART delivery by Igumbor 
et al. (2014) is, however, more difficult to compare given that it was a down-referral model. 
Encouragingly, at 48 months, viral suppression rates were 88.4%, survival was 89.0% (95% CI: 
87.1%–90.0%), and patient retention was 94.3% (95% CI: 93.0%–95.7%). These findings were 
consistent with the analysis of the AfA-managed model presented in Chapter 8, but retention 
was substantially worse in the Aurum-managed programme, with retention rates of less than 
60% at 3 years [67]. 
Given the evidence presented in Chapter 8, a GP model for ART delivery would be cost-
effective and should be considered in South Africa. More research is needed, however, given the 
limited cost data, ongoing concerns regarding the quality of care, and the alternative models 
being proposed (including contracting private GPs to work part-time in government clinics) [65, 
71]. 
2.5  Conclusions  
South Africa has adopted WHO’s “treat all” [72] to reach the 90-90-90 goals [73], which 
according to latest estimates means a further 3.1 million or 44% of PLWH will need to start 
ART over the next few years [74]. New HIV infections remain significant in South Africa 
(110,000 in 2016) and, therefore, it is anticipated that large numbers of PLWH will need to be 
started and maintained on ART for many years to come [71]. Recent studies suggest that most 
PLWH in South Africa now know their status [75] and most rely on public sector services for 
their health care [23]. Addressing factors influencing  ART initiation, ART adherence, and 
retention in care are therefore paramount [76-78]. 
We present outcome and cost-effectiveness analyses for two models of ART provision in 
South Africa in Chapters 6 and 8 respectively that contribute significantly to the literature on 
models of ART delivery in South Africa. The White Paper on the South African National Health 
Insurance (NHI) framework was updated in 2017 [79]. Within this framework, all health care 
professionals are considered potential providers of care for all people in South Africa, thus 
removing the distinction between the public and private sector and the associated inequalities[23, 
71]. To achieve the goal of establishing an NHI in South Africa, it is essential to include 
considerations of cost-effectiveness and budget impact in order to move towards allocations that 
maximize health within the budget constraint [80].  
2.6  References 
1. Byford, S. and J. Raftery, Perspectives in economic evaluation. BMJ : British Medical Journal, 
1998. 316(7143): p. 1529-1530. 
2. Hofstatter, E.W., Understanding Patient Perspectives on Communication About the Cost of Cancer 
Care: A Review of the Literature. Journal of Oncology Practice, 2010. 6(4): p. 188-192. 
3. Johannesson, M., A note on the depreciation of the societal perspective in economic evaluation of health 
care. Health Policy, 1995. 33(1): p. 59-66. 
4. Palmer, S., S. Byford, and J. Raftery, Types of economic evaluation. BMJ : British Medical 
Journal, 1999. 318(7194): p. 1349-1349. 
5. Robinson, R., Cost-utility analysis. BMJ : British Medical Journal, 1993. 307(6908): p. 859-
862. 
6. Phelps, C.E. and A.I. Mushlin, On the (near) equivalence of cost-effectiveness and cost-benefit 
analyses. Int J Technol Assess Health Care, 1991. 7(1): p. 12-21. 
7. Birch, S. and A. Gafni, Cost effectiveness/utility analyses. Do current decision rules lead us to where 
we want to be? J Health Econ, 1992. 11(3): p. 279-96. 
8. Torrance, G.W., Measurement of health state utilities for economic appraisal. J Health Econ, 1986. 
5(1): p. 1-30. 
9. Donaldson, C., The state of the art of costing care for economic evaluation. 1990. 14(4): p. 341-356. 
10. Unit Cost.  [cited 2018 1 February]; Available from: 
https://www.investopedia.com/terms/u/unitcost.asp. 
11. Drummond, M.F., et al., Methods for the economic evaluation of health care programmes. 2005, 
Oxford: Oxford University Press. 
12. Beard, J., F. Feeley, and S. Rosen, Economic and quality of life outcomes of antiretroviral therapy 
for HIV/AIDS in developing countries: a systematic literature review. AIDS Care, 2009. 21(11): p. 
1343-56. 
13. Bango, F., et al., Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and 
access analysis from Khayelitsha, South Africa. Trop Med Int Health, 2016. 21(9): p. 1115-23. 
14. Evans, D.B., et al., Evaluation of current strategies and future priorities for improving health in 
developing countries. BMJ : British Medical Journal, 2005. 331(7530): p. 1457-1461. 
15. Neumann, P.J., et al., A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY 
Averted. PLOS ONE, 2016. 11(12): p. e0168512. 
16. Thokala, P., et al., Cost-Effectiveness Thresholds: the Past, the Present and the Future. 
Pharmacoeconomics, 2018. 
17. Stinson, K., et al., Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South 
Africa. Int J Epidemiol, 2016. 
18. Waldrop, G., et al., Stable patients and patients with advanced disease: consensus definitions to 
support sustained scale up of antiretroviral therapy. Trop Med Int Health, 2016. 21(9): p. 1124-
30. 
19. Bärnighausen, T., D.E. Bloom, and S. Humair, Human resources for treating HIV/AIDS: 
needs, capacities, and gaps. AIDS Patient Care STDS, 2007. 21. 
20. Barnighausen, T., D.E. Bloom, and S. Humair, Human Resources for Treating HIV/AIDS: 
Are the Preventive Effects of Antiretroviral Treatment a Game Changer? PLoS One, 2016. 11(10): 
p. e0163960. 
21. Kanters, S., et al., Interventions to improve adherence to antiretroviral therapy: a systematic review and 
network meta-analysis. Lancet HIV, 2017. 4(1): p. e31-e40. 
22. Rosen, S., L. Long, and I. Sanne, The outcomes and outpatient costs of different models of 
antiretroviral treatment delivery in South Africa. Trop Med Int Health, 2008. 13(8): p. 1005-15. 
23. Mayosi, B.M. and S.R. Benatar, Health and health care in South Africa - 20 years after Mandela. 
N Engl J Med, 2014. 371(14): p. 1344-53. 
24. Kredo, T., et al., Task shifting from doctors to non-doctors for initiation and maintenance of 
antiretroviral therapy. Cochrane Database Syst Rev, 2014(7): p. Cd007331. 
25. Badri, M., et al., When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A 
South African cost-effectiveness study. Antivir Ther, 2006. 11(1): p. 63-72. 
26. Cleary, S.M., D. McIntyre, and A.M. Boulle, The cost-effectiveness of antiretroviral treatment in 
Khayelitsha, South Africa--a primary data analysis. Cost Eff Resour Alloc, 2006. 4: p. 20. 
27. Bachmann, M.O., Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS 
progression with antiretrovirals or antibiotics in Southern African adults. AIDS Care, 2006. 18(2): p. 
109-20. 
28. Cleary, S.M., D. McIntyre, and A.M. Boulle, Assessing efficiency and costs of scaling up HIV 
treatment. Aids, 2008. 22 Suppl 1: p. S35-42. 
29. Badri, M., et al., Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med, 
2006. 3(1): p. e4. 
30. Rosen, S., et al., Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line 
antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr, 2008. 48(3): p. 334-44. 
31. Long, L., et al., Treatment outcomes and cost-effectiveness of shifting management of stable ART 
patients to nurses in South Africa: an observational cohort. PLoS Med, 2011. 8(7): p. e1001055. 
32. Vella, V., et al., Cost-effectiveness of staff and workload profiles in retaining patients on antiretroviral 
therapy in KwaZulu-Natal, South Africa. AIDS Care, 2011. 23(9): p. 1146-53. 
33. Bassett, I.V., et al., Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and 
cost-effectiveness. PLoS One, 2014. 9(1): p. e85197. 
34. Abimbola, T.O. and B.J. Marston, The cost-effectiveness of cotrimoxazole in people with advanced 
HIV infection initiating antiretroviral therapy in sub-Saharan Africa. J Acquir Immune Defic 
Syndr, 2012. 60(1): p. e8-e14. 
35. Pretorius, C., et al., Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its 
impact on HIV-1 transmission in South Africa. PLoS One, 2010. 5(11): p. e13646. 
36. Eaton, J.W., et al., Health benefits, costs, and cost-effectiveness of earlier eligibility for adult 
antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. 
Lancet Glob Health, 2014. 2(1): p. e23-34. 
37. Granich, R., et al., Expanding ART for treatment and prevention of HIV in South Africa: 
estimated cost and cost-effectiveness 2011-2050. PLoS One, 2012. 7(2): p. e30216. 
38. Keebler, D., et al., Cost-effectiveness of different strategies to monitor adults on antiretroviral 
treatment: a combined analysis of three mathematical models. Lancet Glob Health, 2014. 2(1): p. 
e35-43. 
39. Barton, G.R., et al., Cost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South 
Africa: pragmatic cluster randomised trial. Trop Med Int Health, 2013. 18(6): p. 769-77. 
40. Foster, N. and D. McIntyre, Economic evaluation of task-shifting approaches to the dispensing of 
anti-retroviral therapy. Hum Resour Health, 2012. 10: p. 32. 
41. Callaghan, M., N. Ford, and H. Schneider, A systematic review of task- shifting for HIV 
treatment and care in Africa. Hum Resour Health, 2010. 8: p. 8. 
42. Fairall, L., et al., Task shifting of antiretroviral treatment from doctors to primary-care nurses in South 
Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet, 2012. 380(9845): p. 
889-98. 
43. Grimsrud, A., et al., Outcomes of a nurse-managed service for stable HIV-positive patients in a large 
South African public sector antiretroviral therapy programme. Trop Med Int Health, 2014. 19(9): 
p. 1029-39. 
44. Kompala, T., et al., Impact of nurse-delivered community-based CD4 services on facilitating pre-ART 
care in rural South Africa. BMC Health Serv Res, 2016. 16(a): p. 374. 
45. Sanne, I., et al., Nurse versus doctor management of HIV-infected patients receiving antiretroviral 
therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet, 2010. 376(9734): p. 33-40. 
46. Harling, G., L.G. Bekker, and R. Wood, Cost of a dedicated ART clinic. S Afr Med J, 2007. 
97(8): p. 593-6. 
47. Bedelu, M., et al., Implementing antiretroviral therapy in rural communities: the Lusikisiki model of 
decentralized HIV/AIDS care. J Infect Dis, 2007. 196 Suppl 3: p. S464-8. 
48. Uebel, K.E., et al., Task shifting and integration of HIV care into primary care in South Africa: the 
development and content of the streamlining tasks and roles to expand treatment and care for HIV 
(STRETCH) intervention. Implement Sci, 2011. 6: p. 86. 
49. Mbeye, N.M., T. Kredo, and C.S. Wiysonge, The effects of shifting tasks from pharmacy to non-
pharmacy personnel for providing antiretroviral therapy to people living with HIV: a systematic review 
protocol. BMJ Open, 2016. 6(3): p. e008195. 
50. King, R.C. and H.N. Fomundam, Remodeling pharmaceutical care in Sub-Saharan Africa (SSA) 
amidst human resources challenges and the HIV/AIDS pandemic. Int J Health Plann Manage, 
2010. 25(1): p. 30-48. 
51. Silveira, M.P.T., et al., Randomized Controlled Trial to Evaluate the Impact of Pharmaceutical Care 
on Therapeutic Success in HIV-Infected Patients in Southern Brazil. AIDS and Behavior, 2014. 
18(1): p. 75-84. 
52. Jaffar, S., et al., Rates of virological failure in patients treated in a home-based versus a facility-based 
HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet, 2009. 
374(9707): p. 2080-9. 
53. Selke, H., et al., Task-shifting of antiretroviral delivery from health care workers to persons living with 
HIV/AIDS: clinical outcomes of a community-based program in Kenya. J Acquir Immune Defic 
Syndr, 2010. 55. 
54. Mbeye, N.M., et al., Shifting tasks from pharmacy to non-pharmacy personnel for providing 
antiretroviral therapy to people living with HIV: a systematic review and meta-analysis. BMJ Open, 
2017. 7(8): p. e015072. 
55. Babigumira, J.B., et al., Cost effectiveness of a pharmacy-only refill program in a large urban 
HIV/AIDS clinic in Uganda. PLoS One, 2011. 6(3): p. e18193. 
56. Magadzire, B.P., B. Marchal, and K. Ward, Improving access to medicines through centralised 
dispensing in the public sector: a case study of the Chronic Dispensing Unit in the Western Cape 
Province, South Africa. BMC Health Services Research, 2015. 15: p. 513. 
57. Hirsch, J.D., et al., Antiretroviral therapy adherence, medication use, and health care costs during 3 
years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with 
HIV/AIDS. J Manag Care Pharm, 2011. 17(3): p. 213-23. 
58. Nachega, J.B., et al., Community-Based Interventions to Improve and Sustain Antiretroviral Therapy 
Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for 
Achieving the UNAIDS 90-90-90 Targets. Curr HIV/AIDS Rep, 2016. 13(5): p. 241-55. 
59. Grimsrud, A., et al., Implementation of community-based adherence clubs for stable antiretroviral 
therapy patients in Cape Town, South Africa. J Int AIDS Soc, 2015. 18: p. 19984. 
60. Masquillier, C., et al., HIV/AIDS Competent Households: Interaction between a Health-Enabling 
Environment and Community-Based Treatment Adherence Support for People Living with 
HIV/AIDS in South Africa. PLoS One, 2016. 11(3): p. e0151379. 
61. Kennedy, C.E., et al., Should trained lay providers perform HIV testing? A systematic review to 
inform World Health Organization guidelines. AIDS Care, 2017. 29(12): p. 1473-1479. 
62. Myer, L., et al., Differentiated models of care for postpartum women on antiretroviral therapy in Cape 
Town, South Africa: a cohort study. J Int AIDS Soc, 2017. 20(Suppl 4): p. 21636. 
63. Tsondai, P.R., et al., High rates of retention and viral suppression in the scale-up of antiretroviral 
therapy adherence clubs in Cape Town, South Africa. J Int AIDS Soc, 2017. 20(Suppl 4): p. 
21649. 
64. Fatti, G., et al., The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral 
treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study 
protocol for a pragmatic, cluster-randomized trial. Trials, 2018. 19(1): p. 79. 
65. Igumbor, J., et al., A South African public-private partnership HIV treatment model: viability and 
success factors. PLoS One, 2014. 9(10): p. e110635. 
66. Farahani, M., et al., Outcomes of the Botswana national HIV/AIDS treatment programme from 
2002 to 2010: a longitudinal analysis. Lancet Glob Health, 2014. 2(1): p. e44-50. 
67. Innes, C., et al., A novel HIV treatment model using private practitioners in South Africa. Sex 
Transm Infect, 2012. 88(2): p. 136-40. 
68. Fatti, G., et al., The effect of patient load on antiretroviral treatment programmatic outcomes at primary 
health care facilities in South Africa: a multicohort study. J Acquir Immune Defic Syndr, 2011. 
58(1): p. e17-9. 
69. Basu, S., et al., Comparative performance of private and public healthcare systems in low- and middle-
income countries: a systematic review. PLoS Med, 2012. 9(6): p. e1001244. 
70. Mayosi, B.M., et al., Health in South Africa: changes and challenges since 2009. The Lancet. 
380(9858): p. 2029-2043. 
71. Bekker, L.G., et al., Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir 
Ther, 2014. 19 Suppl 3: p. 105-16. 
72. Motsoaledi, A., Health Department Budget Vote 2016/17. 2016. 
73. UNAIDS, 90-90-90 An ambitious treatment target to help end AIDS epidemic. 2014. 
74. UNAIDS. Country Overview: South Africa. 2016  [cited 2017 1 December]; Available from: 
http://www.unaids.org/en/regionscountries/countries/southafrica. 
75. UNAIDS, Ending AIDS: progress towards the 90–90–90 targets. 2017, UNAIDS: Geneva. 
76. Miller, C.M., et al., Why are antiretroviral treatment patients lost to follow-up? A qualitative study 
from South Africa. Trop Med Int Health, 2010. 15 Suppl 1: p. 48-54. 
77. Scanlon, M.L. and R.C. Vreeman, Current strategies for improving access and adherence to 
antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl), 2013. 5: p. 1-17. 
78. Gardner, E.M., et al., The spectrum of engagement in HIV care and its relevance to test-and-treat 
strategies for prevention of HIV infection. Clin Infect Dis, 2011. 52(6): p. 793-800. 
79. The White paper on NHI, D.o. Health, Editor. 2017, Department of Health: Pretoria. 
80. Stinnett, A.A. and A.D. Paltiel, Mathematical programming for the efficient allocation of health care 
resources. J Health Econ, 1996. 15(5): p. 641-53. 
 
Chapter 3: Methods and sources of data 
3.1  Overview 
We have included data from three different HIV programmes in the various studies presented in 
this thesis. Public sector cohorts are the main providers of HIV care in LMICs, yet these data 
have several limitations, particularly in relation to analysing detailed costs and/or outcomes. 
Within public sector programmes in South Africa, electronic medical records (EMRs) were 
limited to CD4 count, VL, clinic visits, status and, in some cases, dispensing events [1, 2]. HIV 
care has been standardized to contain costs and conform with the National Department of 
Health (NDoH) guidelines from 2004, inclusive of several pilot studies [3, 4]. Within the private 
sector, substantially more data are available, allowing for more detailed cost and outcome 
analyses where possible. The intention of this chapter, therefore, is to briefly describe these 
cohorts and contextualize them within the broader health care sector in South Africa.  
3.2  General description of cohorts 
3.2.1  Private sector cohort – Aid for AIDS (AfA) 
In many LMICs, the private sector (which includes non-governmental organisations, 
international funders, and independent practitioners) has played a significant role in both health 
financing and health delivery. This was especially the case in the early 2000s when public sector 
programmes were still being piloted in South Africa and other LMICs [5-8]. A recent review 
estimated that 16% of South Africans belonged to a medical scheme in 2014 and a further 21% 
(i.e., 25% of the uninsured) pay “out of pocket” for health care expenses within the private 
sector [9].  
For those who belong to a medical scheme, HIV care has been included within the list of 
medical conditions in Annexure A (along with diabetes, hypertension, etc.) which were classified 
under the prescribed minimum benefit (PMB) clause, Medical Schemes Act 131 of 1198 [10]. 
For PMB conditions, the Act stipulated that medical insurances were required to cover all 
reasonable costs and, therefore, HIV care soon became standard of care in South Africa. In 
terms of the Act, medical insurers were also able to identify a designated service provider (DSP) 
for a specific aspect of care. This is relevant to this thesis as, in later years when courier 
pharmacy dispensers were established, some companies and, later, even the Western Cape 
Department of Health appointed courier pharmacy dispensers as their DSP for ART and chronic 
medication, respectively [11]. A comparison of outcomes and cost of courier versus collect 
pharmacy is presented in Chapter 6. 
AfA is a private sector programme operating in Southern Africa as a comprehensive 
disease management programme that is responsible for the oversight of HIV-related care for 
contracted private medical schemes and companies in the region. The programme has been 
described in several published studies [12-21] and was established in June 1998 [22]. At the time 
of AfA’s establishment, increased HIV-related hospitalization in particular was driving up costs 
within the public and private sectors in South Africa. Many of the patients who presented with 
AIDS did not know their status [23]. A managed-care model was adopted within the AfA 
programme and a pragmatic clinical guideline, aligned with WHO guidelines for resource-limited 
settings, was established, given that both medical scheme financial resources and provider 
knowledge were limited. Over time, the guidelines and approach to care have evolved in 
conjunction with local and international guidelines. AfA has incentivized standardized care 
through a reimbursement model aligned with these guidelines. Moreover, members were able to 
have their blood tests (CD4 count and VL) performed regularly at their initiative at any of the 
private pathology laboratories in South Africa. 
As of August 2015, the programme had enrolled over 200,000 members from nine 
countries, including South Africa, Malawi, Botswana, Zimbabwe, Namibia, Zambia, 
Mozambique, Lesotho, and Swaziland, noting that more than 80% of these had commenced 
ongoing ART while enrolled with AfA. The AfA programme, therefore, represents a significant 
proportion of the population accessing HIV care through the private sector in South Africa. We 
have included data from the AfA cohort in several studies included in this thesis, with varying 
inclusion and exclusion criteria (see “inclusion criteria and censoring” below). We have included 
a cohort profile paper in this thesis as Chapter 4, where we cover the history of the programme 
in more detail than was possible in previous publications [12-21, 24, 25]. In Chapter 5, we 
present a detailed analysis of the changing determinants of costs over time on ART, as well as 
the impact of adherence on costs over time on ART. In Chapter 6, we compare the costs and 
outcomes of courier pharmacy versus collect pharmacy within AfA.  
Key contributions to published literature from this cohort are described in Chapter 4 in 
more detail, and have resulted from the cohort being largely black South Africans, accessing 
WHO-aligned HIV care, high levels of digitalization of HIV-related care with a centralized data 
system, long follow-up compared with other public sector programmes in South Africa, and 
large numbers in HIV care. The use of electronic records within the private health-care sector is 
a key strength when it comes to economic and outcome studies as presented in this thesis. The 
timely authorization of health care expenses within the private sector has been essential, 
especially when identifying the need for co-payment or up-front payment by members. These 
electronic systems have continued to evolve within the South African private sector, often 
outpacing public sector systems. Centralization and standardization of health-related data within 
private sector programmes like AfA have allowed for detailed analyses of large numbers of 
patients for cost analyses (e.g., tariff rate), adherence (using pharmacy refill data), morbidity 
(hospitalization and other clinical events), and mortality [21]. Moreover, the active tracking of 
AfA members across schemes, together with accurate and extensive capturing of South African 
national identity numbers (RSAIDs), is a key benefit when estimating mortality and loss to 
follow-up (LTFU) accurately [26-28]. Studies from South African public sector HIV programmes 
have shown that reported mortality and LTFU are often inaccurate, and linkage with the national 
death registry, while accurate, was only possible for around half of the patients attending public 
sector clinics in these studies [26-28].  
  
3.2.2  Public sector cohort – Khayelitsha  
The Khayelitsha cohort stems from a Médecins Sans Frontières (MSF) pilot study established in 
in 1999 in Khayelitsha, a thriving urban township in Cape Town with a population over 500,000 
persons [29, 30]. Khayelisha started as an Apartheid era dormitory town to house migrant 
workers in the 1980s. The community remains vulnerable given the high levels of 
unemployment, informal housing [30] and the highest HIV prevalence in the Western Cape 
Province [31]. Alarmingly, 34.3% of the pregnant women attending public sector antenatal clinics 
in the area were HIV positive in 2012 [31]. A recent cohort profile publication from 2016 
describes the cohort in significantly more detail [29]. The focus of this section will, therefore, be 
on specifics relevant to the analysis only. The Khayelitsha cohort consists of a prevention of 
mother to child transmission (PMTCT) programme started in 1999. The first patients to be 
enrolled in ongoing ART were from 2001, making it one of the oldest public sector cohorts in 
South Africa and one of several pilot studies internationally. The establishment of EMRs early 
on is important for this study, as the clinic visit and dispensing data could be used to determine 
health care utilization data. In Chapter 8, we present an analysis in which we used these data to 
compare the cost-effectiveness of public and private-public partnerships using GPs. For this 
analysis, the dataset used was part of an existing publication in 2010 [2], together with cost 
estimates from a previous cost-effective study within the same programme in 2006 [32]. 
In the public sector pilot programmes, including Khayelitsha, the initial regimen 
consisted of zidovudine (ZDV) and lamivudine (3TC) together with nevirapine (NVP) or 
efavirenz (EFV). From late 2003, stavudine (d4T) replaced ZDV in the standard first-line 
regimen in late 2003 to align with the proposed South African national programme and 
guidelines [29, 33], which were implemented in April 2004 [34]. Virological failure was used to 
determine treatment failure, unlike in many LMICs [12], and was defined as two consecutive viral 
loads > 5,000 copies/ml. The standard second-line regimen consisted of stavudine (d4T), 
didanosine (ddI) and indinavir. Over time these regimens were altered: from 2008, 
lopinavir/ritonavir (LPV/r) and 3TC replaced indinavir and ddI respectively; from 2010, TDF 
replaced d4T in the first-line regimen; from 2012, FTC replaced 3TC in first line regimen; and 
from 2013, fixed-dose combination ART was introduced. The CD4 count threshold for initiating 
ART was CD4 count < 200 cells/µL until 2010 which was concerning given the significant early 
mortality observed in South African cohorts [35, 36]. The CD4 count and WHO stage 
thresholds for initiating ART was increased in a stepwise manner in keeping with changing 
WHO guidelines for developing countries [37], and eventually dropped in favour of “treat all” 
[38, 39]. 
3.2.3  Public-private partnership cohort – BroadReach 
Various models of HIV care have been implemented in South Africa, including public-private 
partnerships(PPPs). In a recent review [5], the authors refer to a form of “public-private 
engagement” (PPE); given the diversity of models that have been implemented for HIV care in 
South Africa and other LMICs, they felt that PPE better represented the need to focus on health 
financing and delivery rather than on who is providing the care. Nevertheless, given the history 
of disenfranchisement in South Africa, many remain concerned that an unintegrated private 
sector results in more harm than good as it silos resources for more affluent individuals [9]. In 
the proposed 2017 White Paper for NHI for South Africa, all providers will be integrated 
through a central payment system and free access to healthcare services would be provided 
through accredited health facilities (i.e., clinics, hospitals, and private health practitioners) [40]. 
The model evaluated in the above review is very relevant as it falls within the proposed 
parameters for NHI (i.e., harnessing private/independent practitioners to provide care for public 
sector patients) and therefore contributed significantly to the literature. 
In Chapter 8, we presented an analysis in which we compared the cost-effectiveness of 
public and private-public partnership using GPs. The BroadReach or PPP cohort stems from a 
BroadReach health care initiative funded by PEPFAR, where public sector patients from public 
sector clinics were enrolled in a programme in which HIV care was provided by private GPs in 
the community, ART medication was provided by the state, and laboratory tests were undertaken 
by private laboratories. The GPs were supported by AfA clinical support structures and included 
physicians, pharmacists, and counsellors. Where complications arose requiring further work-up 
at specialized clinics or hospitals, the patients were referred to secondary and tertiary state 
facilities within their areas. 
3.3  Study design 
The studies included in this thesis are all longitudinal. Individuals who started ART within the 
AfA, BroadReach, and Khayelitsha programmes were prospectively enrolled.  
3.4  Definitions 
ART initiation 
For the analyses in this thesis, ART initiation was defined as the date on which ongoing ART 
was first dispensed. While dispensing data were not generally available within the public sector 
programmes in LMICs, including South Africa, they were available within all the cohorts 
included in this thesis. 
LTFU 
The way loss to follow-up is accounted for in HIV cohort analyses can substantially impact the 
findings [41, 42]. Various definitions of LTFU have been proposed within the literature with 
varying timeframes and data requirements (clinic visit versus dispensing events). Thus, we 
proceeded with the following standardized definition of LTFU to ensure comparability between 
the various cohorts and other programmes: a patient has “run out” of the recorded dispensed 
antiretroviral drugs (ARVs) for at least 6 months (i.e., 7 months or 7 x 28 days from last 
dispensed date). 
Death 
The availability in South Africa of an efficient national vital registration system is an important 
resource within cohort studies as it allows for the correction of under-ascertainment of mortality 
observed in cohort studies (usually misclassified as LTFU) [2, 26, 28, 43]. The process required 
linkage to the South African death registry to ascertain deaths and dates of death using RSAIDs 
and was facilitated by the South African Medical Research Council (MRC). Reported deaths 
within cohorts studies from LMICs have been shown to be inaccurate and difficult to distinguish 
from LTFU [2, 26-28, 43]. A previous study using the Khayelitsha cohort dataset found that 
between 90% and 95% of known deaths could be identified using RSAIDs to link with the death 
registry [2]. We repeated this in Chapter 4 and found similar results when looking at the broader 
medical scheme population. 
3.5  Inclusion criteria, exclusion criteria, and censoring 
The following inclusion criteria were applied across all studies (Chapters 5–8) to ensure our 
findings would be more generalizable (i.e., aligned with WHO guidelines for resource-
limited settings): 
 Adult: 19 years or older when first dispensed ongoing ART, i.e., excluding PMTCT 
 Initiated first line therapy: A dispensing event including NNRTI together with two NRTIs 
 Baseline: CD4 count < 200 cells/µL or AIDS-defining illness or WHO stage III/IV 
illness 
Regarding the specific studies, the following additional criteria were applied or relaxed: 
 Chapter 4: We included all members who enrolled before 30 August 2015. The purpose 
of this analysis was to describe the programme and members it has served since its 
inception in 1998. 
 Chapters 5 and 7: We included members from the AfA cohort who were enrolled in 
two of the medical schemes and initiated (first dispensed) ongoing combination ART 
between November 1998 and November 2007. The chosen schemes were South 
African medical schemes, with large numbers of patients and similar treatment 
benefits, requiring no co-payment for ART. This was important as the goal was to 
describe costs and drivers of costs without relation to patients’ ability to pay, which 
has been reported to influence outcomes on ART in LMICs [44]. 
 Chapter 6: We included members from the same schemes in Chapters 5 and 7, who 
enrolled between January 2002 and July 2010. 
3.6  Cost data 
Health care costs were analysed from the healthcare sector’s perspective, i.e., direct costs. 
Indirect costs and direct non health care costs, while often significant in South Africa and 
other similar settings [45], were not accounted for in the analyses presented in this thesis.  
Sources of data 
For the AfA and BroadReach cohorts, health care claims were captured centrally by 
Medscheme and BroadReach Healthcare, the administrators responsible for authorizing, receiving, 
and reimbursing medical claims related to HIV care. In most cases, the providers submitted the 
claims directly and, therefore, patients could access care without any upfront costs. For the 
Khayelitsha data, the utilization (clinic visits, ART dispensing, CD4 count and VL 
monitoring) was recorded at the time of the visit on a centralized computer system 
established for the clinic, which has subsequently been expanded [46]. 
Scope of data for AfA cohort analyses 
For the AfA cohort analyses (Chapters 4, 5, 6, and 7), we included all direct medical costs 
submitted to the medical scheme. These include health care practitioner visits, medication 
dispensed (acute, chronic), hospitalization costs (medication, surgical, accommodation, 
health care practitioner) and other outpatient procedure costs (medication, surgical, 
accommodation, health care practitioner). The tariff amount (which is the amount agreed to 
on an annual basis following negotiations between private health care providers and 
funders) was used in most cases as a proxy for direct health care costs, as opposed to the 
amount charged by the provider or the amount reimbursed to the patient. In Chapter 5, over 
49,517 unique claim categories were identified. Of these, 4,000 accounted for over 95% of 
total costs and these were grouped into the following categories:  
 ART medication 
 other medication 
 maternity-related care (antenatal services, delivery, caesarean section, and post-
delivery paediatric care)  
 GP care 
 specialist care 
 hospital accommodation and procedures 
 CD4 count and VL monitoring 
 other investigations (e.g., laboratory tests and radiology) 
  
Scope of data for Khayelitsha and BroadReach analyses 
For the analysis in Chapter 8, we included all costs related to the direct provision of ART. 
This included antiretroviral drugs (ARVs), CD4 count and VL monitoring, other laboratory 
monitoring (e.g., alanine transferase, lipogram, creatinine, full blood count) and clinic visits. 
The net costs were determined by multiplying the utilization by the cost price for all items.  
For both cohorts, we were provided with actual utilization data for ARVs, CD4 
count and VL monitoring, and clinic visits. We estimated the other laboratory monitoring 
from the guidelines, which was reasonable as most of these costs were incurred when the 
patient first started ART.  
We estimated the costs differently for each cohort. For the clinic visits in the 
Khayelitsha cohort, we inflated the estimated costs from a recently published bottom-up 
analysis within the same programme [32]. For the GP visits in the BroadReach cohort, we 
were provided with the actual reimbursed rate for a GP visit by the administrator. ARV and 
laboratory monitoring costs were determined from the government tender rate at the time 
of the visit.  
Adjustments 
The prices of antiretroviral drugs had fallen dramatically over the period of the studies in 
Chapters 5, 7, and 8. To account for this decrease, we deflated ARV drug prices prior to the 
April 2007 level to 2011 drug prices. All other health care costs have increased; these were 
inflated to the April 2007 level using the consumer price index net of mortgage payments 
(CPIX) [47]. The average ZAR to USD exchange rate in April 2007 (ZAR 7.14 to USD 1) was 
used to convert costs to USD equivalents [48]. 
3.7  Ethics 
The study was approved by the Research Ethics Committee, University of Cape Town, on 
the basis that it was a retrospective cohort analysis and all patient-level identifiers were 
removed in the data extraction process. The approval for 2017 is included in Appendix 1. 
Concerning the AfA data (including BroadReach data), the study was approved by 
the Board of Directors of AfA and by BroadReach. All patients within AfA signed consent 
for their information to be captured in the AfA clinical management database and for 
anonymized extracts to be used for research studies to drive improvements in patient care. 
A specific application was sought for the cohort registration. The approval for 2015–2018 
and the AfA registration form, which was included in the ethics application, are included in 
Appendix 2. 
Concerning the death register, an addendum was sought that granted permission to 
link with a copy of the national death register managed by the regional Medical Research 
Council’s offices in Cape Town. The approval from 2017 is included in Appendix 1. 
3.8  Conclusions 
In summary, the various cohorts included in the analyses of this thesis would be considered to 
be a fair representation of different types of programmes in South Africa. Key strengths of the 
AfA cohort are described in Chapter 4 in more detail, and have resulted from the cohort being 
largely black South Africans, accessing WHO-aligned HIV care, high levels of digitalization of 
HIV-related care with a centralized data system, long follow-up compared with other public 
sector programmes in South Africa, and large numbers in HIV care. The key strengths of the 
Khayelitsha cohort are described briefly in Chapter 8 and comprehensively in a recent cohort 
profile paper [29], and include long duration of follow-up (the pilot study was started in the early 
2000s), capturing of visits (dispensing, laboratory tests, and clinic visits) electronically, and the 
adequate recording (50%) of RSAIDs, from which status death and LTFU rates could be 
estimated. Key strengths of the BroadReach cohort are described briefly in Chapter 9, where it is 
noted that it was a PPP in which ART was initiated (rather than a down-referral), that providers 
were independent general practitioners within communities, the patients were recruited from 
public sector clinics, the patients remained integrated within the public sector system (for 
hospital admissions or complications), and it involved an independent programme 
administration to facilitate the care. 
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Chapter 4: Cohort profile: Adults within Aid for AIDS (AfA) 
antiretroviral programme, South Africa 
4.1  Overview 
The intention of this chapter is to provide an overview of the AfA cohort – a cohort profile. 
This chapter is presented in the style of other cohort profile papers published in the International 
Journal of Epidemiology. 
4.2  Why was the cohort established?  
AfA was established in June 1998 as a comprehensive disease management programme, 
responsible for the oversight of HIV care for contracted private medical schemes, companies, and 
PPPs in Southern Africa (South Africa, Malawi, Botswana, Zimbabwe, Namibia, Zambia, 
Mozambique, Lesotho, and Swaziland) [1]. The surge in HIV/AIDS-related morbidity and 
mortality at the time meant that facilities and budgets within the public and private sectors were 
taking significant strain [1-3]. Emerging evidence from high income country (HIC) settings 
suggested that ART, while costly, would be effective in reversing disease progression, reducing 
morbidity, and improving patient survival [4]. ART, therefore, was desperately needed in LMICs 
[5]. Moreover, a reduction in HIV related morbidity and mortality had potential social and financial 
benefits that would supercede the absolute costs of ART [5]. 
Regarding the public sector,  HIV care including ART was initially only available through 
a few pilot programmes in South Africa [6, 7],  i.e., PMTCT from 1999 and ART from 2001 [8]. 
The eligibility criteria for ongoing ART was conservative: baseline CD4 count < 200 cells/µl or 
WHO stage IV conditions other than extra-pulmonary tuberculosis. At the time, an estimated 
1,600 new infections were occurring daily, with nearly 90% of infected individuals being unaware 
of their status, resulting in late presentation [4]. Given that South Africa was still an emerging 
democracy with significant hurdles to overcome, especially within the fragmented health care 
sector, private sector and workplace HIV programmes soon overtook public sector initiatives [2, 
9]. For those with private health insurance, the 1998 implementation of the Medical Schemes Act 
ensured that several chronic illnesses and emergency care were classified as PMBs [10]. AfA 
implemented a managed care approach with conservative treatment guidelines, outcome 
monitoring, patient counselling, and clinical support for providers. Numbers registering with 
AfA soon swelled [2]. In essence, the AfA programme was aligned with the public health 
approach to HIV care, which was later advocated by WHO for resource-limited settings [11].  
4.3  Which cohorts contribute to the managed-care programme? 
The population accessing care through the AfA programme included closed (company or 
government) and open schemes, along with PPPs within Southern Africa. Recruitment was 
continuous and voluntary; members were able to access HIV-related care without being 
registered with AfA, using personal funds or medical insurance fund savings, but reimbursement 
of HIV related expenses was subject to registration with AfA and authorization by AfA staff. 
Some flexibility was allowed where patients presented late and were started in a hospital or 
around a hospitalization event. Patients completed an enrollment form with their treating 
medical practitioner and gave consent for prospective studies to improve patient care. 
4.4  What data were collected? 
Data were collected prospectively. Patient-level data included sex, date of birth, family structure, 
and region. Identifiers (names, addresses, family units, and policy numbers), physical address, 
and RSAID number (for principal members only in the earlier years) were available within 
patient information systems held by the medical fund and its administrator and shared with AfA 
to avoid duplication errors. AfA captured additional RSAID numbers from the registration form.  
Clinical events, including events before registration with AfA, were captured within the 
same central system and made available to the clinicians and pharmacists. They included events 
such as WHO stage-defining illnesses, pregnancy, tuberculosis, and others which would have 
impacted outcomes or HIV care. ART exposure and HIV-related laboratory monitoring results, 
including before registration with AfA, were captured within the same central system.  
Laboratory tests included CD4 count, VL, full blood count, cholesterol, genotypic 
antiretroviral resistance testing (GART), and liver and renal function tests. Increasing digitization 
has helped improve ascertainment of laboratory results and, over time, nearly all laboratories 
were allowing digital laboratory result transfers on a monthly basis. Moreover, AfA established a 
system allowing patients to do the laboratory monitoring tests themselves (e.g., 6-monthly CD4 
count and VL tests) to improve monitoring.  
Detailed information on HIV-related medication was collected and included prior 
antiretroviral exposure and context (PMTCT, PrEP, PEP, and/or ongoing), authorization within 
AfA and context, dispensed medication with date, quantity, dose and methodology (collect or 
courier pharmacy). Before 2002, combination ART was not available to all members across all 
schemes due to the high costs of ARVs and VL tests. Some patients elected to privately purchase 
a third drug and, therefore, knowledge around the exact regimen those members were on was 
uncertain. From 2002, combination ART was available universally without co-payment across all 
schemes. ART-related toxicities or adverse events which may have impacted either the choice of 
ARVs or required authorization for additional medication were also captured. 
4.5  Who enrolled and what protocols were applied? 
The first patients enrolled with AfA in 1998. Membership swelled rapidly in the first few years 
and again with the establishment of the Government Employment Medical Scheme (GEMS) for 
public servants in 2005. By 2009, GEMS was the second largest private medical scheme in South 
Africa, providing for over a million public servants in South Africa, many of whom had not been 
eligible for private medical insurance before its formation [12]. By 31 August 2015, more than 
180,000 PLWH had been authorized for ongoing ART, and over 40,000 had enrolled with AfA, 
though they had not yet initiated ongoing ART. 
Table 4.1: Characteristics of patients initiating ART, 1998–2015 
 
4.6  Clinical and other support 
All scheme members received ongoing HIV education via their respective medical schemes. 
Additionally, any member who tested positive for HIV was encouraged to register with AfA. 
Medical doctors who registered with AfA and support staff received ongoing communication 
through newsletters, updated clinical guidelines (more recently through a mobile app as well), 
access to continuous medical education (CME) via online learning modules and regular clinical 
meetings. The clinical guidelines were developed by the AfA Clinical Advisory Committee in 
conjunction with the academic and private sector collaborators.  
An important intention of the AfA programme was to identify and capture clinical events 
relevant to the care of an HIV positive person. These events would “unlock” benefits (e.g., 
Bactrim prophylactic antibiotics for CD4 count < 200 cells/µL). The effectiveness was therefore 
dependent on private doctors and patients informing AfA staff, and thereby enabling 
authorization for event-related expenses related to benefits. Clinical and claims data were used to 
support patient-level decisions on programme outcome monitoring. 
In summary, AfA did not manage clinics but reimbursed patients’ HIV related expenses 
either directly or, where the member had already paid, with a refund. If members had depleted 
their general medical funds, AfA would authorize up to two additional visits to the doctor 
registered with AfA for providing their annual  HIV related care to ensure continuity of care. 
Most patients accessed private practice and hospital services within their regions, although there 
were some specialist HIV practices.  
4.7  Eligibility for ART 
At the time of the formation of the AfA programme, internationally accepted guidelines were 
already recommending that ART is started when CD4 count dropped below 500 cells/µl with 
the “hit early hard” approach [13]. Financial constraints within an LMIC setting meant that ART 
was not affordable if started too soon[1] and, furthermore, the benefit for an asymptomatic 
patient starting ART that early was unclear within the literature at the time [2]. Therefore, the 
CD4 count threshold for initiating ART was set at ≤ 350 cells/µl (two occasions, 6 to 12 weeks 
apart) and an AIDS defining illness or WHO stage III/IV illness was also included in the criteria 
for being eligible for ART.  
AfA’s threshold was less conservative than the subsequent 2003 WHO guidelines for 
resource-limited settings broadly adopted in LMICs [11] and the subsequent 2004 South African 
National Department of Health (NDoH) [14]: CD4 count ≤ 200 cells/µl or a WHO stage IV or 
AIDS defining illness. Moreover, eligibility for ART in discordant couples was already allowed 
before it became WHO or NDoH policy to promote supportive environments. Soon afterwards, 
the evidence for treating at higher CD4 counts was established [15, 16] and the threshold in the 
WHO guidelines [17, 18] and NDoH guidelines [19] changed. From 2014, the CD4 count 
threshold for ART in AfA was formally moved to < 500 cells/µl (or any staging illness [20]), and 
from 2015 the threshold was formally abandoned completely [21]; where patients had requested 
to start at a higher CD4 count, a similar incremental approach of increasing CD4 count and 
decreasing stage was echoed within WHO and NDoH guidelines. The impact of changing CD4 
count threshold and earlier initiation of ART over time is shown in Figure 4.1 below. 
 
Figure 4.1. Median baseline CD4+ cell count time by calendar year, indicating changes in AfA 
(and public sector) CD4+ threshold over time. 
4.8  ART regimens 
At the launch of the AfA programme in 1998, the internationally accepted guidelines promoted 
triple therapy or combination ART in any patient with a CD4 count < 500 cells/µl. Given the 
high costs of drugs (PI with 2 NNRTIs) and monitoring, this was not affordable even within the 
private sector schemes in South Africa [1, 22]. AfA, therefore, recommended levels of cover be 
established within medical schemes: PMTCT (level 1) with either dual therapy (level 2) or triple 
therapy (level 3) [1, 2]. Initially, they focused on rolling out level 1 without co-payment and, by 
2002, nearly all schemes were covering triple therapy without co-payment while NDoH 
negotiations with pharmacies had resulted in a reduction in dispensing fees. Additionally, 
international pressure had ensured reduced drug costs through access pricing for LMICs [5].  
As NNTIs became widely available from the 2000s, the recommended initial regimen for 
LMICs including AfA evolved to a combination of two nucleoside reverse transcriptase 
inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) for individuals 
and medical schemes that could afford them. AfA guidelines, however, continued to allow for 
more flexibility in terms of initial regimen – both NNRTI- and PI-containing regimens were 




































those patients on rifampicin for tuberculosis; nevirapine (NVP)-containing therapy was 
recommended for women of childbearing potential who did not commit to using two reliable 
methods of contraception initially (e.g., condoms and hormonal contraceptives) due to concerns 
about the risk of teratogenicity with efavirenz [23]. In keeping with other pilot ART programmes 
in South Africa [6, 24], AfA recommended AZT+3TC as the preferred initial NNRTI backbone; 
many of the public pilot studies later switched to d4T+3TC to align with the first NDoH 
guidelines in 2004. The preferred NNRTI backbone soon switched to TDF+FTC/3TC and the 
use of NVP in women was soon dropped as studies from observation cohorts did not provide 
evidence for EFV causing harm during pregnancy [21]. The changes to the dispensed first line 
regimens by calendar year are shown in Figure 4.2 below. 
 
Figure 4.2: Changing composition of first line therapy by calendar year 
 As NNRTs became available, the recommended second line therapy became a PI 
(later boosted PI) with two NRTIs. Up to 10% of patients in the early phase of the programme 






















the WHO approach grew. Furthermore, ritonavir-boosted saquinavir, indinavir, or lopinavir 
were all initially available as PIs. Ritonavir-boosted lopinavir soon replaced other PIs due to its 
superior effectiveness and tolerability.  
Third line or salvage regimens have been made available since 2007 to patients failing 
second line therapy and consist of either darunavir/ritonavir-, tipranavir/ritonavir-, raltegravir-, 
or etravirine-containing regimens. After an intensive adherence to counselling, those with a 
repeat 3-month VL > 1,000 copies/ml and a history of a possible infection with a resistant strain 
(e.g. from partner) were offered a genotype antiretroviral resistance test (GART); at least one 
major PI mutation was necessary, with regimens individualized on the basis of GART results. 
Patients were then contacted by AfA clinical staff before being switched to assess commitment 
to educating them about the new regimen. After that, adherence support through monthly 
telephonic counselling was implemented until the VL was suppressed. The outcomes were 
encouraging as shown in the recent publication: 82.9% had a VL ≤400 copies/ml and the 
Kaplan-Meir estimate for survival at 2000 days was 87% [25]. The relative proportion of 
exposure per regimen line over time is shown in Figure 4.3 below. 
 
Figure 4.3: Regimen exposure per calendar year in adults, 1998–2015. 
Drugs are collected monthly from private pharmacies (collect pharmacy). As courier 
pharmacy became available, patients increasingly switched to courier pharmacy. Some medical 
aids appointed a courier pharmacy as the preferred supplier as their large purchasing power 
lowered the medical costs for the scheme; patients could still collect medication from their local 
pharmacy but would have to make a co-payment. Others offered both alternatives.  
In summary, the AfA guidelines have allowed for more individual choices regarding the 
regimens and monitoring frequency and intensity than is typically found in LMIC settings. 
However, a public sector approach was strongly influential given the resource-constrained 
context of South Africa. In general, the recommended regimens have, over time, more closely 
resembled WHO guidelines for LMIC settings [26] and South African guidelines [27] than HIC 
guidelines [28-31]. 
4.9  Prophylactic antibiotics, laboratory, and other monitoring 
The AfA clinical guidelines defined which aspects of care related to HIV treatment would be 
covered over time; certain laboratory tests were subject to review and approval by AfA clinical 
staff to ensure that costs were reimbursed. Important baseline investigations, apart from CD4 
count and VL (quantitative PCR), included: full blood count (FBC) and differential count (diff), 
Pap smear, alanine transferase (ALT), Mantoux (tuberculin skin test), syphilis serology, serum 
creatinine (Cr) and estimated glomerular filtration rate (eGFR), hepatitis B surface antigen, 
hepatitis C surface antigen (if ALT is elevated), pregnancy test, urine dipstick (proteinuria), 
serum cryptococcal antigen test, and chest x-ray results. 
Nutritional support was not routine [32] but AfA later recommended a multivitamin and 
Vitamin BCo [33]. Prophylaxis included pneumococcal vaccine repeated every 5 years initially 
[34], though this was found later to be controversial and after that reserved for individuals who 
had had a splenectomy or a chronic lung disease [32]. Annual influenza was recommended as 
well as Hepatitis B immunization for antibody negative members. Cotrimoxazole/dapsone 
prophylaxis was recommended for those with a CD4 < 200 cells/µl, which was only stopped 
once the CD4 count was consistently > 250 cells/µl for at least 6 months (version 1), thereafter 
> 200 cells/µl. Given that tuberculosis was endemic in South Africa, isoniazid (INH) 
prophylaxis was initially recommended for 6 months in patients who had a Mantoux test, which 
was positive [34], then later for those who had had recent contact with open tuberculosis [32] 
and those at risk (e.g., miners) [33].  
CD4 count and VL monitoring can be done 2–3 months after starting ART and after 
that every 4–6 months [34]. This was aligned with the adopted 2003 WHO [11] and 2004 NDoH 
[14] guidelines. The recent shift towards more targeted CD4 count monitoring (only while CD4 
count < 200 cells/µl or while failing virologically (VL > 1,000 copies/ml) is in keeping with HIC 
guidelines [28], and is broadly reflected in both the 2016 WHO [35] and 2015 NDoH [27] 
guidelines. Both NDoH and WHO guidelines, however, also advocated for more targeted VL 
monitoring, which is not reflected in the AfA guidelines. 
4.10  Adherence and medical support 
Given concerns around confidentiality and the complexity of HIV care, a dedicated unit was 
established from the beginning to provide patients, doctors, pharmacists, and hospitals with a 
centralized management and communication portal [1]. For patients, telephonic counselling, 
pharmacist (and specialist) services were provided by AfA on a demand basis. This was 
particularly relevant when salvage therapy was introduced as all patients received intensive 
counselling before commencing treatment [25]. 
For medical staff, reimbursement was subject to authorization by AfA clinical staff; 
decisions to start/alter regimens or HIV related medications (e.g., antibiotics) were therefore 
communicated toAfA clinical staff and authorization established before prescribing. More 
complex decisions (e.g., salvage therapy regimens) were referred to weekly clinical expert 
meetings, where additional input from academic staff and professional 
organizations/associations was available. 
4.11 Transfer in 
Some patients transferred from other schemes or public sector ART programmes (especially in 
later years). Excluding these patients from analyses proved difficult as the baseline VL data and 
baseline questionnaire data, which asked for details on previous ART exposure, proved only 
partially informative [36].  
4.12 What has been measured? 
4.12.1  Clinical outcomes 
Extensive data are available for patients enrolled in the AfA programme. Patients complete the 
registration form (usually with their doctor) at enrollment. This information, which includes 
demographics, prior medication and illness, and HIV-related information (ART exposure, AIDS 
defining or WHO stage illness, CD4 count, and VL monitoring results) is captured digitally and 
presented to the medical team for review for authorization. The medical scheme provides 
information on hospitalization and other outpatient events, including medication dispensed. 
Initially, pathology results were captured manually, but over time links have been established 
with private pathology laboratories to facilitate electronic medical records transfers instead. 
Specific events are tracked over time that may impact HIV care and include pregnancies, 
infections (meningitis, tuberculosis), and adverse drug reactions.  
4.12.2  Mortality ascertainment 
During follow-up, deaths were communicated to AfA by the attending medical practitioner, 
hospital case manager (for in-hospital deaths), medical fund administrator, medical scheme, and 
designated treatments. Other studies from the South African public sector have reported that 
administrator deaths substantially underestimated true deaths when compared with deaths 
ascertained through linkage with the vital registry [37] and between 90% and 95% of known 
deaths have been shown to be identified by the registry [38]. AfA had collected significantly 
more RSAID numbers (as part of the registration process) than either the scheme administrator 
or scheme itself, particularly for non-principal members; reported mortality ascertainment 
improved over time. Most missed deaths were misclassified as censored – i.e., as having left the 
medical scheme. Furthermore, determining mortality from RSAIDs allowed for an improvement 
in LTFU status ascertainment as well [37-40]. 
  
Figure 4.4: Trends in missing RSAID numbers and mortality rates within large medical scheme 
subsets (all lives), illustrating the deaths known to the scheme versus deaths ascertained via the 
RSAID linkage to the South Africa National Death Register 
4.12.3 Loss to follow-up (LTFU) 
The manner in which LTFU is incorporated into HIV cohort analyses can substantially impact 
findings on programme effectiveness [41, 42]. Many studies defined LTFU in a similar manner to 
death, as a terminal state [38], yet many patients were subsequently found to return to care. 
Furthermore, while many studies classify members as being LTFU once they have left the 
programme, many of these may have been seeking treatment elsewhere [43]. Finally, courier 
pharmacy, where medicine is delivered on a regular basis to the member's designated location, 
has been implemented broadly within the private sector (usually the patient’s home). More 
recently, courier pharmacy has been implemented in the public sector (home or community 
adherence clubs) in South Africa [44]. Determining whether members have received their 
medication, especially in the case of adherence clubs, has proved to be logistically challenging. 
  
Most studies have treated LTFU as an alternative state to alive or dead for patients who 
have started ART [45], without taking into account whether the patient is adherent to ART or 
not. With the increasing availability of digital dispensing systems, particularly within the private 
sector as dispensing events generated claims, we defined LTFU in our setting as not having 
received antiretroviral (ARV) medication for 6 months while alive. Given the incentive of 
suppliers to report dispensing events to get paid, and the low barrier for members with no co-
payment for HIV related care and the convenience of using a local private sector doctor, we 
anticipated that this is a more accurate representation of LTFU numbers than in most settings.  
4.12.4  Costs/utilization 
The availability of claims data is unique within the South African context. In previous 
analyses [46, 47], we found 49,517 unique claim categories within the scheme administrators 
database, of which 4,000 accounted for over 95% of total costs and were grouped as follows: 
ARVs, other medication, maternity-related care (antenatal services, delivery, caesarean 
section, and postdelivery paediatric care), general practitioner care, specialist care, hospital 
accommodation and procedures, CD4 count and VL monitoring, and other investigations 
(e.g., laboratory tests and radiology).  
4.13  Conclusions 
AfA is one of the larger cohorts in South Africa, with substantial follow-up on ART at higher 
baseline CD4 counts. The extensive digitization of health systems within the private sector is a 
distinct advantage for analysts, patients, and providers. Each claim contained information about 
the service date, specific medication or care received (and quantity supplied for a drug), thus 
allowing for costs to be determined down to a granular level. The National Strategic Plan on 
HIV, STIs, and TB (2002–2016) [48] highlighted the importance of a unique health sector 
identifier while the increasing reliance on RSAIDs to uniquely identify patients allows for the 
accurate ascertainment of LTFU and death. 
  
4.14  Can I get hold of the data?  
The cohort dataset is curated by the Center for Infectious Disease at the University of 
Stellenbosch and the Division of Clinical Pharmacology at the University of Cape Town. The 
analyses are produced in collaboration with AfA and its various partners (e.g., medical schemes, 
suppliers). Going forward, the cohort will contribute to collaborative analyses, including the 
International Epidemiological Databases to Evaluate AIDS (IeDEA) Southern Africa 
collaboration. For these analyses, the data were stripped of all identifiers. Patient consent was 
sought at registration with AfA, and all data were considered routinely collected data as part of 
standard-of-care service provision with HIV. Approval to perform routine data analysis has been 
granted by the Human Research Ethics Committee at the University of Cape Town. Requests 
for external collaboration are welcomed, and decisions about participation in analyses and the 
sharing of data are taken jointly by the collaborators on the cohort study. Enquiries related to 
data access or collaborative studies should be directed to the principal investigators 
[mcot@sun.ac.za and gary.maartens@uct.ac.za]. 
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Abstract
Background: There is a paucity of data on the health care costs of antiretroviral therapy (ART) programmes in Africa. Our
objectives were to describe the direct heath care costs and establish the cost drivers over time in an HIV managed care
programme in Southern Africa.
Methods/Findings: We analysed the direct costs of treating HIV-infected adults enrolled in the managed care programme
from 3 years before starting non-nucleoside reverse transcriptase inhibitor-based ART up to 5 years afterwards. The CD4 cell
count criterion for starting ART was ,350 cells/ml. We explored associations between variables and mean total costs over
time using a generalised linear model with a log-link function and a gamma distribution. Our cohort consisted of 10,735
patients (59.4% women) with 594,497 mo of follow up data (50.9% of months on ART). Median baseline CD4+ cell count and
viral load were 125 cells/ml and 5.16 log10 copies/ml respectively. There was a peak in costs in the period around ART
initiation (from 4 mo before until 4 mo after starting ART) driven largely by hospitalisation, following which costs plateaued
for 5 years. The variables associated with changes in mean total costs varied with time. Key early associations with higher
costs were low baseline CD4+ cell count, high baseline HIV viral load, and shorter duration in HIV care prior to starting ART;
whilst later associations with higher costs were lower ART adherence, switching to protease inhibitor-based ART, and
starting ART at an older age.
Conclusions: Drivers of mean total costs changed considerably over time. Starting ART at higher CD4 counts or longer pre-
ART care should reduce early costs. Monitoring ART adherence and interventions to improve it should reduce later costs.
Cost models of ART should take into account these time-dependent cost drivers, and include costs before starting ART.
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Introduction
Access to combination antiretroviral therapy (ART) is rapidly
expanding in resource-limited settings. Data on the costs of
providing HIV health care and how these change over time are
important for guiding resource allocation. However, there are few
good quality studies of the direct health care costs of HIV
infection, as illustrated by a recent systematic review that found
only nine studies from the ART era that fulfilled inclusion criteria
[1]. Data on costs prior to starting ART are limited as most cost
studies only report costs once ART has been commenced. A
recent South African study reported that health care costs were
almost twice as high in the first year on ART in comparison with
the second year [2]. However, the sample size was small, patients
had advanced disease, follow up was relatively short, and the
period of higher costs in the first year on ART was not defined.
Delays in establishing public ART programmes in South Africa
until 2003 [3], together with studies highlighting the detrimental
effects of HIV in the workplace [4], resulted in the scaling up of
access to ART through private medical insurance funds from as
early as 1998 [5]. Given the level of need for improved access to
ART in South Africa, which has the world’s largest number of HIV-
infected people [6], the government has identified partnerships with
the private sector as a key mechanism for enhancing access [7]. In
the private sector, starting ART is encouraged earlier than current
WHO guidelines for resource-limited settings [8], thus enabling
exploration of the cost implications of starting ART earlier.
The objective of this study was to explore health care costs in a
South African private sector HIV/AIDS programme, with a
special focus on the determinants of costs around the period of




The study was approved by the Research Ethics Committee,
University of Cape Town and by the Board of Directors of Aid for
AIDS (AfA). Informed consent was not required as the data were
analyzed anonymously, but all patients signed consent for their
information to be entered into the AfA database.
Data Source
Data for this study were extracted from a database of patients
enrolled with AfA, a group that manages HIV-related care for a
number of medical insurance funds and companies in the private
sector in Southern Africa [9]. Registration of eligible patients with
AfA is done by the private doctor looking after the individual
patient (i.e., there are no clinics, but some private doctors run
exclusive HIV practices). Demographic data, CD4+ cell count,
viral load, and previous ART history is captured centrally. Patients
are managed according to a clinical guideline and any decision to
start ART, change ART regimen, and treat certain opportunistic
infections is subject to review and approval by AfA clinical staff.
The antiretroviral guidelines are similar in many respects to WHO
guidelines for resource-poor settings [8] and the South African
public sector programmes, but ART is initiated earlier and there is
room for choice of individual antiretroviral drugs. For example
several ritonavir-boosted protease inhibitors (PIs) are available
rather than the single one available in the South African public
sector. ART can be initiated at CD4+ cell counts ,350 cells/ml
rather than ,200 cells/ml in the South African public sector, but
similar to WHO guidelines that recommend initiation with CD4+
cell counts ,350 cells/ml with symptomatic disease. The recom-
mended initial regimen is a combination of two nucleoside reverse
transcriptase inhibitors (NRTIs) and a non-nucleoside reverse
transcriptase inhibitor (NNRTI). Second line therapy consists of a
boosted PI with two NRTIs. CD4+ cell counts and viral loads are
monitored 6 monthly. There is a telephonic counselling service
provided by AfA, although counselling is not routine but done on
demand. Drugs are collected monthly from private pharmacies.
Inclusion Criteria
Two of the medical insurance funds contracted to AfA were
selected on the grounds that they had large numbers of patients,
similar treatment benefits, and required no co-payment for ART.
This selection allowed us to describe costs and drivers of costs
without relating to the patient’s ability to pay, which has been
reported to influence outcomes on ART [10–12]. Patients were
included in the study if they were ART naı̈ve at entry (women who
had received prophylaxis for prevention of mother-to-child
transmission were not excluded); adult (19 y or older at the time
of approval for ART); and if ART was started between November
1998 and November 2007. Patients were excluded if they had
missing cost data over the entire period. To make our findings
more generalisable, we only included patients starting ART with
an NNRTI plus two NRTIs, as recommended by the WHO for
resource-limited settings [8].
Cost Data
Direct health care costs were analysed from the provider’s
perspective [13], and indirect costs were not assessed. Submitted
health care claims were captured into a central database. The tariff
amount (which is the amount agreed to annually following
negotiations between private healthcare providers and funders)
was used as a proxy for direct health care costs, as opposed to the
amount charged by the provider or the amount reimbursed to the
patient. Of the 49,517 unique claim categories in the AfA
database, 4,000 accounted for over 95% of total costs. These 4,000
claim categories were grouped into the following categories: ART,
other medication, maternity-related care (antenatal services,
delivery, caesarean section, and postdelivery paediatric care),
general practitioner care, specialist care, hospital accommodation
and procedures, CD4+ cell count and viral load monitoring, other
investigations (e.g., laboratory tests and radiology).
The prices of antiretroviral drugs have fallen dramatically over
the period of our study. To account for this decrease we deflated
ART prices to the April 2007 level. All other health care costs have
increased; these were inflated to the April 2007 level using the
consumer price index net of mortgage payments (CPIX) [14]. The
average South African rand to US$ exchange rate in April 2007
(R7.14 to US$1) was used to convert costs to US$ equivalents [15].
Exploratory Cost Analysis
The mean total cost and its components were explored from
36 mo before starting ART to 60 mo on ART. Costs were broken
down into the following components: ART, other medication,
hospitalisation, investigations, CD4+ cell count and HIV viral load
monitoring, general practitioner consultations, specialist consulta-
tions, maternity, and auxiliary care. This exploratory analysis
revealed a marked peak in cost from 4 mo before starting ART
until 4 mo on ART. This 8-mo interval is denoted the ‘‘peri-
ART’’ period in this study.
Statistical Methods
Even though health care costs are often right-skewed, with a
minority of patients incurring very high costs, the health
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economics literature argues that health care policy decisions are
best guided by analyses of arithmetic mean costs, as the mean
provides information on the costs of treating the entire population
[16]. Thus ordinary least squares (OLS) regression models and
generalised linear models (GLM) were considered [16,17]. The
month in which patients started ART was set as the zero month
for all patients, which provided a common reference point for all
the patients in our analysis. We divided the period from 4 mo
before to 60 mo after starting ART into 4-mo intervals and
determined the mean total cost in each interval. As many months
had zero costs (.10%), using the mean cost over 4 mo intervals
resulted in few zero values in the outcome variable, thus avoiding
the need for zero-inflated models. A GLM with a gamma
distribution and a log-link function was selected on grounds that
it could describe the distribution of the data. An OLS model was
abandoned because it was unable to adequately account for the
patients with very high costs, which was a significant proportion of
total costs. With a log-link function, the variables are associated
with a proportional change in total mean costs. Improved residual
diagnostics, lower Akaike Information Criteria (AIC), and
improved trend prediction were used in the model development
and refinement.
The time-varying associations between mean total cost and the
variables was modelled using three methods: a separate model for
each 4-mo time interval using categorical variables, and two
models with categorical or continuous variables over the entire
interval with time included as a variable, which also interacted
with the other variables. Effect estimates and their significance at
the 95% level were assessed using robust standard errors with
clustering at an individual level. Data storage, basic calculations,
and data extraction was handled in Microsoft Access 2003 [18]
and statistical analysis was performed in Stata 10 [19].
The following variables were considered in our analysis:
baseline CD4+ cell count and HIV viral load (baseline was
defined as the most recent result within 6 mo before starting
ART), ART adherence assessed by monthly pharmacy claims,
age, sex, the NNRTI and the NRTI combination used in patients
on first line therapy, whether the patient switched to PI-based
second line ART, and the duration of CD4+ cell count monitoring
(as a proxy for being in HIV care) prior to starting ART. Patients
with less than 4 mo of claims data after starting ART were
excluded on the grounds that we were unable to assess their ART
adherence over shorter time intervals. We split the continuous
variables into the following categories: (1) Baseline CD4+ cell
count was divided into four groups: 0–49, 50–199, 200–349, and
$350 cells/ml. (2) HIV viral load was categorised as
$100,000 copies/ml or ,100,000 copies/ml. (3) The mean
ART adherence was determined using pharmacy refill data and
divided into quartiles. (4) The NNRTI was included as a binary
variable (either efavirenz or nevirapine); whereas (5) the NRTI
combination in first line was divided into three groups: zidovudine
and lamivudine, stavudine and lamivudine, or any other
combination. (6) A binary variable was used to reflect whether
or not the patient was on second line ART. (7) Age was divided
into quartiles. (8) Sex was included as a binary variable. (9) Patient
follow-up for HIV prior to starting ART was measured by the
length of time between the first CD4+ cell count and the date of
starting ART, and was categorised as less than 6 mo and more
than 6 mo.
Results
10,735 patients met our eligibility criteria. The characteristics of
the cohort are described in Table 1. There were almost 600,000
patient months of observation, about half of which were on ART.
Median follow-up on ART was 26 mo. Baseline body mass index
(BMI) was only available for 4,416 of the patients: 13% were
,18.5 kg/m2, 52% were $18.5 kg/m2 and ,25 kg/m2, and
35% were $25 kg/m2. The most common first line and second
line antiretroviral regimens were zidovudine, lamivudine, and
efavirenz and lopinavir/ritonavir, zidovudine, and didanosine,
respectively. CD4 and viral load monitoring were done 1.5 times
per annum on average. Hospitalisation rates were 441 d per 100
patient years of observation (PYO) in the first 6 mo of ART and
179 d per 100 PYO subsequently. Hospitalisation incidence was
highest in patients in the lowest CD4 count stratum.
The proportion of patients who left the scheme was 31% overall
and 24% at 2 y. Patients who left the scheme either changed their
employment, switched to a different medical insurance scheme, or
voluntarily stopped their contributions to the insurance scheme.
Patients who left the scheme differed from those who did not leave in
the following baseline characteristics (established using the Wilcoxon
rank sum test for continuous variables and Chi-squared test for
categorical variables): viral load (median of 5.2 versus 5.1 log10,
p = 0.0016), proportion female sex (57% versus 60%, p = 0.0001), and
age (37.4 y versus 37.0 y, p = 0.0006). Importantly, these baseline
differences are not clinically significant and the CD4+ cell count did
not differ significantly (median of 127 versus 123 cells/ml, p = 0.137).
Exploratory Cost Analysis
The cost data were highly skewed with 10% of the population
accounting for 90% of the costs. Figure 1 shows the mean monthly
cost and its components. The mean monthly cost rose from a
plateau of around US$100 per month before ART, to a peak of
around US$500 in the peri-ART period, before dropping down to
a new higher plateau of around US$200 on ART. Median (IQR)
monthly costs are shown in Figure S1.
Multiple Regression Analysis
After excluding patients with missing demographic and baseline
viral load and CD4+ cell count data, 7,427 patients were included
in this analysis, and their characteristics are shown in Table 1. The
summary statistics for this subset were comparable with the full
dataset.
In our first analysis, we modelled each 4-mo time interval
separately. We found that lower baseline CD4+ cell counts and
high HIV viral loads were associated with increased mean total
cost predominantly from 4 mo before to 8 mo after starting ART.
In contrast, the highest ART adherence quartile was increasingly
associated with lower mean total cost over time when compared
with the lowest quartile (Figure 2A). When ART-related costs were
excluded (on the grounds that high adherence would result in
more ART-related costs), the association was more marked. In a
subanalysis, the effect of lagged ART adherence (adherence in the
prior 4 mo) on costs per 4-mo period was assessed. Again higher
adherence in the prior 4 mo was associated with lower costs
(Figure 2B). Being on second line (PI-based) ART was associated
with higher costs throughout the time period. The other variables
were associated with small effects (,10%), which were largely not
significant. In a subanalysis, we excluded maternity (which is
associated with high costs as nearly all women deliver by caesarean
section) and ART costs (a lower proportion of women started
efavirenz, which is teratogenic and more expensive than
nevirapine) and found the association between sex and mean total
cost was not consistent and marginal (,10%).
Mean total costs fell over the first 24 mo on ART and thereafter
cost remained constant. Similarly, the associations between many
variables and mean total costs changed over the first 24 mo and
Drivers of Antiretroviral Treatment Costs
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thereafter remained constant. We found that splitting time into
four periods (24 to 4 mo, 5–12 mo, 13–24 mo, and .24 mo)
described time-dependent association between time and total
mean cost and its interaction with the other variables. The results
from this multiple regression analysis are found in Table 2.
We found that costs were very high in the peri-ART period.
Mean monthly costs were more than 3 times higher in this period
and the association between costs and baseline CD4 count and
baseline viral load were more marked in the peri-ART than in
later time periods. In the above analysis, we excluded patients who
died within the first 4 mo on ART because we could only estimate
ART adherence over a period of 4 mo or longer. However given
that patients who died might incur significant costs, we performed
an additional subanalysis including these early deaths. This subset
included 8,559 patients. The findings were similar but the
associations between variables and total mean costs diminished
marginally when we repeated the multiple regression analysis with
the ART adherence variable excluded (unpublished data).
Finally, we explored continuous models for ART adherence,
age at starting ART, baseline viral load, and baseline CD4+ cell
count (only counts ,350 cells/ml were analysed as patients with
higher counts were started on ART for serious HIV-related
morbidity): polynomial functions of the 2nd degree were used for
all the variables except ART adherence (4th degree polynomial)
and baseline HIV viral load (3rd degree polynomial) were used.
We felt that the duration of CD4+ cell count monitoring before
staring ART was better handled as a categorical variable. Time
and its interactions with the other variables displayed nonlinear
associations with total mean cost for the first 24 mo; thereafter
trend was approximately linear. A restricted cubic spline (a cubic
spline with linear tails) with three knots placed 24 to 21 mo, 4–
7 mo, and 16–19 mo fitted the observed trends in our data; we
experimented with the placement and number of knots using the
Akaike Information Criteria and predictive plots to guide the final
model selection. An interaction with the spline function for time
was used for all variables except ART (first line versus second line)
as the trend over time was difficult to quantify. Overall, the model
was able to describe the trends in the data well, though in some
intervals the trends in the baseline viral load and age variables
were not well approximated at the extremes. While the main
findings from this analysis using continuous variables did not differ
from the previous analysis using categorical variables, some
subtleties not previously shown were found in the relationships
between costs and baseline CD4+ cell count and ART adherence.
The association between baseline CD4+ cell count and mean
total costs over time is shown in Figure 3; costs within each
interval were compared with a referent group (CD4+ cell
count = 200 cells/ml). Initially, the association with mean total
cost followed a j-shape, with low CD4 counts associated with very
high costs but also a modest increase in costs in patients with high
counts. Over time the association between CD4+ cell count and
mean total costs became less marked but costs were lowest for
patients with higher CD4 counts. The association between ART
adherence and mean total costs is shown in Figure 4; costs within
Table 1. The characteristics of the cohort.
Characteristics Overall n = 10,735 Regression Subset n = 7,427
Patient months included in analysis Overall 594,497 282,141
On ART 302,579 (50.9%) 252,433
Duration on ART (mo) Median 26 33
IQR (9–44) (16–50)
Age at starting ART (y) Median 37 37
IQR (32–43) (32–43)
Sex Female 6,379 (59.%) 4,557 (61%)
Male 4,356 (41%) 2,897 (39%)
Patient status at end of study period Active 6,339 (59%) 4,217 (56%)
Left scheme 3,329 (31%) 2,669 (36%)
Dead 1,067 (10%) 1,067 (8%)
Baseline CD4+ cell count Median 125 cells/ml 125 cells/ml
IQR (49–203) (55–204)
Missing 1,726 N/A
Baseline viral load (log10) Median 5.20 5.16
IQR (4.70–5.60) (4.66–5.59)
Missing 2,031 N/A
NNRTI used in first line Nevirapine 2,655 (28%) 2,432 (28%)
Efavirenz 6,711 (72%) 6,127 (72%)
NRTI combination in first line AZT+3TC 6,950 (65%) 4,945 (67%)
D4T+3TC 1,564 (15%) 1,684 (23%)
Other 2,221 (20%) 798 (10%)
Duration of CD4+ cell count monitoring before starting ART (mo) Median 1.5 1.5
IQR (0.7–4.2) (0.7–4.2)
3TC, lamivudine; AZT, zidovudine; D4T, stavudine; IQR, interquartile range; N/A, not applicable.
doi:10.1371/journal.pmed.1000189.t001
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each interval were compared with a referent group (ART
adherence 75%). Initially, the model found three peaks: one
around highly adherent patients, another around 50% adherence,
and a smaller peak at very low adherence. Over time the lower
peak fell away, the middle dominant peak moved to be centred at
around 30% adherence, while the highly adherent patients were
now associated with the lowest costs. Very low ART adherence
was associated with low costs in all time intervals except in the
peri-ART period. The association between mean total cost and
baseline viral load (Figure S2) age at starting ART (Figure S3) are
found in the supporting information (Figures S1–S3).
Discussion
We analysed the direct health care costs of treating over 10,000
HIV-infected adults enrolled in a Southern African managed care
ART programme with almost 600,000 patient months of follow-
up, spanning 3 y before ART to 5 y on ART. We found a peak in
costs in the period around the time of ART initiation, thereafter
total mean costs dropped off to a plateau that persisted for 5 y. An
important and novel feature of our study was the presentation of
time-dependent associations between total mean costs and relevant
variables. We identified lower baseline CD4+ cell count, higher
baseline viral load, and shorter duration of CD4+ cell count
monitoring before starting ART (as a proxy for HIV care) as being
independently associated with higher costs in the early time
periods. Lower ART adherence, being on second line ART, and
starting ART at an younger age were most strongly associated with
lower mean costs in later time periods, and the association with
ART adherence became more marked over time.
The peak in costs in the peri-ART period we observed was
largely driven by the high proportion of patients requiring
hospitalisation. High rates of early morbidity, often resulting in
hospitalisation or death, are characteristic of antiretroviral
programmes in resource-limited settings. Patients on ART in
low-income countries have higher early mortality compared with
high-income countries, even after correcting for baseline differ-
ences in CD4+ cell counts [20]. A strength of our study is the
analysis of cost data before starting ART. Few ART cost analyses
include the period before starting ART. Higher costs in the first
year on ART compared with later years with high rates of
hospitalisation was reported in another South African study of a
public sector ART programme, but they only assessed costs for
1 mo before starting ART and did not attempt to more accurately
define the period of high cost [2]. Given our finding of high costs
in the 4-mo period before starting ART, which was equivalent to
1.5 y of cost in patients on ART after the first year, other studies
might have significantly underestimated the costs of providing
HIV care just prior to starting ART.
We found that higher ART adherence was associated with lower
costs particularly after removing antiretroviral drug costs. The
magnitude of this association becomes greater as duration on ART
increases. However, the continuous model showed that while highly
adherent patients (.92%) were associated with the lowest total
mean costs in later time intervals, they were associated with higher
costs in the early time intervals. A similar association was found with
high baseline CD4+ cell counts (.300 cells/ml) being associated
with higher costs initially. These findings could be attributed to
increased health-seeking behaviour leading to increased costs
initially, but reduced costs over time. Very low ART adherence
was associated with low total mean costs in all time intervals as these
patients are presumably accessing minimal services. Our group has
previously reported that ART adherence assessed by pharmacy
refills in this cohort predicted both virological suppression [21] and
survival [22]. Poor adherence limits the effectiveness of ART, drives
resistance to first line regimens, and thus leads to earlier switching to
costly second line ART. Despite the important role of ART
adherence, existing economic models fail to include it.
Figure 1. Mean categorised total monthly costs from 36 mo before starting to 60 mo on ART.
doi:10.1371/journal.pmed.1000189.g001
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Figure 2. The proportional change in mean total costs associated with ART adherence with 95% confidence intervals. (A) The highest
overall ART adherence quartile was compared with the lowest adherence quartile within each time interval (ART costs included and excluded) from
4 mo before starting ART to 60 mo on ART. (B) The highest lagged ART adherence group was compared with the lowest group ($3 monthly versus
#1 monthly refills in the previous 4-mo period) within each time interval from 4 mo before starting ART to 60 mo on ART.
doi:10.1371/journal.pmed.1000189.g002
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Our analysis of the time-dependent associations with increased
costs has several important public health implications. The high
early costs of ART programmes could be reduced by starting
ART at a CD4+ cell count of ,350 cells/ml rather than
,200 cells/ml (for patients without major symptomatic HIV
disease). Our cohort does not allow for an evaluation of starting
ART in patients with baseline CD4+ cell counts $350 cells/ml
because AfA guidelines only allow these patients to start ART
following an AIDS-defining illness or with other serious co-
morbidity: costs were actually higher in this group compared
with those starting ART with baseline CD4+ cell counts 200–
349 cells/ml, presumably reflecting the costs of treating the
morbidity that was the criterion for starting ART. The second
intervention that could reduce early costs would be the earlier
identification of HIV infection, illustrated by our finding that
being in HIV care for more than 6 mo prior to starting ART
reduced costs in the peri-ART period. The key driver of later
costs with public health implications is ART adherence. Higher
adherence prolongs time on the cheaper first line regimen, but
also reduces non-ART direct costs in our study. The third
intervention that might reduce costs would be to encourage ART
programmes to invest in systems to monitor ART adherence and
implement effective interventions if adherence is suboptimal.
ART adherence could be monitored over short time periods of 3
to 4 mo, which identifies patients incurring higher costs and
those at risk of virological failure [23].
We estimate that annual total direct health care costs are
approximately US$2,400 (after the peak in costs in the peri-ART
period) for patients accessing ART in the private sector. Lower
costs were reported in two other South African studies. Harling
reported costs of $2,502 in year one and $1,372 in year two of a
donor-funded public sector program [24]. Rosen estimated the
ART component of care to be US$757–US$1,126 in the first year
of several different models of ART delivery to public sector
patients, but non-ART–related clinic visits and hospitalisations
were not included [25]. The incidence rate of hospitalisation we
found in the first 6 mo on ART was similar to that reported in a
South African public sector ART programme in the first 48 wk on
ART, but our incidence was higher in later periods, which would
increase costs [24]. Higher rates of hospitalisation in the private
sector compared with the public sector after the initial period of
ART probably reflect greater access in the private sector. Other
factors driving higher costs in the private sector compared with
public sector are higher costs for hospitalisation (US$340 versus
US$202 per day, respectively) and viral load tests (US$62 versus
US$42, respectively) [26].
Table 2. The proportional change in mean total cost modelled using a multiple generalised linear model regression.
Variable Time Intervals (mo)
24 to 4 5–12 13–24 .24
Mean monthly total cost (US>$) — 377 (337–418) 183 (160–206) 161 (138–183) 115 (98–131)
Baseline CD4 count (cells/ml) ,50 1.98 (1.74–2.22) 1.35 (1.07–1.63) 1.28 (1.05–1.51) 1.23 (0.97–1.48)
50–199 1.34 (1.20–1.48) 1.08 (0.94–1.21) 1.02 (0.87–1.17) 1.31 (1.11–1.51)
200–349 1 (referent) — — —
$350 1.57 (1.21–1.92) 1.39 (0.97–1.8) 1.43 (0.96–1.89) 1.12 (0.78–1.45)
Baseline viral load (copies/ml) $100,000 1.24 (1.10–1.37) 1.08 (0.93–1.23) 1.08 (0.94–1.23) 1.09 (0.95–1.23)
,100,000 1 (referent) — — —
Age at starting ART (y) ,25 1.03 (0.81–1.26) 0.82 (0.64–0.99) 0.83 (0.60–1.06) 0.85 (0.59–1.12)
25–49 1 (referent) — — —
$50 1.20 (0.97–1.43) 1.14 (0.87–1.42) 1.01 (0.79–1.23) 1.52 (0.72–2.32)
Sex Male 0.98 (0.87–1.10) 1.00 (0.83–1.17) 0.91 (0.77–1.06) 0.91 (0.75–1.06)
Female 1 (referent) — — —
NNRTI Nevirapine 0.87 (0.77–0.96) 0.89 (0.78–1.00) 1.11 (0.96–1.27) 1.02 (0.86–1.18)
Efavirenz 1 (referent) — — —
NRTI combination D4T/3TC 1.05 (0.88–1.22) 1.01 (0.80–1.22) 0.95 (0.74–1.16) 0.96 (0.61–1.32)
Other 0.91 (0.81–1.02) 0.98 (0.82–1.14) 1.05 (0.88–1.22) 1.06 (0.84–1.27)
AZT/3TC 1 (referent) — — —
Duration CD4+ cell count monitoring $6 mo 0.76 (0.67–0.85) 0.98 (0.84–1.12) 1.01 (0.87–1.16) 1.30 (1.06–1.54)
,6 mo 1 (referent) — — —
Therapy Second line 1.65 (1.09–2.2) 3.10 (0.43–5.76) 1.94 (1.45–2.44) 2.06 (1.53–2.58)
First line 1 (referent) — — —
Mean overall ART adherence ,38% 0.84 (0.75–0.94) 1.00 (0.86–1.14) 1.17 (0.98–1.35) 1.54 (1.21–1.86)
38%–73% 1.08 (0.97–1.20) 1.25 (1.01–1.49) 1.12 (0.97–1.27) 1.28 (1.07–1.50)
74%–92% 0.85 (0.77–0.94) 1.25 (1.06–1.44) 1.06 (0.92–1.21) 1.09 (0.92–1.26)
.92% 1 (referent) — — —
A log-link function with a gamma distribution was used in the model. Numbers in parentheses are the 95% confidence intervals. 3TC, lamivudine; AZT, zidovudine; D4T,
stavudine.
doi:10.1371/journal.pmed.1000189.t002
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Some findings of other ART programme cost studies differed
from our analysis. We found that the ART component of costs was
relatively small compared with other studies in resource-limited
settings [2,25,27], which could be related to higher hospitalisation
and other costs in our private sector setting. Younger age has been
found to be associated with increased costs in some [28,29], but
not all studies [2]. We found a significant age effect with younger
age (,25 y) associated with lower early but higher later costs and
older age ($50 y) associated with higher early and especially later
costs. Finally, unlike the finding of another South African study
[2], sex was not independently associated with costs, even after
controlling for pregnancy-related costs and the higher proportion
of men being on efavirenz. It is possible that our inclusion of ART
adherence in our multiple regression model adjusted for sex
differences, as we have previously shown that men have lower
ART adherence than women [30].
There are a number of limitations to this analysis. First, our
cohort consisted of private sector patients when the majority of
patients in resource-limited settings are treated in the public sector.
However, the baseline characteristics of our cohort (CD4+ cell
count, proportion of females, and age) are comparable with
cohorts from low-income countries [20,31]. The BMI was
,18.5 kg/m2 in 13% of our cohort compared with 19% in a
South African public sector cohort [32], but their patients had
more advanced disease as evidenced by their lower baseline CD4+
cell counts. These baseline nutritional differences would likely
impact outcomes. We restricted our analysis to patients receiving
NNRTI-based first line ART regimens, in keeping with WHO
recommendations for resource-limited settings [8]. While we
would not claim that our actual cost findings are generalisable to
public sector settings or to other countries, we would argue that
the variables that drive early and late costs are likely to be relevant
even if the magnitude of the effect could differ.
Second, the impact of specific AIDS-defining illnesses on
outcomes and costs was not included in this analysis because
these data were not available. Third, as a provider’s perspective
was chosen for this analysis, the cost to society is not fully
represented because we did not have data on direct non-health
care costs and indirect costs. However, a provider’s perspective is
more appropriate for the aim of this study, which was to unpack
the key drivers of health care costs in order to inform appropriate
budgeting and planning. Fourth, the characteristics of the patients
who left the scheme were different from those who remained,
which may have affected our findings. However, there was no
significant difference in the key baseline characteristic of CD4+
cell count and many of the other differences (e.g., age, difference of
0.1 log10 viral load) were small and are of questionable
importance. Fifth, we chose to use the tariff amount as opposed
to the amount claimed or reimbursed so that similar services
would take the same monetary value and have further assumed
Figure 3. The proportional change in mean total monthly costs over time associated with baseline CD4 cell count. Baseline CD4 count
was compared with the referent group (200 cells/ml) within each time interval from 4 mo before starting ART to 60 mo on ART with lighter blue
indicating higher relative costs.
doi:10.1371/journal.pmed.1000189.g003
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that these tariffs are a suitable proxy for opportunity costs. While
this could be a shortcoming, it is common to assume that market
prices are a proxy for opportunity costs in economic evaluation
given the difficulties in evaluating the latter [33]. Finally, cost
minimisation should not be the only goal of health care providers,
and other important aspects of care such as quality and outcomes
are not addressed by our analysis.
In conclusion, we have described the temporal trends of costs of
a large private sector HIV disease management programme in
Southern Africa and shown that associations with costs change
over time. Interventions that should reduce early costs include
starting ART at higher CD4 counts and being in HIV care for
longer periods before starting ART. Our results also indicate that
systems to detect suboptimal ART adherence and interventions
that improve adherence would reduce later costs. The increasing
impact of ART adherence on costs over time suggests that this
variable should be incorporated in economic models of ART.
Supporting Information
Figure S1 Total monthly costs from 36 mo before starting ART
to 60 mo on ART. Median and interquartile range, mean, and
running-line least squares smooth are shown.
Found at: doi:10.1371/journal.pmed.1000189.s001 (0.15 MB
TIF)
Figure S2 The proportional change in mean total monthly costs
over time associated with baseline HIV viral load. Baseline HIV
viral load was compared with the referent group ($100,000 cop-
ies/ml) within each time interval from 4 mo before starting ART
to 60 mo on ART with lighter blue indicating higher relative costs.
Found at: doi:10.1371/journal.pmed.1000189.s002 (0.31 MB
TIF)
Figure S3 The proportional change in mean total monthly costs
compared over time associated with age at starting ART. Age at
ART was compared with the referent group (37 y) within each
time interval from 4 mo before starting ART to 60 mo on ART
with lighter blue indicating higher relative costs.
Found at: doi:10.1371/journal.pmed.1000189.s003 (0.40 MB
TIF)
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Editors’ Summary
Background. About 30 million people (22 million people in
sub-Saharan Africa alone) are infected with the human
immunodeficiency virus (HIV), the cause of acquired
immunodeficiency syndrome (AIDS). HIV destroys immune
system cells (including CD4 cells, a type of lymphocyte),
leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, on average HIV-positive people
died within 10 years of infection. Then, in 1996, highly active
antiretroviral therapy (ART; combinations of powerful
antiretroviral drugs) was developed. For people living in
affluent, developed countries HIV/AIDS became a chronic,
treatable condition, but for the millions of HIV-infected
people living in low- and middle-income countries, effective
treatment was unavailable and HIV/AIDS remained a fatal
illness. In 2003, this situation was declared a global health
emergency and governments, international agencies, and
funding bodies began to implement plans to increase ART
coverage in developing countries. By the end of 2008, of the
9.5 million people in need of ART in low- and middle-income
countries, more than 4 million people were receiving
treatment.
Why Was This Study Done? Good progress is being made
towards achieving universal access to ART, partly because
the cost of antiretroviral drugs has plummeted in developing
countries. But the provision of antiretroviral drugs is not the
only direct cost associated with ART. General practitioner,
specialist, and maternity-related care for patients receiving
ART, hospital accommodation when necessary, and the
investigations that are needed to monitor the progress of
HIV infection such as CD4 cell counts and viral load
measurements all incur considerable costs. To use their
limited resources effectively, public-health officials in
developing countries need to know as much as possible
about the direct costs of HIV health care but few studies
have investigated these costs, particularly those incurred
before an individual starts taking ART. In this study, the
researchers explore health care costs in a South African
private-sector HIV/AIDS program and examine the variables
that drive the costs of HIV health care around the time of
ART initiation and during later phases of ART.
What Did the Researchers Do and Find? The researchers
analyzed the direct costs of treating more than 100,000 HIV-
infected adults enrolled in a private HIV care program in
South Africa from 3 years before they started ART until up to
5 years after ART initiation; within this program, individuals
began to receive ART when their CD4 cell count fell below
350 cells/ml of blood. The researchers found a peak in direct
health costs from 4 months before to 4 months after starting
ART (the ‘‘peri-ART’’ period), which was driven mainly by
hospital costs. After the peri-ART period, costs dropped
(although not to the levels seen before this period) and
stabilized at an intermediate level for the next 5 years.
Detailed statistical analyses suggest that the key variables
associated with higher costs in the peri-ART period were a
low baseline CD4 cell count, a high baseline HIV viral load,
and a shorter time in HIV care before ART initiation. The key
variable associated with higher costs later in ART was lower
adherence to the drug therapy. That is, costs were higher
among patients who did not take their antiretroviral drugs
regularly.
What Do These Findings Mean? This study involved
patients enrolled in a private health care program in which
the criteria for initiating ART differed somewhat from those
recommended by the World Health Organization for ART
initiation in resource-limited settings. Thus, the absolute
mean total costs calculated by the researchers are unlikely to
be generalizable to public HIV care systems in South Africa
and in other resource-poor settings. However, the finding
that the drivers of mean total costs change considerably over
time may be generalizable and provides some useful
information for public-health planners that can now be
tested in other, more resource-limited patient populations. In
particular, the findings of this study suggest that the high
early costs of ART programs could be reduced by starting
ART at higher CD4 cell counts or by providing longer pre-
ART care. In addition, the findings suggest that monitoring
ART adherence and introducing interventions to improve
ART adherence could reduce the later direct costs of ART
programs.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000189.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on the HIV and AIDS in Africa, and on universal access
to AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment, including the Septem-
ber 2009 progress report (in English and French)
N The US Centers for Disease Control and Prevention also
provides information on global efforts to deal with the
HIV/AIDS epidemic
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Chapter 6: The impact of  antiretroviral therapy home-refill by 
courier compared to self-refill on patient clinical, immunological, 
and virologic outcomes: a cohort analysis in HIV-positive adults 
6.1  Overview 
The intention of this Chapter is to present an outcome analysis of home-refill (by courier) versus 
self-refill. The structure is consistent with a publication in an academic journal.  
6.2  Introduction 
Adherence to ART is an important factor driving key outcomes in antiretroviral programs, 
including viral suppression [1-6], the emergence of drug resistance [7-11], disease progression 
and death [4, 12, 13], hospitalization rates [4], and direct health care costs [14-16]. There are 
numerous barriers to adherence, many of which are unique to LMICs, e.g., structural barriers, 
including long waiting time at the clinic and cost of transport to collect antiretroviral drugs 
(ARVs) [17-19], and few interventions are consistent across settings [20-22]. Improving 
adherence is, however, critical if we are to achieve the UN’s 90-90-90 goals, namely to ensure 
that 90% of PLWH know their HIV status, 90% of all people diagnosed with HIV receive 
ongoing ART, and 90% of PLWH on ART will have viral suppression by 2020 [23]. 
The importance of adherence in chronic illness was highlighted by WHO in 2003 [1]. 
Adherence is driven by several factors, including patient, medication and prescriber factors [3-5]. 
In recent systematic reviews and network meta-analysis [22], two-way short message service 
(SMS) was found to be effective in many settings, and effects were additive when a combination 
of interventions was applied (e.g., peer-support). Importantly, effects waned over time, 
suggesting that several parallel and/or staggered interventions may be needed if we are to achieve 
the 90-90-90 targets. 
Indirect costs remain a significant and largely unaddressed barrier to HIV care [18, 24] and ART 
adherence [25-27]. Travel costs represent a significant component of indirect costs and are 
particularly important to people who live far from clinics and have a limited income [24, 28]. 
Home-refill represents a potential intervention to reduce substantial indirect costs and has 
already been implemented in the Western Cape province, South Africa, for clinically stable 
patients on medication for chronic diseases such as hypertension and diabetes [29]. We 
hypothesized that ART delivery by courier to the patient’s home would improve ART adherence 
and, therefore, lead to better outcomes. We compared outcomes between patients with home-
refill (central pharmacy) and self-refill (local pharmacy) in a South African private sector 
HIV/AIDS programme. 
6.3  Methods 
6.3.1  Ethics  
We obtained approval for this study from the Research Ethics Committee, University of Cape 
Town. All patients consented for their information to be entered into the AfA database.  
6.3.2  Sources of data 
We analyzed patients enrolled with AfA, a disease management group that manages HIV-related 
care for a number of medical insurance funds and companies in the private sector in Southern 
Africa [30]. The cohort has been described in detail in several earlier publications [5, 12, 15, 16, 
30-38]. In brief, doctors working within their private practices registered patients with AfA, after 
completing online training and registration themselves, and continued to manage patients in their 
private practices. Demographic data, CD4+ cell count, viral load, and previous ART history were 
captured into a central database on registration and made available to the staff, who then 
authorized ART initiation and switches, in addition to other components of HIV care (e.g., 
prophylaxis of opportunistic infections, infant formula feeding, and some specialized 
investigations). The criteria for the initiation of ART at the time of the study were CD4+ cell 
counts <350 cells/µL or WHO stage III/IV illness. The recommended initial regimen was a 
combination of two NRTIs and a NNRTI but some flexibility was allowed. The recommended 
second line therapy consisted of a boosted PI with two NRTIs and the recommended salvage 
therapy consisted of either darunavir/ritonavir-, tipranavir/ritonavir-, raltegravir-, or etravirine-
containing regimens. CD4+ cell counts and viral loads were recommended for monitoring every 
6 months. The vital status of a member was determined by linking with the National Death 
Register using the RSAID number , as described in previous publications [36, 38, 39].  
6.3.3  Inclusion criteria 
We included open medical funds (i.e., not closed which were restricted to employees) for this 
analysis only, with no co-payment for ART. Patients were included if they were ART naïve 
(women who had received prophylaxis for PMCT were not excluded), were 19 years or older on 
starting ART, started ART between January 2002 and July 2010, and started first line ART. 
6.3.4  Pharmacy dispensing data 
ART dispensing data were collected by the medical schemes from electronic submissions by 
pharmacies. For each dispensing event, the medical administrator (Medscheme) recorded the 
date, details of the medication, quantity dispensed, and dispensing pharmacy. Courier pharmacies 
were identified and dispensing marked accordingly.  
We found that patients often collected their medication in the first month on ART while the 
courier pharmacy was appointed. We, therefore, assigned patients who started home-refill by 
courier pharmacy during the second month of ART to the home-refill group from the start of 
the analysis. Most patients did not self-select but were instead assigned to courier pharmacy 
proactively by the scheme on registration with AfA. The schemes did allow for non-courier 
pharmacies, but this would incur a co-payment in some schemes and therefore, over time, 
courier pharmacies became the preferred providers. 
6.3.5  Statistical methods 
The following baseline variables were considered in our analysis: CD4+ cell (CD4) count, body 
mass index (BMI), VL, age, sex, and initial ART regimen. For CD4 count, VL, and weight, the 
baseline level was defined as the most recent result within 12 months before starting ART. We 
divided patients into three groups based on their mode of ART delivery:  those that received all 
their ART through courier services (home-refill), those who collected their ART from private 
pharmacies (self-refill), and those who initially collected ART from private pharmacies and then 
switched or were switched to courier services (mixed-refill).  
Some data were missing for baseline CD4 count, baseline VL, baseline weight, and height 
(see Table 1). For the missing variables, we imputed five datasets using multiple imputations by 
chained equations (MICE). The imputation model included the following baseline variables: sex, 
baseline weight, height, age, CD4 count, VL, death, time on ART. CD4 count and VL were 
actively imputed, and BMI was passively imputed (using actively imputed baseline weight and 
height). We checked the results of the imputation model by comparing the imputed data with the 
actual data [40, 41]. 
Our primary endpoint was all-cause mortality; secondary endpoints were viral 
suppression (VL< 400 copies/ml) and median CD4 response (from baseline) at 6-month 
intervals. We assessed differences in baseline characteristics with 2-sample Student t-tests 
(continuous variables) and Chi-Square tests (categorical variables). We compared the crude 
survival of self-refill and home-refill groups using a Kaplan–Meier plot and a log-rank test. We 
used Cox proportional hazards regression to model the individual and simultaneous effects of 
baseline variables and mode of ART delivery on all-cause mortality. We used plots of -log[-
log(survival)] against log (analysis time) and analysis of scaled Schoenfeld residuals to assess the 
proportionality assumption (data not shown). We included the following variables based on 
significance in the univariate analyses in multivariate models, stratified into discrete categories: 
age, sex, CD4 count, VL, year of starting ART, NNRTI, and NRTI. We considered a model with 
the propensity score included as a covariate to adjust for possible confounding in observational 
studies and compared the results [42]. All statistical analyses were performed using Stata, version 
14.2 (StataCorp, College Station, Texas).  
6.4  Results 
Table 6.1 shows baseline socio-demographics and clinical characteristics. Between January 2002 
and June 2011, 40,939 patients met our eligibility criteria. In total, 66,204 years of follow-up were 
recorded. The most common first line regimens were EFV+3TC+ZDV initially, followed by 
EFV+FTC+TDF in later years. CD4 and viral load monitoring were done 1.5 times per annum 
on average. Given the high numbers of entrants towards the end of the study period, the median 
follow-up on ART was less than 2 years for both self- and home-refill groups; the patients who 
switched had had significantly longer exposure to ART. Other baseline variables were similar 
between groups but statistically significantly different. 
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6.4.1  CD4 response to ART over time 
We compared the CD4 response on ART over time in two analyses. In Figure 6.1 below we (a) 
compare the median and interquartile range (IQR) CD4 response over time between the home-
refill by courier and self-refill groups from baseline until 60 months on ART and (b) repeat the 
analysis for those who switched from self- to home-refill by courier. There was a clear trend 
toward a better CD4 response over time in the home-refill by courier group than in the self-refill 
group, with curves separating already from 2 years on ART (e.g., at 36-month median CD4: 451 
versus 387, p < 0.0). After 5 years, these two groups merged. Again, in (b) those who switched to 
home-refill by courier had better CD4 responses after switching than those remaining in the self-
refill group (60-month Median CD4: 503 vs. 321; p <0.001). 
 
 
Figure 6.1: Comparing median CD4+ cell count (cells/µl) response from baseline to 60 months 
on antiretroviral therapy with interquartile ranges for home-refill by courier with (a) self-refill and 
(b) switching from self-refill to home-refill by courier 











































































































































































6.4.2 VL response to ART over time 
We compared VL suppression on ART over time in two similar analyses. In Figure 6.2, we (a) 
compared the percentage with VL suppression (<400 copies/ml) over time between the home-
refill by courier and self-refill groups from 6 months until 60 months on ART and (b) repeated 
the analysis for those who switched from self- to home-refill by courier. VL suppression was 
significantly better over time in the home-refill by courier compared with the self-refill group, 
with curves separating already from the first year on ART (e.g., at 36-month VL suppression: 
81% versus 71%, p <0.001). Again, in (b) those who switched to home-refill by courier had 
better VL suppression after switching than those remaining in the self-refill group (e.g., at 60-
month VL suppression, 77% versus 45%, p <0.001).   
 
 
Figure 6.2: Comparing median HIV viral load (copies/ml) response from baseline to 60 months 
on antiretroviral therapy with interquartile ranges for home-refill by courier with (a) self-refill and 
(b) switching from self-refill to home-refill by courier 


















































































































































































































6.4.3 Survival analysis 
We identified 5,150 (12.6%) deaths over 106,461 patient-years of follow-up (PYFU), giving a 
crude incidence of 48.3 deaths per 1000 PYFU. The Kaplan Meier analysis together with log-
rank tests of all-cause mortality in self-refill versus home-refill is shown in Figure 6.3 below. The 
curves diverge and remain so with a significant (p<0.001) difference between home-refill via 
courier and self-refill. 
 
Figure 6.3: Kaplan-Meir plot of home-refill versus self-refill with log-rank test  
The results of the multivariable analysis are shown in Table 6.2 below. In this analysis, 
home-refill was associated with a lower hazard of all-cause mortality than self-refill, adjusted 
hazard ratio (aHR) 0.90 (95% confidence interval (CI): 0.84-0.96). NRTI backbones other than 
tenofovir or zidovudine, EFV-containing regimens, male, were all associated with an increased 
adjusted hazard of all-cause mortality. Increasing age, increasing baseline VL, decreasing baseline 
CD4, and decreasing year of starting ART, decreasing BMI were also all associated with an 
increased adjusted hazard of all-cause mortality.  
  
Table 6.2: Cox regression table comparing univariate and multivariate regression analyses 
 
 
   
Hazard ratio (95% CI) p‐value Hazard ratio (95% CI) p‐value
home‐refill 0.86   (0.83 to 0.88) <0.001 0.9   (0.84 to 0.96) 0.003
self‐refill
efavirenz 1.42   (1.3 to 1.55) <0.001 1.14   (1.04 to 1.25) 0.006
nevirapine
tenofovir
other 2.28   (1.5 to 3.46) <0.001 1.91   (1.24 to 2.94) 0.003
zidovudine 1.1   (1 to 1.2) 0.051 0.87   (0.78 to 0.96) 0.008
stavudine 1.35   (1.23 to 1.49) <0.001 0.99   (0.88 to 1.1) 0.813
female
male 1.51   (1.42 to 1.6) <0.001 1.15   (1.08 to 1.23) <0.001
<25 0.73   (0.57 to 0.93) <0.001 0.74   (0.58 to 0.94) 0.014
25‐49
>50 1.48   (1.36 to 1.61) <0.001 1.58   (1.45 to 1.73) <0.001
<100,000 0.61   (0.5 to 0.74) <0.001 0.73   (0.44 to 1.21) 0.217
100,000‐999,999
>1,000,000 3.43   (2.89 to 4.08) <0.001 1.85   (1.2 to 2.85) 0.005
0‐49 5.39   (5.16 to 5.64) <0.001 4.38   (3.92 to 4.89) <0.001
50‐199 2.26   (2.16 to 2.36) <0.001
200‐349 2.02   (1.81 to 2.26) <0.001
>350 0.6   (0.55 to 0.66) <0.001 1.09   (0.85 to 1.39) 0.494
2002‐2003 2.72   (2.62 to 2.82) <0.001 2.25   (2.03 to 2.49) <0.001
2004‐2005 1.85   (1.77 to 1.92) <0.001 1.55   (1.39 to 1.73) <0.001
2006‐2007 1.31   (1.27 to 1.36) <0.001 1.19   (1.09 to 1.31) <0.001
2008+
<18 1.86   (1.56 to 2.23) <0.001 1.56   (1.33 to 1.83) <0.001
18‐24
25‐34 0.64   (0.58 to 0.72) <0.001 0.8   (0.7 to 0.91) 0.003



































Finally, the results of the Cox-proportional hazard regression which included the propensity as a 
covariate is presented in Table 6.3. The propensity score (2.66 95% CI: 1.07-6.62) attenuated the 
effect of baseline NRTI (stavudine and zidovudine) and sex, but the effect of home-refill by 
courier remained similar.  




Hazard ratio (95% CI) p‐value Hazard ratio (95% CI) p‐value
home‐refill 0.88   (0.82 to 0.95) <0.001 0.9   (0.84 to 0.96) 0.003
self‐refill
efavirenz 1.13   (1.03 to 1.23) 0.012 1.14   (1.04 to 1.25) 0.006
nevirapine
tenofovir
other 1.95   (1.26 to 3) 0.003 1.91   (1.24 to 2.94) 0.003
zidovudine 1   (0.85 to 1.19) 0.957 0.87   (0.78 to 0.96) 0.008
stavudine 1.09   (0.94 to 1.26) 0.255 0.99   (0.88 to 1.1) 0.813
female
male 1.04   (0.92 to 1.17) 0.562 1.15   (1.08 to 1.23) <0.001
<25 0.81   (0.63 to 1.06) 0.121 0.74   (0.58 to 0.94) 0.014
25‐49
>50 1.5   (1.35 to 1.66) <0.001 1.58   (1.45 to 1.73) <0.001
<100,000 0.71   (0.43 to 1.18) <0.001 0.73   (0.44 to 1.21) 0.217
100,000‐999,999
>1,000,000 1.78   (1.15 to 2.76) 0.19 1.85   (1.2 to 2.85) 0.005
0‐49 4.04   (3.53 to 4.62) 0.009 4.38   (3.92 to 4.89) <0.001
50‐199 1.96   (1.75 to 2.2) <0.001
200‐349 2.02   (1.81 to 2.26) <0.001
>350 1.11   (0.87 to 1.42) 0.415 1.09   (0.85 to 1.39) 0.494
2002‐2003 2.4   (2.13 to 2.71) <0.001 2.25   (2.03 to 2.49) <0.001
2004‐2005 1.53   (1.38 to 1.71) <0.001 1.55   (1.39 to 1.73) <0.001
2006‐2007 1.16   (1.06 to 1.28) 0.002 1.19   (1.09 to 1.31) <0.001
2008+
<18 1.52   (1.3 to 1.78) <0.001 1.56   (1.33 to 1.83) <0.001
18‐24
25‐34 0.82   (0.72 to 0.93) 0.007 0.8   (0.7 to 0.91) 0.003









































6.5  Discussion and conclusions 
The main finding of this analysis is that home-refill of ARVs by courier was associated with 
significant improvements in CD4 count, viral suppression, and overall survival over a 10-year 
period relative to self-refill in AfA, a large managed-care programme in the private sector in 
South Africa. Moreover, in patients who switched from self-refill to home-refill while enrolled 
with AfA, significant improvements in CD4 count and viral load suppression were observed as 
well post switching. To our knowledge, this is the first large-scale study investigating home-based 
delivery of ARVs by courier in the healthcare system [43, 44]. This study has important 
implications for LMICs as home-refill represents a potential model for ART delivery in LMICs 
that could reduce patient burden while simultaneously improving outcomes [45].  
Home-based ART, which included clinical management, laboratory monitoring, and 
ARV delivery has been shown to be effective in a systematic review [46], but only one study has 
looked purely at ARV delivery, this time in a HIC setting [47]. In this study, home delivery of 
ARVs was associated with improved non-significant outcomes: lower virologic failures, lower 
outpatient attendances, less frequent laboratory monitoring, and less frequent abnormal liver 
function tests [47]. In terms of survival, the positive relationship between treatment outcome and 
year of treatment initiation has been described in previous analyses [48, 49], together with 
improved outcomes for females [34, 50], lower baseline VL [34], higher baseline CD4 count [34, 
48, 49], and higher BMI [51]. The choice of NNRTI and NRTI has been shown to impact 
outcomes on ART but usually favours efavirenz-containing first line regimens and first line 
regimens which do not contain stavudine [52]. 
Our data have important clinical and public health implications. First, given the burden 
that can be associated with self-ART refills (travel to a clinic, long waiting time, loss of a day job, 
etc.) [24, 53], home delivery of ART represents a possible effective intervention to improve 
clinical outcomes while reducing patient burden in clinics in LMICs. Second, such an ART 
delivery model can be considered as part of the emerging DSD, a patient-centred approach that 
simplifies and adapts services across the HIV cascade to reflect the preferences and expectations 
of different PLWH subpopulations, while reducing unnecessary burdens on the health system 
[54]. Third, with the aging of the HIV population and increasing incidence of NCD co-
morbidities [55], such home delivery models can include other chronic medication (e.g., 
hypertension, diabetes) [38]. Finally, home-based care and support strategies have been found to 
achieve retention and treatment outcomes that are comparable and even superior to those 
reported by mainstream health facilities, further underscoring the need to increase community 
service delivery [45, 56].  
This is the first large-scale study to evaluate the impact of home-refill by courier versus 
self-refill and switch from self- to- courier refill in LMICs, with a large sample size and well-
defined and documented clinical, immunological, and virological outcomes. While the study is 
informative and innovative, its limitations include its retrospective and observational nature, 
limited confounder variables in our multivariate analysis, the data being from a private-sector and 
not a public-sector cohort, and that the analysis was based on baseline characteristics. Most 
patients were adherent and remained on their initial regimen for several years. We did not 
include time-updated values (e.g., regimen, CD4, or VL), including patients who switched to 
home-refill by courier at this stage in the regression analysis, but the findings would support the 
development of a marginal structural model to confirm the results [57]. Further analyses are 
needed to address these and other limitations. 
In summary, this analysis of data from a South African private-sector programme 
suggests that home delivery of ART is associated with improved clinical, immunological, and 
virologic outcomes for PLWH in Southern Africa. As ART programmes continue to expand in 
LMICs and in aging HIV populations with an increased incidence of NCD co-morbidities, such 
community-based ART delivery models add to the growing number of differentiated service 
delivery models in LMICs and need to be investigated further and scaled-up in these settings, if 
proved cost-effective. An existing public sector initiative within the Western Cape, South Africa, 
where a central pharmacy already prepares chronic medication “packs” to speed up existing 
clinic-based dispensing, could be adapted to include home delivery for patients to alleviate clinic 
congestion and patient costs incurred in clinic attendance [29]. 
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Improving the evidence base of Markov models
used to estimate the costs of scaling up
antiretroviral programmes in resource-limited
settings
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Abstract
Background: Despite concerns about affordability and sustainability, many models of the lifetime costs of
antiretroviral therapy (ART) used in resource limited settings are based on data from small research cohorts,
together with pragmatic assumptions about life-expectancy. This paper revisits these modelling assumptions in
order to provide input to future attempts to model the lifetime costs and the costs of scaling up ART.
Methods: We analysed the determinants of costs and outcomes in patients receiving ART in line with standard
World Health Organization (WHO) guidelines for resource poor settings in a private sector managed ART
programme in South Africa. The cohort included over 5,000 patients with up to 4 years (median 19 months) on
ART. Generalized linear and Cox proportional hazards regression models were used to establish cost and outcome
determinants respectively.
Results: The key variables associated with changes in mean monthly costs were: being on the second line
regimen; receiving ART from 4 months prior to 4 months post treatment initiation; having a recent or current CD4
count <50 cells/µL or 50-199 cells/µl; having mean ART adherence <75% as determined by monthly pharmacy refill
data; and having a current or recent viral load >100,000 copies/mL. In terms of the likelihood of dying, the key
variables were: baseline CD4 count<50 cells/µl (particularly during the first 4 months on treatment); current CD4
count <50 cells/µl and 50-199 cells/µl (particularly during later periods on treatment); and being on the second
line regimen. Being poorly adherent and having an unsuppressed viral load was also associated with a higher
likelihood of dying.
Conclusions: While there are many unknowns associated with modelling the resources needed to scale-up ART,
our analysis has suggested a number of key variables which can be used to improve the state of the art of
modelling ART. While the magnitude of the effects associated with these variables would be likely to differ in other
settings, the variables influencing costs and survival are likely to be generalizable. This is of direct relevance to
those concerned about assessing the long-term costs and sustainability of expanded access to ART.
Introduction
With access to antiretroviral therapy (ART) now rapidly
expanding in low and middle-income countries, atten-
tion is increasingly turning to the affordability and sus-
tainability of these programmes [1]. Given the potential
effectiveness of treatment coupled with the scale of the
response needed, it is important that planning takes a
long term perspective. While many studies have
focussed on the effectiveness of ART in resource-limited
settings, cost studies are limited, especially those docu-
menting costs in routine and established programmes
and over longer periods of time. In recent years, the
management of ART programmes in low and middle
income countries has increasingly conformed to the
World Health Organization (WHO) guidelines for
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resource-limited settings [2]. These include guidelines
for when to start ART based on the patient’s CD4 count
or WHO stage, guidelines for monitoring ART as well
as guidelines regarding which antiretrovirals (ARVs)
should be administered within distinct first and second
line regimens. These guidelines therefore provide a good
framework for understanding disease progression and
the costs of patients in ART programmes.
Because ART has only recently been available in
resource-limited settings, lifetime costs – a key input
into the costs of scaling up - are calculated through
extrapolating primary data, with the Markov model
being the most common framework used for this extra-
polation. Many models include the baseline and current
CD4+ cell count (i.e. the most recent test value), viral
load and WHO staging, but other potential determi-
nants of costs such as adherence have been excluded.
This raises questions of the accuracy of the resulting
estimates which could have implications for attempts to
plan for expanded access to ART.
A Markov model consists of a number of mutually
exclusive and collectively exhaustive Markov states, with
at least one of these being an “absorbing state” (e.g.
death). Patients remain in each state for an equal incre-
ment of time, called a Markov cycle, before being
allowed the option of moving to a different state (or
staying in the current state) as determined by one or
more transition probabilities. In addition to time (or
survival) increments, health care costs are attached to
each state. Over a large number of cycles, lifetime costs
and life expectancy is estimated [3,4].
To establish appropriate Markov states it is thus
necessary to estimate which variables have a sizeable
impact on the costs associated with being in a state
together with the transition probabilities determining
movements between states. While many types of transi-
tion probabilities are possible, the most important is the
probability of dying as this determines overall life expec-
tancy. Because the majority of the costs of ART are
associated with ARV drugs, accurate calculation of life
expectancy is crucial for the estimation of lifetime costs
which in turn is a key input into calculations of the
costs of scaling up [5].
This paper seeks to identify the variables that have an
impact on direct health care costs and the likelihood of
dying with a view to informing the development of Mar-
kov models for estimating lifetime costs and the costs of
scaling up ART in resource-limited settings. We initially
review the ART Markov model and cost determinant lit-
erature to establish the variables and variable categories
that have been used to date. Thereafter, we assess the
importance of these through the analysis of a large
cohort from a private health care disease management
programme. While this analysis would ideally be
conducted using data from individuals receiving ART in
a range of routine models of care, including those found
in the public health care sector, these routine data are
not available. We have attempted to improve the gener-
alisability of our findings by restricting our analysis to
those patients in the private disease management pro-
gramme that receive ART in line with the WHO guide-
lines for resource-limited settings [2].
Methods
Literature review
Our literature review included all cost, cost-effectiveness
and cost-utility analyses of HIV-treatment including
ART in resource-poor settings. While most economic
analyses of ART focus on the annual per patient cost or
the cost per specified outcome measure (e.g. per patient
virally suppressed), we restricted our review to studies
that had used Markov modelling to extrapolate available
data to calculate lifetime costs and life expectancy. The
reason for this is that the life expectancy of a patient on
ART is a key determinant of lifetime costs and of the
number of patients surviving and remaining in care over
any projection period; it is therefore one of the most
important inputs into any estimation of the costs of
scaling up. A previous study by our group showed that
20% more patients would be remaining in care after a
scale-up period of 10 years if life expectancy on ART of
13 years were assumed instead of 8.5 years [6]. However,
we also included studies that attempted to ascertain the
variables influencing costs over shorter time frames
given that these could provide input into the construc-
tion of Markov states. A Pubmed search using the key-
words “cost”, “resource-poor”, “low-income country/
countries”, “middle-income country/countries”, “devel-
oping” and “antiretroviral” was conducted for all papers
published before 1 May 2009.
Model comparison and refinement
Data source
The determinants of costs and survival on ART were
evaluated using a large database of patients enrolled
with Aid for AIDS (AfA), a group that manages HIV-
related care for a number of medical insurance funds in
the private health care sector in Southern Africa. Aid
for AIDS does not manage patients directly, but rather
provides guidelines for private medical practitioners’
care of its participants and reimburses claims. Medical
care is provided via patients’ own general practitioner,
therefore there are no formal “sites” but rather several
thousand general practitioners and specialist practices
taking care of patients, including those participating
in Aid for AIDS. Treatment is funded by contracted
companies or medical aid funds (composed of
pooled monthly contributions from members) which
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substantially cover co-morbid conditions including those
not related to HIV. Data collected by AfA include
demographics and previous medical history, CD4+ cell
count, viral load and claims (including ART dispensing
data). These claims are captured monthly by AfA from
the medical insurance funds, pathology laboratories or
from the patients or treating doctors directly using rou-
tine electronic administrative systems. Claim reimburse-
ment is subject to established AfA protocols, including
protocols for ART initiation, change of ART regimen,
and the treatment of certain opportunistic infections.
Despite this being a private sector programme, antire-
troviral guidelines are similar in many respects to WHO
guidelines for resource-poor settings as well as
the South African public sector guidelines [2,7]. The
recommended initial regimen is a combination of two
nucleoside reverse transcriptase inhibitors (NRTIs) and
a non-nucleoside reverse transcriptase inhibitor
(NNRTI). Second line therapy consists of a boosted pro-
tease inhibitor (PI) with two NRTIs. Health services pro-
vided for patients within AfA include additional primary
care doctor visits for patients that have exceeded their
routine medical insurance benefits, telephonic counsel-
ling services and antiretroviral drugs dispensed monthly
from private pharmacies or delivered via courier to the
patient’s home. While ART can be initiated at CD4
<350 cells/µL rather than CD4 <200 cells/µL, we
restricted the analysis to the latter group as this is the
more common starting criterion in resource poor set-
tings, including the South African public sector at the
time of this study (these guidelines have recently been
revised to recommend ART initiation at CD4 <350
cells/µL [8]). Furthermore, we only included patients
starting ART with a NNRTI plus two NRTIs, as recom-
mended by the WHO for resource-limited settings [2].
We determined average adherence to ART using
monthly pharmacy refill data. This approach has been
shown to correlate well with adherence assessment by
therapeutic drug levels [9,10], and has been found to
reliably predict virologic suppression [11], development
of HIV drug resistance [12], and survival [13]. Previous
analyses of these AfA data have in addition shown that
this measure of adherence is a determinant of costs
[14,15]. We expressed pharmacy claim adherence as a
percentage and calculated it as the number of months
with ART claims submitted divided by the number of
complete months from ART initiation to death, withdra-
wal from the Aid for AIDS program, or study end.
Two of the medical insurance funds that contract AfA
were selected on the grounds that they had large
numbersof patients, similar treatment benefits, and no
co-payment for ART. This allowed us to describe deter-
minants of costs and outcomes without biases associated
with the patient’s ability to pay, which has been reported
to influence access to health care and outcomes on ART
[16,17]. Patients were included in the study if they were
ART naïve at entry (the exception being women who
had received prophylaxis for prevention of mother-to-
child transmission), adult (19 years or older at the time
of approval for ART) and if ART was started between
November 1998 and November 2007.
Direct health care costs were analysed from the provi-
der’s perspective. The tariff amount was used as a proxy
for these costs, as opposed to the amount charged by
the provider. This is because providers may charge dif-
ferent rates for services with the same tariff code. The
use of the tariff rate allows for the same cost to be
assumed for the same type of service.
The prices of antiretroviral drugs have fallen dramati-
cally over the past ten years. To account for this we
deflated ARV prices to the April 2007 level. All other
health care costs have increased; these were inflated to
the April 2007 level using the Consumer Price Index
net of mortgage payments (CPIX) [18]. The average
South African Rand to United States Dollar (US$)
exchange rate in April 2007 (R7.14 to US$1) was used
to convert costs to US$ equivalents [19].
Establishment of Markov states
As the distribution of mean health care costs was right-
skewed in our data, ordinary least squares regression
was not appropriate [20,21]. Generalised linear regres-
sion models (GLM) have been proposed as they deter-
mine the impact of variables on the arithmetic mean
and thus provide a method for identifying variables
strongly associated with varied costs [20]. A GLM with
a log-link function and a gamma distribution described
the trends in the data well. To account for multiple
measures within an individual as well as potentially
strong correlations between the variables, we used gen-
eralised estimated equations with an unstructured corre-
lation matrix. Variable coefficients and their 95%
confidence intervals were determined using robust stan-
dard errors and the model fit was evaluated using
deviance residuals [20].
Multiple Cox proportional hazard regression analysis
was used to identify variables associated with a likelihood
of dying. Based on the findings of both the cost and out-
come analyses, a pragmatic decision on which Markov
states to include in the final model is needed; as the
number of states increases, so the model complexity
increases exponentially. Data storage, basic calculations
and data extraction was handled in Microsoft Sequel Ser-
ver 2008. Statistical analysis was performed in Stata 10.
Ethics statement
The study was approved by the Research Ethics Com-
mittee, University of Cape Town and by the Board of
Directors of Aid for Aids. All patients signed consent
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for their information to be entered into the AfA
database.
Results
Existing models in literature
Over 300 cost, cost-effectiveness and cost-utility ana-
lyses of ART were found via a Pubmed search, but these
included only 6 different Markov models of ART in low
and middle income countries, some of which were used
in more than one publication [6,22-27]. A number of
variables were used in these studies to define Markov
states, as outlined in Table 1. These included the base-
line (i.e. pre-ART) CD4 count category, the current
CD4 count category, baseline and current viral load
categories, time on ART, being on a first or second line
ARV regimen, opportunistic infections or WHO staging;
and adverse events on ART. These variables could be
combined in a variety of ways to create distinct Markov
states depending on the model.
Model comparison and refinement
Dataset
The characteristics of the cohort are described in
Table 2. After exclusions, 5,177 patients met our eligibil-
ity criteria, with over 136,600 patient months of obser-
vation, about half of which were on ART. Median
follow-up on ART was 19 months (IQR: 10 to 32). The
proportion of patients who left the medical insurance
fund was 34%. These patients either changed their
employment, switched to a different medical insurance
scheme or voluntarily stopped their contributions to the
insurance scheme. The most common first line antire-
troviral regimen was zidovudine/lamivudine/efavirenz
(65 %). Lopinavir/ritonavir/zidovudine/didanosine was
the most common second line regimen. CD4 and viral
load monitoring was done 1.5 times per annum on
average.
Markov states
To determine the most important variables on which to
base Markov states, we assessed whether variables had a
sizeable effect on costs or on the likelihood of dying.
The literature review identified a number of differences
in the ways that variables were categorised. Using the
categories described in the literature as a starting point,
we determined the most appropriate categories for the
variables in our dataset guided by residual diagnostics,
whether overall model fit improved with a changed cate-
gorisation, and whether the p-value was significant at
the 95% confidence interval. The variables included in
the analysis were: (1) baseline CD4+ cell count (cate-
gorised as 0-49, 50-199 cells/µL) (following Cleary et al
[6,22] and Goldie et al [25]); (2) current or most recent
(carried forward for up to 12 months) CD4+ cell count
(0-49, 50-199, 200 to 349, 350 to 499, and ≥500 cells/µl)
(similar categories as Bachman [24], Badri et al [23] and
Goldie et al [25]); (3) baseline viral load (categorised
below or above 100,000 copies/ml) (Goldie et al [25]
include this variable, but use far more categories); (4)
Current or most recent viral load (categorised as <400,
400-10,000, 10,000-100,000, >100,000 copies/ml) (Goldie
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et al [25] and Vijayaraghavan et al [26] include this vari-
able, but use different categories); (5) ART regimen
(either first line or second line) (used by all except
Bachman [24]); and (6) time periods relative to ART
initiation (-4 to 4, 4 to 12, 12 to 24, 24 to 48 months on
treatment) (similar to Cleary et al [6,22]). In addition to
the variables identified in the literature, we also consid-
ered: (7) overall adherence, as determined using monthly
pharmacy claim data and divided into quartiles based on
the observed distribution of adherence in the cohort
(<42%, 42%-75%, 75%-92%, >92%); (8) the NNRTI
included in the initial first line regimen (either efavirenz
or nevirapine); (9) the duration of CD4 count monitor-
ing prior to starting ART, a proxy for duration within
pre-ART care (≤6 months and > 6 months); (10) age at
starting ART (<25, 25 to 50 and >50 years old); and (11)
sex. Our data did not allow us to include variables relat-
ing to WHO disease staging, opportunistic infections or
adverse events.
All the variables were included in the analysis explor-
ing the determinants of costs and the likelihood of
dying. In the baseline, the following initial parameter
states were assumed: (1) baseline CD4 cell count
between 50 and 199cells/µL; (2) current CD4+ cell
count between 50 and 199cells/µL; (3) baseline viral
load < 100,000 copies/ml; (4) current viral load < 400
copies/ml; (5) on first line ART; (6) time period 12 to
23 months on ART; (7) overall adherence in the upper
quartile (>75%); (8) NNRTI = efavirenz; (9) >6 months
of CD4 monitoring prior to starting ART; (10) age at
starting ART 25 to 50; and (11) sex = female
The results from the multiple regression analysis of
costs (all variables were included in the model) are
found in Table 3. Mean cost per patient month is pre-
sented for each variable or variable category and is
compared to a reference or baseline which is the mean
cost across all patients and time periods. We found
higher current CD4 counts were associated with lower
costs while having a current viral load above 100,000
copies/ml was associated with increased costs. Being
on efavirenz was more costly than nevirapine, and
being on second line was more costly than being on
first line; these findings are likely to relate to the
higher costs of the ARV drugs in these states as
opposed to other health care costs. Lower adherence
was an important driver of costs, as was time on treat-
ment, with monthly costs in the period from 4 months
before starting ART to 4 months on ART being almost
double the monthly costs thereafter. After this time,
the size and significance of the association between
costs and time on treatment waned dramatically. Fig-
ure 1 illustrates the full set of variables and their influ-
ence on the mean total monthly direct health care
costs relative to the baseline scenario.
The results from the multiple Cox proportional
hazards regression analysis of the likelihood of dying
Table 2 The characteristics of the cohort (IQR = interquartile range)
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are found in table 4. The relative likelihood of dying is
compared with the same referent groups as in the cost
analysis, but a separate model was used for each of the
time periods. We found higher current CD4 counts,
higher ART adherence, and current viral loads below
100,000 copies/ml were associated with lower likeli-
hoods of dying across all periods, with baseline values
for CD4 and viral load contributing very little addi-
tional effect after the first 4 months on treatment.
Longer duration of monitoring prior to starting ART
was associated with a lower likelihood of dying in ear-
lier periods and being greater than 50 years or younger
than 25 years at starting ART was associated with a
higher likelihood of dying in later periods. Being on
second line was associated with an increased likelihood
of dying across all periods.
Discussion
We analysed determinants of direct health care costs
and survival in 5,197 HIV-infected adults enrolled in a
South African managed care ART programme with
136,672 patient months of follow-up, spanning -4
months before ART to 4 years on ART. If each Markov
state is defined to include unique combinations of these
variables, thousands of states could be defined. A corre-
spondingly large dataset would then be needed to calcu-
late the costs and transitions associated with each of
these states. For this reason, it becomes necessary to
focus only on variables that have the most marked
effects on costs and outcomes within reasonable confi-
dence intervals. The key variables associated with
changes in mean monthly costs were: being on the sec-
ond line regimen; receiving ART from 4 months prior
Table 3 Multiple generalised linear regression analysis of the determinants of total mean monthly costs (US$)
Variables Value % change from referent p-value
Time period relative to ART initiation (months) -4 to 4 384 (321 to 459) 80% <0.001
4 to 12 238 (204 to 277) 12% 0.158
12 to 24 Referent
24 to 48 222 (182 to 270) 4% 0.705
Baseline CD4 count (cells/µL) 0 to 49 193 (164 to 227) -10% 0.228
50 to 199 Referent
Current CD4 count (cells/µL) 0 to 49 352 (290 to 426) 65% <0.001
50 to 199 Referent
200 to 349 190 (161 to 223) -11% 0.16
350 to 499 166 (141 to 195) -22% 0.002
≥500 158 (123 to 202) -26% 0.017
Baseline viral load (copies/ml) <100 000 Referent
≥100 000 220 (195 to 248) 3% 0.601
Current viral load (copies/ml) <400 Referent
400 to 9 999 219 (191 to 250) 3% 0.717
10 000 to 99 999 195 (164 to 232) -8% 0.317
≥100 000 249 (209 to 296) 17% 0.082
Overall adherence <42% 264 (235 to 297) 24% <0.001
42 to 74% 263 (233 to 295) 23% 0.001
75 to 92% 244 (218 to 273) 14% 0.019
≥92% Referent
ARV regimen First line Referent
Second line 409 (255 to 656) 92% 0.007
NNRTI in first line Nevirapine 197 (182 to 213) -8% 0.042
Efavirenz Referent
Duration of CD4 count monitoring (months) ≤6 181 (161 to 204) -15% 0.008
>6 Referent
Sex Male 206 (188 to 226) -3% 0.463
Female Referent
Age at starting ART (years) <25 194 (164 to 230) -9% 0.282
25 to 50 Referent
>50 230 (194 to 271) 8% 0.384
Referent cost 213 (178 to 256) NA NA
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to 4 months post treatment initiation; having a recent or
current CD4 count <50 cells/µL or 50-199 cells/µl; hav-
ing mean ART adherence <75% as determined by
monthly pharmacy refill data; and having a current or
recent viral load >100,000 copies/mL. In terms of the
likelihood of dying, the key variables associated with
changes in survival were: baseline CD4 count<50 cells/µl
(particularly during the first 4 months on treatment);
current CD4 count <50 cells/µl and 50-199 cells/µl (par-
ticularly during later periods on treatment); and being
on the second line regimen. Being poorly adherent and
having an unsuppressed viral load was also associated
with a higher likelihood of dying.
The relationships between these variables and costs
and outcomes were consistent with trends described in
the literature, though the scale did differ in some cases:
lower CD4 count, higher viral load, lower adherence,
and being on second line therapy was associated with
higher costs and worse outcomes. In addition, sub-opti-
mal adherence drives resistance to first line therapy,
leading to second line therapy being initiated. There was
a relative small and limited association between costs
and outcomes and the baseline pathology results (CD4
count and the viral load), most likely due to the current
or most recent CD4 and viral load results being domi-
nant. The finding that lower adherence is associated
with higher costs (in addition to its known effects on
biological variables such as CD4 count and viral load
and starting second line therapy) further supports the
need to include this variable in Markov models.
Based on the above, one would anticipate that Markov
models that use these variables as the bases of their
Markov states may have superior accuracy. However, in
our literature review, the only Markov model that
specified costs and outcomes in relation to duration on
ART was Cleary et al [6,22]. Most of the models sepa-
rated first from second line ART to capture the cost dif-
ferences, but were unable to estimate different survival
transition probabilities because data on outcomes of
patients on second line was limited. Bachmann [24],
Goldie et al [25] and Badri et al [23] all included the
current CD4 count but Cleary et al [6,22] only included
the baseline CD4 count. Baseline and current viral load
was only included by Goldie et al [25]. Opportunistic
infections or WHO staging were included in all the
models except Cleary et al [6,22]. Unfortunately these
data were not available within the AfA cohort, and we
were therefore unable to assess the importance of these
for the construction of Markov states. None of the mod-
els included sex, ART adherence, age or duration of pre-
ART care.
There are a number of limitations to this analysis.
First, our cohort consisted of private sector patients
when the majority of patients in resource-limited set-
tings are treated in the public or NGO sector. However,
the baseline characteristics of our cohort (CD4+ cell
count, proportion female and age) are comparable with
cohorts from low-income countries [28] and we
restricted our analysis to patients receiving NNRTI-
based first line ART regimens and starting ART at
CD4<200 cells/µl, in keeping with WHO recommenda-
tions for resource-limited settings [2]. While we would
not claim that our actual cost findings are generalisable
to public sector settings or to other countries, we would
argue that the variables that influence costs and out-
comes are likely to be relevant even if the magnitude of
their effects could differ. Second, the impact of specific
opportunistic infections, disease staging or adverse
Figure 1 The influence of variables on mean monthly costs
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events on costs and outcomes was not included in this
analysis as these data were not available. We are there-
fore unable to comment on the validity of this aspect of
some of the Markov models in the literature.
Conclusion
In conclusion, we have analysed the determinants of
direct health care costs and outcomes in a private health
care sector managed ART programme. Our focus has
been to use statistical techniques to determine the key
variables to include in Markov states and to use these
findings to inform future modelling of the costs of scal-
ing up ART. Our results suggest that important drivers
of costs and outcomes include time on ART, being on
first versus second line regimens, the current CD4 cell
count, the current viral load, age at starting ART and
adherence. The inclusion of these variables should be
considered for future modelling of the costs of scaling
up ART programmes.
Acknowledgments
This work was funded by the Doris Duke Charitable Foundation, Operations
Research on AIDS Care and Treatment in Africa Program, grant #2005050;
the DFID funded Consortium for Research into Equitable Health Systems and
Tibotec’s Research and Education in HIV/AIDS for Resource-Poor Countries
initiative. The funders had no role in the design of the study, analysis of the
data, or decision to publish. We are grateful to Kara Hanson and two
anonymous reviewers for their detailed comments on earlier versions of this
paper.
This article has been published as part of BMC Health Services Research
Volume 10 Supplement 1, 2010: Scaling-up health services in low- and
Table 4 Multiple Cox proportional hazard regression analysis of the relative risk of dying
Variables 0 to 4 months
on ART
5 to 12 months
on ART




co-eff (95% CI) p-
value
co-eff (95% CI) p-
value
co-eff (95% CI) p-
value








<50 N/A N/A 1.89 (0.96 to 3.72) 0.065 3.88 (2.03 to 7.41) <0.001 3.54 (2.17 to 5.75) <0.001
50-199 Referent
200-349 N/A N/A 0.58 (0.25 to 1.34) 0.206 0.19 (0.06 to 0.55) 0.002 0.74 (0.38 to 1.44) 0.376
≥350 N/A N/A N/A N/A 0.36 (0.12 to 1.09) 0.071 0.42 (0.15 to 1.17) 0.098










N/A N/A 1.09 (0.44 to 2.66) 0.270 1.42 (0.57 to 3.59) 0.967 1.32 (0.56 to 3.14) 0.033
10 000 –
99 999
N/A N/A 0.64 (0.29 to 1.41) 0.106 1.02 (0.44 to 2.36) 0.394 2.24 (1.07 to 4.7) 0.001
≥100 000 N/A N/A 1.76 (0.89 to 3.47) 0.541 1.42 (0.63 to 3.2) 0.298 3.6 (1.68 to 7.7) 0.413
ART adherence
(quartiles)
<42% 2.14 (0.69 to 6.67) 0.188 1.89 (1 to 3.57) 0.049 1.40 (0.59 to 3.29) 0.443 2.21 (0.87 to 5.63) 0.096
42 to
75%
3.18 (1.05 to 9.61) 0.04 1.78 (0.92 to 3.43) 0.086 0.65 (0.26 to 1.64) 0.362 2.58 (1.04 to 6.39) 0.041
75 to
92%
N/A N/A 1.76 (0.9 to 3.46) 0.098 0.91 (0.37 to 2.23) 0.84 1.48 (0.56 to 3.91) 0.427
>92% Referent





0.071 5.25 (2.11 to 13.06) <0.001 1.4 (0.64 to 3.06) 0.402 1.67 (1.09 to 2.56) 0.018
NNRTI in first line efavirenz Referent






<6 2.9 (0.28 to 1.26) 0.296 1.15 (0.8 to 2) 0.692 1.67 (0.85 to 2.85) 0.328 1.05 (0.59 to 1.34) 0.890




<25 0.63 (0.15 to 2.7) 0.531 2.06 (0.51 to 8.4) 0.312 1.82 (0.25 to 13.22) 0.555 2.15 (0.52 to 8.83) 0.289
25-49 Referent
≥50 1.69 (0.32 to 9.03) 0.540 2.39 (0.52 to 10.98) 0.263 1.34 (0.14 to 13.03) 0.801 3.86 (0.81 to 18.35) 0.090
Leisegang et al. BMC Health Services Research 2010, 10(Suppl 1):S3
http://www.biomedcentral.com/1472-6963/10/S1/S3
Page 8 of 9
 
117
middle-income settings. The full contents of the supplement are available
online at http://www.biomedcentral.com/1472-6963/10?issue=S1.
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Abstract
Introduction: Providing private antiretroviral therapy (ART) care for public sector patients could increase access to ART in
low- and middle-income countries. We compared the costs and outcomes of a private-care and a public-care ART program
in South Africa.
Methods: A novel Markov model was developed from the public-care program. Patients were first tunneled for 6 months in
their baseline CD4 category before being distributed into a dynamic CD4 and viral load model. Patients were allowed to
return to ART care from loss to follow up (LTFU). We then populated this modeling framework with estimates derived from
the private-care program to externally validate the model.
Results: Baseline characteristics were similar in the two programs. Clinic visit utilization was higher and death rates were
lower in the first few years on ART in the public-care program. After 10 years on ART we estimated the following outcomes
in the public-care and private-care programs respectively: viral load ,1000 copies/ml 89% and 84%, CD4 .500 cells/ml 33%
and 37%, LTFU 14% and 14%, and death 27% and 32%. Lifetime undiscounted survival estimates were 14.1 (95%CI 13.2–
14.9) and (95%CI 12.7–14.5) years with costs of 18,734 (95%CI 12,588–14,022) and 13,062 (95%CI 12,077–14,047) USD in the
private-care and public-care programs respectively. When clinic visit utilization in the public-care program was reduced by
two thirds after the initial 6 months on ART, which is similar to their current practice, the costs were comparable between
the programs.
Conclusions: Using a novel Markov model, we determined that the private-care program had similar outcomes but lower
costs than the public-care program, largely due to lower visit frequencies. These findings have important implications for
increasing and sustaining coverage of patients in need of ART care in resource-limited settings.
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Introduction
Expanding capacity to deal with the HIV epidemic is a
formidable task in low- and middle-income countries given the
scale of the epidemic and the limited public health infrastructure.
While much has been achieved to make antiretroviral therapy
(ART) affordable, access to care is still inadequate. According to
the latest UNAIDS report, only 46% of those who were in need
had started ART by the end of 2010 in low- to middle-income
countries [1].
One way to expand access to ART and improve retention
within ART care for public sector patients is to utilize the private
sector. In many low- and middle-income countries a high
proportion of doctors work in the private sector [2]. Contracting
private doctors to initiate ART and follow up public sector
patients in their private rooms according to the public sector
guidelines has been successfully implemented in Botswana [2] and
other developing country settings [3]. However, there are concerns
about the ability and willingness of individual private doctors to
implement the public health approach to ART management, and
about high costs in the for-profit private sector. To date there have
been no published comparisons of clinical and economic outcomes
of the provision of ART care to public patients between the private
sector and public sector.
In addition to the debates about public versus private ART
care, there are also questions about how frequently patients should
be followed up, and by whom. In the earlier years of ART
provision, patients were required to attend facilities for regular
consultations with doctors or nurses [4]. More recently, however,
there has been a move towards less frequent follow-up, and
towards task shifting from doctors to nurses, and from nurses to
counselors [5]. It is however unclear whether this changing
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intensity in follow-up will impact negatively on patient adherence
and outcomes.
We assessed the costs and outcomes of providing ART care for
public patients in the private versus public sector in two South
African ART programs where no co-payment from patients was
required: a grant-funded program providing care for public
patients in private practices and a public-sector program providing
care for public patients in public sector community clinics. We
utilized a newly developed Markov-model, which addresses many
of the limitations of existing models [6].
Methods
Study design
We assessed the costs and outcomes of ART provision in the
private-care and public-care models to provide care to public
sector dependent patients. We took the provider’s perspective and
only included ART-related costs: antiretroviral drugs, CD4+ cell
count (CD4) and viral load (VL) monitoring, toxicity laboratory
monitoring, and public clinic or private general practitioner (GP)
visits. We used Markov modeling to extrapolate primary data in
order to estimate results over 10 years and lifetime for costs, rates
of loss to follow-up and life years. Zero and three percent annual
discount rates were used. The model was developed using data
from the public-care cohort, and validated externally using data
from the private-care cohort. Uncertainty was assessed using
multi-way and probabilistic sensitivity analyses.
Study setting
ART care for patients in both programs followed the 2003
South African national guidelines, which were based on the 2003
World Health Organization guidelines for resource-limited settings
[7]. Patients were eligible for ART when they met the following
criteria: either a CD4 below 200 cells/mL or a WHO stage 4 illness
(other than extra-pulmonary tuberculosis) irrespective of the CD4
count. The first line ART regimen consisted of two nucleoside
reverse transcriptase inhibitors (NRTI), zidovudine (ZDV) or
stavudine (D4T) with lamivudine (3TC), with a non-nucleoside
reverse transcriptase inhibitor (NNRTI), nevirapine (NVP) or
efavirenz (EFV). Viral load and CD4 counts were monitored
6 monthly. Patients with confirmed virologic failure (two consec-
utive viral loads . = 5000 copies/ml) in spite of enhanced
adherence promotion, were switched to a second line regimen of
two NRTIs, ZDV and didanosine (DDI), in combination with a
boosted protease inhibitor, lopinavir/ritonavir (LPV/r). Safety
monitoring was limited to serum alanine aminotransferase (ALT),
complete blood count, and lipogram for patients on NVP, ZDV,
and LPV/r respectively.
Cohort Description
The public-care cohort was the Khayelitsha HIV treatment
program, which is a public sector program operating in an urban
area in Cape Town, South Africa. The program is jointly funded
by the state and a donor, Medecins Sans Frontieres. ART care was
provided at three primary care clinics. ART was initiated by
doctors but routine follow up was largely done by nurses. The
clinics operated on a queue system and therefore patients would
spend between 1–4 hours at the clinic. Counselors and peer-
educators played an important role in educating and encouraging
patients while they waited to see clinical staff. Most patients
returned to the clinic every month to collect medicines, attend
group or individual counseling sessions, and/or for clinical
assessments. We included data from the inception of the program
on 15 January 2000 until 25 Jan 2008.
The private-care cohort was the BroadReach Healthcare
program, a donor-funded (President’s Emergency Plan for AIDS
Relief (PEPFAR)) managed-care ART program. Patients were
recruited into the program at several urban and rural public sector
clinics in the Mpumulanga, Eastern Cape and Kwazulu-Natal
provinces in South Africa. ART care was provided by local
contracted general practitioners (GPs) in their private practices on
an appointment basis and visit frequency was pre-specified. The
private doctors had to successfully complete internet-based
training on the national ART guidelines before they could enroll
patients. Telephonic counseling support for the patients and
clinical guidance for the doctors was provided by Aid for AIDS, a
private sector disease management program. Patients collected
their medication from the doctors’ rooms monthly, but clinical
consultations were performed less frequently. We included data
from the inception of the program on 1 May 2005 until 31 July
2010. New patient enrollment was stopped in March 2008.
In both cohorts severely ill or complicated patients were referred
to secondary level public sector hospitals for further management
and then re-integrated back into the program once their condition
had stabilized. Data were entered prospectively into databases.
Deaths were ascertained by several mechanisms: (1) clinic staff or
private practice practitioners who learnt of a death from family
members or friends, would either complete a specific form and fax
it to a central office or capture it on a computer-based system
onsite; (2) staff and program administrators identified patients who
had missed several appointments and contacted a family member
or treatment supporter of the patient to determine whether the
patient was deceased and if so the date of death; and (3) the
patient’s South African identity number, where available, was used
to cross-reference the South African national death register to
establish whether a death was recorded.
We included adult patients (19 years and older) who started first
line ART within the programs and had a baseline CD4 count
below 200 cells/mL. The study intervals differed somewhat for
each cohort, although the median year of starting ART was 2005
in both cohorts. A patient’s follow-up period was truncated on the
date they either: transferred out of the program, died, on the study
end date, or on the last date seen if they were not seen within six
months of the end of the study period and their identity number
was not available (and we were therefore unable to ascertain
whether they had died).
Healthcare utilisation and cost data
GP or clinic utilisation was determined from the electronic
database records for both cohorts. The cost in South Africa Rands
(ZAR) for a public-sector clinic visit was determined from a
previously published estimate [4]. In that study, the unit clinic visit
costs included time allocations for nurses, doctors, and counselors,
and this has changed in more recent times due to increased task
shifting. Together with improved economies of scale and learning
by doing, cost would have fallen substantially had it not been for
substantial increases in doctor’s salaries over the same period. We
therefore decided to only use the consumer price index table [8] to
inflate costs to April 2010 levels. Private GP visit costs were
determined from contracted rates in April 2010.
Drug utilisation was divided into first line (2NRTIs and
NNRTI) and second line (2NRTIs and PI) therapy, and the
average utilisation of each drug was determined within each line of
therapy. Because estimates of ARV drug utilization were not
available within our dataset, we conservatively assumed that all
patients had received their ARVs each month and therefore
allocated full monthly ARV drug costs within the ART model.
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ARV drug costs were set at the public sector tender prices for April
2010.
There was some under-reporting of CD4 and VL monitoring,
and ARV laboratory toxicity monitoring was not recorded in both
programs. We conservatively assumed all patients underwent
laboratory monitoring as per the South African public-sector
guidelines. The guidelines recommended six monthly CD4 and
VL monitoring. Laboratory toxicity monitoring, which occurred
predominant in the first six months on ART, was limited to ZDV,
NVP, and LPV/r. We scaled the specific toxicity monitoring
utilisation associated with a specific ARV drug in accordance with
its relative proportion within the two regimen lines. All laboratory
costs were set at the public sector tender prices for April 2010. All
costs were converted from ZAR to United States Dollars (USD) in
April 2010 (7.34 ZAR per USD).
The Markov model framework, development and
uncertainty analysis
WHO stage, current CD4, and current VL were identified as
key determinants of lifetime costs and outcomes [9]. Many patients
categorized as ‘‘LTFU’’ in studies return to ART care and
therefore are not truly LTFU [10]. This is important as: (a) ART-
related resources are not consumed while a patient is LTFU, (b)
the CD4 count falls rapidly to pre-ART levels in patients who
interrupt ART [11], (c) additional resources are consumed in
patients restarting ART [9], (d) treatment interruptions increase
resistance to first line regimens [9][9][9][9][9](9)(9)(8), and (e)
treatment interruptions increase deaths [9] and attenuate CD4
recovery [12].
We based the structure of the Markov model on these
determinants of costs and outcomes as well as on our own analysis
of the public-care program – the larger of the two cohorts. We
implemented this Markov model in Treeage 2009 [13] and
populated it with parameter estimates derived in Stata 11 [14]
using survival models for time-to-event analyses and generalized
linear models for clinic/GP utilisation. We evaluated the model fit
and adjusted the model design where appropriate. Then, using the
data from the private-care program, we derived new parameter
estimates and evaluated the ability of the model to predict
outcomes and costs. This procedure allowed us to assess the
external validity of the model [4,15]. The model was run for two
durations: 10 years and until all members of each cohort were
dead (i.e. lifetime duration). Finally, we conducted probabilistic
sensitivity analysis to assess uncertainty. This entailed specifying
distributions on utilization and outcome parameters, where
possible and propagating uncertainty through the model by way
of first and second order Monte Carlo simulations. The models
were run using a 1 month cycle length [16,17].
The Markov Model
The overall Markov model was divided into two parts: an ART
model and a LTFU model (see figure 1). All patients started in the
ART model, and remained there until they either died or became
LTFU. Healthcare utilisation and mortality has been shown to be
significantly higher in the first 6 months on ART [4,6]. Therefore
the ART model was divided into two phases: 0–6 months on
starting or restarting ART and .6 months on ART. We defined
LTFU as defaulting ART for more than 6 months. Patients
entering the LTFU model remained there until they either died or
restarted ART. We used parametric survival analysis with an
exponential distribution to determine the transition probabilities to
outcomes (death, LTFU, CD4 category change, and VL category
change), and generalized regression models to determine utilisa-
tion (GP and clinic visits) within the Markov states. Covariates
included time on ART, on-ART CD4 category, on-ART VL
category, and year of starting ART (normalizing findings to 2005).
We assumed that non-HIV related deaths of a typical individual
(34 years) were included in the recorded deaths. We modeled the
increasing relative contribution of non-HIV related deaths over
time using the mortality curves for South Africa (less the typical
mortality for a 34 year old adult) before the onset of South Africa’s
HIV epidemic (prior to 1990).
In the first 6 months after starting or restarting ART, patients
were split according to their pre-ART CD4 count category (0–49
or 50–199 cells/mL), and remained within this CD4 category for
6 months. At the end of 6 months, the remaining patients (i.e. not
LTFU or dead) were distributed into the Markov states of the
.6 months on ART model using a competing risks regression
model with the pre-ART CD4 category as the only covariate. The
.6 months on ART phase was defined by fifteen Markov states.
These included: five on-ART CD4 categories (0–49, 5–199, 200–
349, 350–499, and $500 cells/mL) and three on-ART VL
categories (,1,000; 1,000–99,999; and $100,000 copies/mL).
Within each Markov cycle, we limited transitions between these
Markov states to either a CD4 or VL category change but not
both, as this reduced model complexity.
We distributed patients entering the LTFU model into the two
pre-ART CD4 categories (0–49 and 50–199 cells/mL) with the
relative proportions being derived from the observed data. Given
the limited LTFU data within our cohorts, we used the transition
probability from the higher to the lower pre-ART CD4 category
on a previously published natural history HIV model [4], and
adapted the transition probabilities from these CD4 categories to
death to match the observed trends in deaths within our cohorts.
We used a regression model to determine the transition probability
of restarting ART for patients LTFU, with time since first starting
ART as the covariate.
The transition probability from first line to second line ART
was determined separately within the two phases of the ART
model and the covariates for the regression model included pre-
ART CD4 category, on-ART VL category, on-ART CD4
category, and time since starting ART. Within the second line
ART model all transition probabilities were the same as the first
line ART model, but the ARV drug utilisation and therefore costs
differed. Patients within the LTFU model were assigned no ART-
related utilisation and therefore no costs.
Uncertainty analysis
We assessed the uncertainty in the data and model design using
probabilistic sensitivity analysis (first and second-order Monte
Carlo simulations). First-order simulations were used to capture
the variability in the simulated population and tracked the varying
paths taken by patients moving through the model in order.
Second-order simulations were used to capture the variability in
the parameter estimates by randomly sampling from the
triangular-shaped distribution for the parameter, which approx-
imated the 95% confidence interval. We ran 1,000 second-order
and 10,000 first-order simulations to determine the 95%
uncertainty intervals around the lifetime costs and outcomes. We
assessed uncertainty related to extrapolation of the data and the
generalizability of the model in three ways: (1) we externally
validated the model derived from public-care cohort using the
private-care cohort dataset, (2) we extrapolated our estimates over
10 year and life-time durations and compared the results, and (3)
we compared our outcomes and cost estimates with other
published studies. Finally, we assessed the uncertainty related to
analytical methods by comparing the findings with 0% and 3%
annual discounting of costs and outcomes.
A Model Comparing Private and Public ART Programs
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Scenario analysis
Clinic visit utilisation within the public-care program was
intensive due to a policy decision by the program managers that all
patients should be seen by a nurse or doctor every one to two
months. In more recent years, the clinic visit utilisation has been
substantially reduced to accommodate the growing number of
patients. We therefore explored the impact of reduced clinic visit
utilisation within the public-care program on the overall results.
Ethics statement
The study was approved by the Research Ethics Committee,
University of Cape Town. All patients signed consent for their
information to be entered into the central databases and analysed.
Anonymity was ensured using generated identifiers and all
personal data were deleted from the datasets.
Results
Cohorts
The characteristics and overall outcomes of the study cohorts
are described in Table 1. We included 6372 and 963 patients from
the public-care and private-care programs respectively. Median
follow-up time on ART was shorter in the public-care cohort. No
patients were transferred out to other facilities from the private-
care program. The model fit diagnostics for both the private-care
and public-care programs are shown in figures S1 and S2
respectively. These include current CD4, current VL, line of
therapy and status (current, LTFU or dead).
Health care utilization and unit costs in Markov states
Over the study period, 212,175 clinic visits in the public-care
cohort and 10,477 GP visits in the private-care cohort were
recorded. The contracted rate for a GP visit was 31.04 USD and
the estimated cost of 24.53 USD for a clinic visit was derived by
inflating the cost estimate from a previous publication [4]. The
average monthly GP/clinic utilisation (with 95% confidence
intervals) and the cost estimates are shown in table S1. Within
both cohorts, utilisation was highest in patients restarting ART
and, to a lesser extent, during the 0–6 months after starting ART,
compared with the .6 months on ART phase. In this latter phase,
monthly visit utilisation was lower in both cohorts. Importantly,
the public-care cohort had approximately 2 to 4 times higher visit
utilisation within the .6 months on ART phase compared with
the private-care cohort.
The South African public sector guidelines were used for
laboratory utilisation – the costs and utilisation are shown in
table S2. CD4 and VL were taken 6 monthly, whilst other
laboratory utilisation related to toxicity monitoring depended on
the specific antiretroviral drugs and was higher in the first
6 months on ART.
Figure 1. Markov model diagram.
doi:10.1371/journal.pone.0053570.g001
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The utilisation of individual drugs within the first and second
line ART regimens, the ART-related costs, and the hazard
coefficients and transition probabilities for the model describing
the transition between first and second line ART are shown in
table S3 and figure S3. We assumed 100% utilisation of both ARV
drugs and laboratory tests while within the ART model. The
public-care cohort had higher zidovudine but lower efavirenz
utilisation in the first line ART regimen. The public-care cohort
had higher didanosine utilisation in the second line ART regimen.
The transition probability of moving to second line ART was
lowest in the 0–6 months after starting ART and highest in the 0–
6 months after restarting ART. In the .6 month on ART phase,
the transition probability of moving to second line ART decreased
with lower VL and higher CD4 categories respectively, increased
with time on ART and plateaued at about 3 years. The transition
probabilities to second line ART were generally lower in the
private-care cohort. The estimated distribution of time between
first and second line ART was 61% and 39% in the public-care
cohort versus 66% and 34% in the private-care cohort.
Effectiveness
The transition probabilities for the CD4 and VL models on
ART are shown in table S4. The baseline CD4 category
distribution for patients starting ART was similar in both cohorts:
30% in the 0–49 cells/mL category and 70% in the 50–199 cells/
mL category. A lower baseline CD4 category was associated with a
lower CD4 category distribution after 6 months on ART, but
lower baseline CD4 category did not impact on the VL
distribution. Public-care patients were more likely than private-
care patients to have VL ,1000 copies/ml (92% versus 87%) and
CD4 counts $200 cells/mL (64% versus 42%) after the first
6 months on ART. This trend was similar for patients restarting
ART, but the outcomes were worse: 61% and 43% had VL,1000
copies/ml, and 49% and 63% had CD4 counts ,200 cells/mL for
patients in the public-care and private-care cohorts respectively.
The transition probabilities and hazard coefficients for deaths
on ART are shown in table 2. The transition probability to death
was highest in the first 3 months on ART and in patients with a
low pre-ART CD4 category. The transition probability to death
was lowest for the first 6 months after restarting ART. For patients
in the .6 months on ART phase, the transition probability to
death decreased with lower VL category, higher CD4 category,
and time on ART (using a Gompertz time function). The median
of the Gompertz time function was 20 months in both cohorts, but
the scaling constant was higher in the private-care cohort (1.19
versus 1.04). Thus there were more early deaths in the private-care
cohort.
The hazard coefficients and transition probabilities related to
the LTFU model are shown in table 3. The transition probability
from ART to LTFU was lowest in the first 6 months after starting
ART and highest in the first 6 months after restarting ART.
Thereafter, the transition probability from ART to LTFU
increased with higher VL category, lower CD4 category, and
time on ART. We modeled the effect of time on ART by adapting
the Gompertz function so that it plateaued. The median of the
adapted Gompertz function was longer (12 months versus 8) and
the scaling constant has higher (1.5 versus 0.5) in the public-care
compared with the private-care cohort. We distributed patients
entering the LTFU model as follows based on our analysis of the
data: 30% to the 0–49 cells/mL and 70% to the 50–199 cells/mL
CD4 categories. The transition probability from LTFU to
restarting ART was higher in the private-care cohort (26% versus
13%) and independent of LTFU CD4 category.
The highest death rates were observed within the first year on
ART for both cohorts, especially in the private-care cohort: 8%
and 15% had died by 12 months and 32% and 39% had died by
120 months in the public-care and private-care cohorts respec-
tively. The distribution of VL categories stabilized by 3 years to
90% and 85% of patients having a VL ,1000 copies/ml within
public and private-care cohorts respectively. The distribution of
CD4 categories was more dynamic over time and the private -care
cohort fared better with 50% versus 40% of patients having a CD4
$500 cells/mL by 10 years. The percentage of patients who were
alive and still on ART stabilized at approximately 80% for both
cohorts, although the private-care cohort achieved this earlier due
to generally higher transition probabilities to and from LTFU.
Ten-year and lifetime costs, outcomes, probabilistic
sensitivity and scenario analysis
We ran Monte Carlo simulations for 10 years and until
everyone had died to generate lifetime costs and outcomes
together with their 95% confidence intervals, as shown in table 4.
The conclusions we derived from the 10 year and lifetime
estimates (with and without discounting) were congruent: the
private-care program was approximately as effective, but was less
costly than the public-care program. These reduced costs were
predominantly driven by the lower level of utilisation in the
private-care program. Given that the outcomes between the two
programs were not significantly different, this finding suggests that
reduced visit utilization has the potential to be cost saving
(reducing costs without impacting on patient outcomes).
When we reduced the frequency of clinic visits in the
.6 months on ART phase by two-thirds in the public-care
program (in line with the changes introduced in late 2011 by the





IQR (28,7 to 39,3) (30,4 to 41,9)
Sex (%)
Female 67,7 68,3
CD4 count (cells/ml) baseline
Median 99 92
IQR (44 to 161) (44 to 146)
Unknown 435 3
Viral load (log10) baseline
Median 5,1 5,1
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program administrators), the estimated 10-year and lifetime costs
within the public-care program approximated the levels observed
in the private-care program. In other words, the programs were
equivalent in terms of costs and outcomes.
Discussion
We determined that the private-care program had lower costs
and similar outcomes to the public-care program at the time of the
study using a novel Markov model. Key differences between the
programs were less frequent visits and higher rates of returning to
care after loss to follow-up in the private-care program, and lower
early death rates on ART, but more deaths while LTFU in the
public-care program. We estimated that the recent shifts towards
less frequent visits in the public-care ART program would achieve
large cost savings, making the costs of the two programs similar.
These findings suggest that properly managed private-care
programs can ease the burden of ART care in endemic countries
by looking after public sector patients without increasing costs.
Further, reducing clinic visits may be a viable strategy to save costs
while maintaining outcomes in public sector programs.
Our Markov model included several significant improvements
on previously published models [4,18–22]. First, we separated out
the first six months on ART, as outcomes and costs in this period
are driven by baseline CD4 count and program protocols (higher
frequency of clinic visits and toxicity monitoring) [6]. Second, we
developed a novel LTFU model, in which patients transitioned
between ART and LTFU, changed baseline CD4 count within
LTFU, and transitioned to death within LTFU. Third, we
developed Markov models to account for CD4 and VL category
changes within the ART and LTFU models. Fourth, we developed
a more detailed model describing the transition between first line
and second line ART, which is a major cost driver [23]. Fifth, the
model included the impact of time on ART on the transition to
LTFU, death, and second line ART. Finally, we assessed the
external validity of the model by first developing the model using
the public-care program data and then validating it using private-
care program data. The fact that our novel Markov model was
able to describe the data from two very different models of ART
care suggests that its utility may be generalizable.
We are aware of one other study that compared costs and
outcomes after 1 year in public-care and private-care programs for
Table 2. Transition probabilities and hazard coefficients for deaths on antiretroviral therapy.
Variables
Transition probabilities and hazard coefficients (95% CI) per 1
month cycle
Public-care Private-care
First 6 months after starting antiretroviral therapy
Transition probability
3 months CD4 0–49 cells/mL 0,035 (0,029 to 0,044) 0,040 (0,029 to 0,056)
3 months CD4 50–199 cells/mL 0,010 (0,008 to 0,012) 0,017 (0,013 to 0,022)
6 months CD4 0–49 cells/mL 0,011 (0,010 to 0,014) 0,027 (0,021 to 0,036)
6 months CD4 50–199 cells/mL 0,003 (0,003 to 0,004) 0,011 (0,009 to 0,014)
First 6 months after restarting antiretroviral therapy
Transition probability: 0–6 months 0,008 (0,004 to 0,016) 0,004 (0,001 to 0,010)
.6 months on antiretroviral therapy
Hazard coefficient due to CD4 and VL
CD4 0–49 cells/mL VL ,1,000 copies/ml 25,01 25,03
CD4 0–49 cells/mL VL 1,000–100,000 copies/ml 24,71 24,69
CD4 0–49 cells/mL VL .100,000 copies/ml 23,83 24,13
CD4 50–199 cells/mL VL ,1,000 copies/ml 26,00 26,5
CD4 50–199 cells/mL VL 1,000–100,000 copies/ml 25,69 26,16
CD4 50–199 cells/mL VL ,1000 copies/ml 24,82 25,6
CD4 200–349 cells/mL VL .100,000 copies/ml 27,25 27,48
CD4 200–349 cells/mL VL 1,000–100,000 copies/ml 26,94 27,14
CD4 200–349 cells/mL VL ,1000 copies/ml 26,07 26,58
CD4 350–499 cells/mL VL .100,000 copies/ml 27,63 28,53
CD4 350–499 cells/mL VL 1,000–100,000 copies/ml 27,32 28,19
CD4 350–499 cells/mL VL .100,000 copies/ml 26,45 27,63
CD4 $500 cells/mL VL ,1,000 copies/ml 27,76 28,16
CD4 $500 cells/mL VL 1,000–100,000 copies/ml 27,46 27,82
CD4 $500 cells/mL VL .100,000 copies/ml 26,58 27,26
Hazard coefficients for Gompertz function
alpha 0,93 (0,52 to 1,34) 1,73 (1,17 to 2,28)
beta – half-life (months) 20 20
doi:10.1371/journal.pone.0053570.t002
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Table 3. Transition probabilities and hazard coefficients related to loss to follow-up.
Variables Transition probabilities and hazard coefficients (95%) per 1 month cycle
Public-care Private-care
Transitions within ART model
Transition probability to LTFU within 0–6 months on ART
On starting ART 0,0085 (0,0080 to 0,0091) 0,0006 (0,0006 to 0,0006)
On restarting ART 0,0270 (0,0205 to 0,0356) 0,0251 (0,0251 to 0,0251)
Hazard coefficient to LTFU within .6 months on ART
CD4 0–49 cells/mL VL ,1,000 copies/ml 24,7 25,13
CD4 0–49 cells/mL VL 1,000–100,000 copies/ml 23,79 24,16
CD4 0–49 cells/mL VL .100,000 copies/ml 24,00 24,37
CD4 50–199 cells/mL VL ,1,000 copies/ml 25,31 25,44
CD4 50–199 cells/mL VL 1,000–100,000 copies/ml 24,4 24,47
CD4 50–199 cells/mL VL ,1000 copies/ml 24,61 24,68
CD4 200–349 cells/mL VL .100,000 copies/ml 25,73 24,52
CD4 200–349 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 200–349 cells/mL VL ,1000 copies/ml 25,03 23,76
CD4 350–499 cells/mL VL .100,000 copies/ml 25,73 24,52
CD4 350–499 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 350–499 cells/mL VL .100,000 copies/ml 25,03 23,76
CD4 $500 cells/mL VL ,1,000 copies/ml 25,73 24,52
CD4 $500 cells/mL VL 1,000–100,000 copies/ml 24,82 23,56
CD4 $500 cells/mL VL .100,000 copies/ml 25,03 23,76
Hazard coefficients for Gompertz function
alpha 1,5 0,5
beta – half-life (months) 12 8
Initial distribution within LTFU model
CD4 0–49 cells/mL 0,278 (0,255 to 0,302) 0,243 (0,217 to 0,269)
CD4 50–199 cells/mL 0,722 (0,745 to 0,698) 0,757 (0,783 to 0,731)
Transitions within LTFU model
Transition probability between CD4 category
CD4 50–199 to CD4 0–49 cells/mL 0,005 (0,005 to 0,005) 0,006 (0,006 to 0,006)
Transition probability back to ART
CD4 0–199 cells/mL 0,134 (0,128 to 0,141) 0,146 (0,139 to 0,154)
Transition probability to death
CD4 0–49 cells/mL 0,006 (0,005 to 0,008) 0,006 (0,005 to 0,008)
CD4 50–199 cells/mL 0,001 (0,001 to 0,017) 0,001 (0,001 to 0,017)
doi:10.1371/journal.pone.0053570.t003
Table 4. 10 year and lifetime estimates of cost and outcomes of the private-care and public-care programs.
Treatment option 10 year estimates Lifetime estimates
Costs (95% CI) in USD Life years gained (95% CI) Costs (95% CI) in USD Life years gained (95% CI)
Undiscounted
Public-care 8,825 (8,614 to 9,036) 7.6 (7.4 to 7.8) 18,734 (17,385 to 20,083) 14.1 (13.2 to 15.0)
Private-care 6,187 (5,997 to 6,377) 7.2 (7.0 to 7.4) 13,062 (12,077 to 14,047) 14.0 (13.1 to 14.8)
Discounted
Public-care 7,688 (7,513 to 7,863) 6.7 (6.5 to 6.8) 13,305 (12,588 to 14,022) 10.4 (9.9 to 10.9)
Private-care 5,407 (5,250 to 5,564) 6.3 (6.2 to 6.5) 9,273 (8,704 to 9,842) 10.0 (9.4 to 10.5)
doi:10.1371/journal.pone.0053570.t004
A Model Comparing Private and Public ART Programs
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e53570 
126
public sector patients [24]. Their private-care program had
significantly lower costs due to fewer GP visits and poorer patient
retention than their public care program. The costs of providing
ART care were similar, although patient retention was better in
our programs. Lifetime analyses using Markov models populated
with data from resource-limited settings predicted varying survival
on ART (6 to 13 years) and varying discounted total costs (3,000
to 9,500 USD from the provider’s perspective) [16,18,21–
23,25,26]. Many of these models were developed using short
term follow up data. Furthermore, retention within ART
programs and cost of providing ART care in resource-limited
settings varies dramatically [27,28]. We estimated that average
survival on ART was longer than most resource-limited setting
model estimates.
The patients included in this analysis were public-sector patients
receiving ART care in accordance with WHO public sector ART
program guidelines. Therefore the results from this analysis have
important policy implications that are relevant to other resource-
limited settings. The rapid expansion of access to ART in
resource-limited settings is both needed [29] and challenging [30].
Our findings suggest that managed private-care for public sector
patients could be used to increase access to ART, provided that
the private practices follow national protocols and that loss to
follow-up is managed – key components of the private-care
program in our study. A similar model was implemented in
Botswana to expand access to ART in areas where limited public-
sector resources were available, by utilising doctors working in
private practice to look after public sector patients [2]. Their
findings suggested that ART care coverage was extended by 10%
and public-sector programs were strengthened by the interaction
[2]. We found that reduced utilisation of clinic visits, especially
after the initial six months of care, would considerable lower costs
of public-care programs. Finally, our model predicted that LTFU
contributed significantly to deaths, utilisation of ART-related
resources (on restarting ART), and attenuated CD4 recovery. This
suggests that focusing on reducing LTFU could be a cost-saving
strategy.
There were several limitations to our study. First, the findings in
our study are based on a model that extrapolated the trends we
observed over the first 3–5 years on ART predominantly. Second,
we limited costs in this study to direct ART care costs, while the
other components of care represent a significant portion of total
costs [31]. Data on these other cost components were not
available. Third, we did not account for the impact of adherence
on the total cost of ART drugs, nor the changing composition of
specific drugs within the therapy lines over time [31,32]. Fourth,
given the limited data on actual laboratory utilisation, especially
for toxicity monitoring, we set the laboratory utilisation to those
recommended in national guidelines. Fifth, it is likely that the
patients within the public-care program had better access to HIV
clinic services than typical public-sector patients in South Africa,
and this would have increased costs, and possibly enhanced patient
retention and improved outcomes [33]. Sixth, the relative
proportions of individual drugs within the lines of therapy differed
between cohorts: the average ART costs were marginally lower in the
private-care program and the different regimens may have impacted the
outcomes. Seventh, given the different models of ART care and
different settings in which the programs were based, these
programs were not completely comparable and therefore the
overall conclusions in terms of costs and outcomes cannot be
regarded as definitive. Finally, our public sector clinic visit cost was
based on secondary data, which may not capture recent
programmatic changes in ART provision (including task shifting)
and economies of scale and scope. However, it is difficult to predict
the extent to which this unit cost may under or overestimate costs.
In moving towards universal access to ART, South Africa intends
to offer ARVs from all primary care facilities, which will have
implications for the efficiency of service provision and the resulting
unit cost. Economies or diseconomies of scale can equally arise in
small new facilities during start-up and in older large facilities with
high patient volumes.
While analyses of provider costs and patient outcomes are
crucial in guiding resource allocation for HIV care, it is equally
important to consider barriers to patient access, particularly within
the context of lifelong care [34]. Evidence suggests that the key
barriers to ongoing ART care include the cost of transport to
facilities as well as the opportunity cost associated with long
waiting times in facilities [34,35]. Less frequent visits would
mitigate these access barriers. One advantage of private care is
that waiting times are usually shorter.
Conclusions
In conclusion, we have developed a novel Markov model that
has the potential to improve the accuracy of estimations of future
costs and outcomes of long-term ART care. We have used this
model to evaluate two ART programs, and have shown that
managed private-care ART programs have the potential to
complement the public sector platform in resource poor settings,
thereby enhancing and sustaining coverage of patients in need.
Our findings suggest that cost savings could be achieved through
reducing clinic utilization without compromising patient out-
comes.
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Chapter 9:  Conclusion 
9.1  Overview  
In light of the 90-90-90 goals for 2020, it is crucial that LMICs address barriers to screening, 
ART initiation, adherence to ART, and retention in care if they are to eradicate the epidemic by 
2030 [1]. In this thesis, we present a collection of studies focusing on the outcomes and cost-
effectiveness of different models of ART delivery in South Africa. The focus on different 
models of ART delivery is relevant given that only 56% of the estimated 7.1 million PLWH in 
South Africa were accessing ART in 2016 [2] and yet many of the public sector clinics are already 
congested. This thesis presents novel approaches, including the possibility of home-refill by 
courier or using GPs to treat public sector patients, thereby reducing the burden faced by 
primary health care services while simultaneously improving patient outcomes. Such approaches 
are required both to reach the untreated and retain treated PLWH in resource-limited high-
burden settings like South Africa [3]. 
The data for the studies presented in this thesis come from a variety of South African 
programmes, from which cohort data were extracted and prepared for analysis. This involved 
working closely with the programme administrators to extract and prepare the cohort dataset 
with an understanding of the various limitations and strengths of these data systems. The 
importance of real-world or observational data and their potential to inform policy decisions 
have been established [4, 5]. Working with these data, however, presents several challenges. For 
example, in the case of claims data from the AfA programme, this process was significant given 
the sheer volume of the data and the difficulty of assigning nearly 50,000 distinct items into 
sensible categories. A summary of these data and the methodologies is presented in Chapter 3, 
together with a cohort profile in chapter 4 of adults within the AfA programme. While the 
majority of patients receiving care through AfA were of black ethnicity and from South Africa, 
their socio-economic status would have been significantly better than that of most South 
Africans accessing HIV care through the public sector clinic system. The choice of antiretroviral 
drugs was also different. Therefore, given that the findings were based on observational data and 
included private sector programme data, their generalizability into public sector HIV 
programmes remains uncertain.  
This thesis is presented as a series of studies, which together represent the typical journey 
followed within an economic evaluation, starting with source data, from which a cohort is 
established, then onto cost and outcome analyses and, finally, the development of a Markov 
model for the purpose of establishing the cost-effectiveness of a particular intervention for the 
purpose of informing policy at a national level.  
In Chapter 5, a detailed cost analysis is presented, including the period leading up to 
ART initiation, which is not typically available for large numbers of patients in LMICs. The 
determinants of early and late costs are explored within the same chapter. In Chapter 6, an 
outcome analysis of a potential model of care for HIV patients is presented. In this analysis, we 
compare CD4 count, VL response, and survival on ART in home-refill by pharmacy and self-
refill. In Chapter 7, an outcome analysis and cost analysis is presented, together with a literature 
review of Markov models from LMIC settings. The intention of this chapter is to provide a 
foundation for the establishment of a Markov model, the most common framework for 
evaluating cost-effectiveness. Finally, in Chapter 8, a novel Markov model is presented, where we 
compare the costs, outcomes, and cost-effectiveness of GPs versus standard of care (i.e., a 
primary HIV clinic in Cape Town) for public sector patients starting ART.  
9.2  Key findings 
In Chapter 5, we described the costs of HIV treatment and related care, taking into account the 
patients’ CD4 and timing relative to starting ART (before, around, and long-term after starting 
ART). We found that variables associated with higher mean total costs changed considerably 
over time. Starting ART at higher CD4 counts or longer pre-ART care should reduce early 
costs. Monitoring ART adherence and implementing interventions to improve it should 
reduce later costs. Cost models of ART should take into account these time-dependent cost 
drivers and include costs before starting ART.  
In Chapter 6, we compared home-refill by courier pharmacy with self-refill outcomes 
and found CD4 response, VL suppression rates, and adjusted survival (hazard ratio 0.90, 95% 
CI: 0.70–0.91) were improved in the home-refill group. Moreover, median CD4 count (390 
versus 363 at 2 years and 483 versus 414 at 4 years) and viral suppression (81% versus 71% at 2 
years and 82% versus 69% at 4 years) were significantly higher in those that switched from self-
refill to home-refill. 
In Chapter 7, the key variables associated with changes in mean monthly costs were: 
being on the second line regimen; receiving ART from 4 months prior to 4 months post-
treatment initiation; having a recent or current CD4 count <50 cells/µL or 50-199 cells/µl; 
having mean ART adherence <75% as determined by monthly pharmacy refill data; and having a 
current or recent viral load >100,000 copies/mL. In terms of the likelihood of dying, the key 
variables were: baseline CD4 count<50 cells/µl (particularly during the first 4 months on 
treatment); current CD4 count <50 cells/µl and 50-199 cells/µl (particularly during later periods 
on treatment); and being on the second line regimen. The findings were informed by standard 
statistical approaches (i.e., GLM, survival model) but alternative approaches could include 
machine learning, which focuses more on data than hypotheses and is less vulnerable to missing 
priors. 
In Chapter 8, we applied the lessons from Chapter 7 and built a Markov Model. Clinic 
visit utilization was higher, and death rates were lower in the first few years on ART in the public 
care compared with the private care programme. The model analysis found lifetime 
undiscounted survival estimates were 14.1 (95% CI 13.2– 14.9) and (95% CI 12.7–14.5) years 
with costs of USD 18,734 (95% CI 12,588–14,022) and USD 13,062 (95% CI 12,077–14,047) in 
the private care and public care programmes respectively. When clinic visit utilization in the 
public care programme was reduced by two-thirds after the initial 6 months on ART, which is 
similar to current practice, the costs of the programmes were comparable. 
9.3  Strengths and limitations of the studies 
The focus of this thesis on models of ART delivery and the inclusion of under-represented or 
novel models, namely using private GPs to care for public sector patients and home-refill by 
courier pharmacy, respectively, are significant strengths of this thesis. There are few published 
studies on these approaches to patient care from which to inform policy, and the positive 
findings lend support to those wishing to undertake the necessary pilot studies to validate these 
associations. Improving patient outcomes and retention through differentiated models of care is 
key if we are to achieve the 90-90-90 UNAIDS goals, especially in LMICs where the burden of 
disease as well as the impact of socioeconomic status on the ability to access care are significant. 
Moreover, the NHI plan for South Africa seeks to draw in the private sector and engaging with 
strategies such as those presented in this thesis (using private GPs to treat public sector patients 
and courier pharmacy companies to dispense chronic medications) approaches would seem to be 
positive for both patients and providers of health care in LMIC settings. 
The major limitation of this body of work is that it is based on observational data and, 
therefore, the findings are subject to the limitations of selection bias and non-similarities in the 
cohorts and comparison groups. We were rigorous in the methodologies we applied but were 
constrained by confounder variables available for the analyses and the settings in which the 
studies were based. Marginal structural models offer a means of improving the robustness of the 
calculations and therefore could better inform policy and clinical trial decisions. The approach of 
using cohort data – in combination with rigorous methodologies – to inform policy is relevant 
given the contracting donor funding for research and operational systems in Africa. 
Furthermore, we were able to extract significantly more detailed and comprehensive cost data 
from the private sector cohort than is usually available in public sector settings. While the 
magnitude of the effects would be likely to differ in other settings, the variables influencing costs 
and survival in private settings are likely to be generalizable and therefore relevant to public 
sector programmes.  
9.4  Policy recommendations 
Our data have important clinical and public health implications for South Africa and other 
resource-limited settings. In spite of the limitations of the methodologies and datasets, these 
studies were able to influence policy decisions and shape the direction of future research because 
of the importance of research in ART delivery models and the limited availability of published 
research on the topic in LMIC settings. 
An ART delivery model should be considered part of the emerging differentiated service 
delivery (DSD), a patient-centred approach that simplifies and adapts services across the HIV-
cascade to reflect the preferences and expectations of different PLWH sub-populations while 
reducing unnecessary burdens on the health system [6]. Adherence to ART is complex and likely 
to be confounded; the burden that can be associated with self-ART refills is significant (travel to 
a clinic for ART refills, long waiting time, loss of a day job, etc.) [7, 8], and therefore home 
delivery of ART represents a possible effective intervention to improve clinical outcomes while 
reducing patient burden in clinics in LMICs. An existing public-sector initiative within the 
Western Cape, South Africa, where a central pharmacy already prepares chronic medication 
“packs” to speed up existing clinic-based dispensing, could be adapted to include home-delivery 
for patients to alleviate clinic congestion and patient costs incurred in attending the clinic to 
collect ARVs [9]. With the aging of the HIV population and increasing incidence of non-
communicable disease (NCD) co-morbidities [10], such home delivery models can include other 
chronic medication (e.g., hypertension, diabetes) [11]. 
A GP model for ART delivery for public sector patients has been successfully 
implemented in other resource-limited settings like Botswana [12]. Our findings suggest that 
such a model  is cost-effective (saving costs and generating additional benefits) and should, 
therefore, be considered in South Africa. The findings are particularly relevant in view of the 
intention to incorporate private doctors, hospitals, administrators, and medical schemes into the 
NHI. 
9.5  Recommendations for future research 
1. Further research is needed to confirm the findings that home-refill by courier for the 
provision of ART in a public sector setting is indeed associated with improved outcomes. 
We are currently developing a marginal structural model (MSM) which will allow those 
who switched from home-refill by courier to self-refill to be included in the regression 
analysis. If the findings of an MSM analysis prove similar, we would recommend a pilot 
study be conducted to determine the impact in the public sector. 
2. Further research is also needed to establish the cost-effectiveness of home-refill by 
courier for the provision of ART in a public sector setting in light of the positive findings 
in Chapter 6 and literature on adherence clubs. Ensuring adequate patient adherence to 
ART and retention in care through novel strategies is critical if we are to eliminate the 
HIV epidemic. Home-refill by courier would likely be associated with higher ART costs 
due to higher dispensing rates; given that less than 100% of medicine is collected in a 
self-refill setting, the outcome of the cost-effectiveness analysis will be uncertain. 
3. Further research is needed on the impact and costs of centralized dispensing systems for 
public sector clinics (e.g., the Chronic Dispensing Unit in the Western Cape, South 
Africa, which simplifies dispensing for the pharmacist and shortens waiting times at 
public sector clinics in the Western Cape) [13]. 
4. Ongoing research is being conducted on a GP model for ART delivery in South Africa in 
anticipation of NHI implementation [14].  
5. Further research is needed on the relationship between HIV and other chronic illness 
requiring ongoing medication as polypharmacy in itself creates further pill burden and, in 
some cases, additional visits. There is a renewed drive within government to launch the 
NHI in South Africa and independent GPs are key resources which have remained 
untapped in South Africa [15].  
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Appendix 2:   





AfA does not dispense medication . Please fax this completed form to 0800 600 773 or email it to afa@afadm.co.za 




Gender MALE FEMALE 




Date of Birth 
[ 
r· MALE I FEMALE :1 
I D / D I M I M / v / v / v / v / 
Treatment Support is a vital part of the AfA programme. Contact details must be supplied to enable us to provide you with this support. 
Confidential Email 




Preferred form of 
communication 
What time of day is 
the best time for 
AfA to contact you? 
First Name 
Surname 
~==========-=·====:J==: Telephone(Home) ::==============-==~l 
Telephone(Work) _ 
EMAIL =r FAX Cellphone 
First Language ~[=================~ 
Second Language L ________________ _ --1 
C MORNING AFTERNOON J 
"=::J Telephone(Home) 
'.=== ========; ::::-==-=-=-=======~ 
'-- --- ---- ---- -__J Telephone(Work) l_================ 
Cellphone J 
I understand that all personal clinical information supplied to the Aid for AIDS (AfA) programme will be used to determine access to specific benefits 
for people with HIV infection. AfA will take all reasonable steps to maintain confidentiality. The programme's medical staff will review this 
information in order to make recommendations regarding the provision of these benefits. Your doctor, however, retains responsibility for your care. 
irrespective of the benefits so authorised. 
I/we therefore, authorise any doctor. hospital, clinic, laboratory and/or medical facility in possession of any medical information regarding myself. 
the applicant or any dependant (atso newly born baby), to provide the AfA programme with information that it may require. I warrant that the 
information in this application form is correct. 
I acknowledge that completion of the application form does not automatically entitle me to any benefits and that acceptance to the programme is 
within the sole discretion of AfA. I acknowtedge that I am familiar with the conditions and benefits of the programme. notwithstanding 
representation by any other party; and agree to abide by and undertake to familiarize myself with the rules of the programme as amended from time 
to time. I acknowledge that benefits authorised by the AfA programme are subject to scheme rules and that non adherence to the programme 
could result in my benefits from this programme being cancelled. I acknowledge that I will be responsible for any co-payments as per scheme rules 
or payment for any medication and/or investigations not authorized by AfA. 
I understand that acceptance onto Aid for AIDS means that an AfA treatment support counsellor will contact me. 
I herewith authorize AfA and ijs agents/medical staff to disclose the medical information relevant to my HIV infection to third parties for the purpose 




- ====]/~D;ep;Cod;e=: ==J/~Pa;lie~-nt~N;a~m~e=: ====-----------------,,.-==--





AfA does not dispense medication - Please fax this completed form to 0800 600 773 or email it to afa@afadm.co.za 
This page needs to be completed by - The Doctor 




Preferred form of 
communication 
When was HIV infection first diagnosed? (Please attach reports) 
Type of screening test 
Type of confirmatory test 
Is the patient currently being treated for tuberculosis? I YES I NO 
Has the patient previously been exposed to antiretrovirals? 
Test date I D I D j M i M I y I y I y I y j 
Test date I D I D I M ! M I y I y / y / y j 
If YES, specify start date @.li_[~_ [iii.I~] 
I YES - MTCT prophylaxis / YES - Other I NO 
Drugs Start Date End Date Duration (Months) Reason for discontinuation 
1--- - - - - - - - - - - - ---t- - - --- ~-- --t-- --- ---t~ - - - --- - - --- ----- --1 
1--- -- - --- --- - ---t- --- -+-- ---+-- --- --+---- --- --- ---- - --- - - -
1-- -- --- - - --- ----t--- - -+-- - - -+-- - - - --+- -- --- - -- - ---------
Current combination patient is taking ' Start Date I D I D I M : M / Y / Y I Y I Y I 
~ ---------- --- - - --- --~ 
Please list all other medication the patient is taking, including prophylaxis 
~- ----- --- --- - - - - - --- - - - ~ 
Is the patient allergic to any medication? Sulphonamides I YES I NO I Other allergies? j YES I NO / If YES, specify [ ___ _ ___ _ _ __] 
f1r,~'!11a![!~ ·f!q~1l!~}9 Pr~~!n{t~~y,pfse !,~e.[i!f~~~ct ~C~ffak1~ 'd~~~~ ii~ ;'-.-~.'~:t.~-::t,i~-. :, ·r: !: i~ .. :·i':~ ~-?~-ii:; ~'---~-~ :;: _ i _::  ! _____ -_; ;, ·,;-; :~~ '.~- '~ n 
Current heavy alcohol intake? (i.e. more than 4 drinks per day for a long period of time) I YES I NO 
Current recreational drug use? (Cannabis, Cocaine, Ecstasy, LSD etc.) I YES I NO 
Current depression or psychiatlic illness? [ YES I NO 
If YES, specify treatment 
Current use of traditional or herbal remedies? I YES I NO I 
Medical Aid No: Dep Code: Patient Name: ;_page 2~f 4' 




Your /Jfe_ Our life. 
Application Form 
Confidential 
AfA does not dispense medication - Please fax this completed form to 0800 600 773 or email it to afa@afadm.co.za 




WHO Clinical Staging 2 
Please tick disease below if Stage 3 or 4 
3 
clinical Stage 3 --Adult I Adolescent · 
Unexplained severe weight loss (>10% of body weight) 
Unexplained chronic diarrhoea > one month 
Unexplained persistent fever > one month 
Persistent oral candidiasis 




Severe bacterial infections (e.g pneumonia) 
--------- -------
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis ' I 
I 
Unexplained anaemia,neutropaenia.chronic thrombocytopaen;- - : 
Clinical Stage 3 -Paediatric - · 
Unexplained moderate malnutrition 
----------------------------- f---
Unexplained persistent diarrhoea (14 days or more) 
Unexplained persistent fever > one month 
~rsistent oral_ candidiasis (~fter first~ ~eeks o~ ~f-e)___ _ ---
Oral hairy leukoplakia 
Acute necrotizing ulcerative gingivitis/ periodontitis 
I Lymph n~de-~ __ 
1 PulmonaryTB ----- ---------- ----
Severe recurrent bacterial pneumonia 
Symptomatic lymphoid interstitial pneumonitis 
Chronic HIV-associated lung disease including bronchiectasis 
Unexplained anaemia,neutropaenia,chronic thrombocytopenia 
Is there any degree of peripheral neuropathy? I YES I NO 
If YES, please specify I MILD 
Is there any other significant clinical finding? 
If YES, please specify 
I 
Medical Aid No: Dep Code: Patient Name: 
Pregnant 
If YES, specify: 
Expected date of delivery inTofMTM71v:vJvl L':-'__ L'--1:'. L__ _ _1__ _'_J 
Expected mode of delivery 
Expected date of C/S 
I NVD: C/S I 
~--~--- . --------····- .,. ---~-- ·--~------,-= 
Clinical Stage 4 :.. Adult / Adolescent I Paediatric 
H H 
HIV wasting syndrome (See Clinical Guidelines for definitions) 
Pneumocystis pneumonia 
------------ - ---- - ---------t--- - -
Recurrent severe bacterial pneumonia 
Chronic herpes simplex infection 
------- ----- ------
Oesophageal candidiasis 
~------ - ----- - -----------------
Extrapulmonary tuberculosis 
J 
Kaposi's sarcoma I 
r- ----~---- - ------------ __ _J 
Cytomegalovirus infection (retinitis or infection of other organs) 
~ ----- - ----- - - --------- - - ---- - - ----
Central nervous system toxoplasmosis 
HIV encephalopathy 
-- - -· 
~ 
Extrapulmonary cryptococcosis including meningitis 
~------ - ---- - --- - -----
Disseminated non-tuberculous mycobacterial infection 
I 
! 




- ---- - - ----- - - ---------- -------- -
Chronic isosporiasis 
Disseminated mycosis 
Recurrent septicaemia (including non-typhoidal Salmonella) 
---------- ---------- - ---
Lymphoma (cerebral or B-cell non-Hodgkin) 
Invasive cervical carcinoma 
Atypical disseminated leishmaniasis 
Symptomatic HIV-associated nephropathy 






AfA does not dispense medication - Please fax this completed form to 0800 600 773 or email it to afa@afadm.co.za 
This page needs to be completed by - The Doctor 




CD4% (must be provided for Viral Load 
children) (copies / ml) 
Additional Investigations Test Done? If yes, specify results 
Blood count(s) (Essential prior to approval of Zidovudine) 
Baseline ALT (Essential prior to approval of Nevirapine 
Serum creatinine/eGFR (Essential for patients with renal 
failure or prior to approval of Tenofovir) 
Antiretrovlral Therapy 
I YES I 
I YES I 








• Tariff code 0199 will only be paid for the first time completion of the application form. 
The form must be completed in full and signed by both the patient and the doctor. 
Directions 













• Approval for ongoing antiretroviral therapy will only be considered if the result and date of a recent CD4 count and viral load is supplied. 
Only medication recommended in the Aid for AIDS Clinical Guidelines will be considered for reimbursement. Please refer to these 
guidelines or contact Aid for AIDS on 0800 22 7700, or at afa@afadm.co za for further information. Motivations will however always be 
considered. Please contact AfA for assistance if required. 
I certify that the above particulars are - to the best of my knowledge and belief- true and accurate, having conducted a personal examination and 
procured the tests and/or other diagnostic investigations referred to. I confirm that I have counselled the patient on the importance of adhering to 
medication and monitoring test regimens. I acknowledge that the Aid for AIDS programme will rely on such particulars when making any 
recommendations regarding payment for treatment to the relevant medical scheme. I acknowledge that telephonic discussions will be taped for 
medico-legal purposes. 
Doctor's Signature 
Medical Aid No: DepCode: Patient Name: Pag~4of4 ·• 
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